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The evolution of the Host-Parasite relationship in terms of the fascinating
interaction of the evolution of the host and parasite over the last 50 years is
considered. This includes the evolution of new therapies such as intensive care
and new drugs. The shifts in the sort of pathogens causing nosocomial infection
and the evolution of their resistance mechanisms to antimicrobial agents are
described.
The various classification schemes for (^-lactamases are reviewed. The evolution
and origin of (3-lactamases are discussed. The newer forms of resistance mediated
to third generation cephalosporins are evaluated. Finally the introduction
considers briefly the genus Acinetobacter with particular reference to its 'up and




This deals with a survey of 200 strains of cefuroxime-resistant, Gram negative,
oxidase negative aerobic bacilli, collected in the Royal Infirmary of Edinburgh.
The predominant species within this group was Enterobacter spp. followed by
Acinetobacter spp. The (3-lactamases produced by these 200 strains were
investigated using isoelectric focusing. It was apparent that most of the
cefuroxime resistance was the result of 'typical' chromosomal (3-lactamases.
There was no evidence of transferable third generation cephalosporin resistance.
Hospital cefuroxime/gentamicin resistance study
This study employed computer records and looked at cefuroxime and gentamicin
resistance over 5 years in Gram negative, oxidase negative aerobic bacilli (14,000
isolates) within 18 distinct units of the RIE. This showed a remarkable variation
between units. Overall the resistance to cefuroxime was much higher than to
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gentamicin. Resistance to cefuroxime, within the hospital, was much higher in
the ITU areas. Over the five year period cefuroxime resistance was increasing
(clearly significant in the Surgical hospital and ITU areas) and gentamicin
resistance was decreasing (clearly significant in the Medical hospital) or stable.
An attempt to relate the differences in resistance rates was made with respect to
antimicrobial usage within these areas over a 1 year period coupled with the bed
occupancy figures. No clear relationship was found but the possible reasons for
these findings were discussed.
Acinetobacter chromosomal (3-lactamases
These enzymes were studied with the aim of characterising them fully by means
of pi, Mr, substrate profiles, kinetic data and inhibition studies. 9 enzymes were
considered. It was found that these enzymes do not focus on conventional IEF
polyacryiamiae gels and therefore a novel technique was devised employing an
agarose, urea and sorbitol (AUS) gel. Four ACE (Acinetobacter Chromosomal
Enzyme) groups were elucidated. Mr estimates on conventional low pressure gel
permeation showed that many of these enzymes seemed very large with Mr's of
500 - >l,000Kd. Biochemically their place as Bush group 1 (CEP-N)
cephalosporinases was confirmed. Further studies using high performance ion
exchange chromatography, employing FPLC, and Reversed polarity SDS-free
electrophoresis on the PhastSystem, confirmed the groupings of the ACE 1, 3 and
4 enzymes, however ACE 1 and ACE 2 were found to be very similar.
A purification scheme was devised employing high performance ion exchange
chromatography on FPLC, followed by gel permeation on FPLC and with SDS-
PAGE on the PhastSystem. This revealed that these enzymes exist as different
ionic variants of at least three molecular sizes, in the case of the ACE 1 enzyme
produced by H63 the predominant size in this system was around 10-15Kd with
variants at around 40Kd and 700Kd. Further purification techniques and more
research were therefore required.
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The position of the ^-lactamase within the structure of the Acinetobacter cell was
shown to be predominantly in the periplasm and not membrane bound.
Therefore these enzymes appear to be cephalosporinases which exist as
aggregated proteins which partially explains their unusual behaviour in
conventional gel permeation and polyacrylamide gel systems. Further directions
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In 1884, a nurse from King's College Hospital came under the care of
Joseph Lister for the treatment of a deep gluteal abscess after she had been
injured by a horse - drawn cart. He treated this locally with an extract of
Peni.cilli.um glaucum (therefore presumably crude penicillin). The patient herself
related this much later (Fraser - Moodie, 1971).
MacFarlane (1984) in his superb biography of Alexander Fleming
mentions two occasions in which Fleming used crude penicillin to treat infections
in his colleagues. Firstly, 1ml of "mould filtrate" was instilled into the antrum of a
co-worker (Craddock) who had acute sinusitis. The result was inconclusive.
Secondly he relates the successful treatment of a pneumococcal conjunctivitis in
Dr K B Rogers a research assistant and key member of Fleming's rifle team just
prior to an important competition. These cases were also mentioned by SeKvyn
(1980).
None of these cases were objectively assessed and published in reputable
journals. Therefore the era of the serious therapeutic use of the Beta-lactam
antibiotics commenced on the 12 February 1941 in the John RadclilTc Hospital,
Oxford when Dr Charles Fletcher injected 200mg of penicillin into a 43 year old
policeman.
This unfortunate man, who previously had been fit and healthy, had
developed a primary infection with Staphylococcus aureus with a secondary
infection with Streptococcus pyogenes. The infection which had started from a
sore at the corner of his mouth, had within a month spread to involve severe
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infections of both orbits,the lung, osteomyelitis, and multiple abscesses of his face
and scalp. There had been little improvement with a course of sulphapyridine.
He then received, over a period of 5 days, a total dose of 4.4g of
penicillin. This resulted in a dramatic improvement of his condition with
complete resolution of the infections at most sites. At this point the stocks of
penicillin ran out and although he remained stable for a further 10 days he
subsequently deteriorated and died of overwhelming sepsis. (Abraham et al., 1941;
Fletcher, 1984). This is a cautionary tale of the devastating effect of infection in
the pre-antibiotic era.
This case, however, gives us a taste of the bitter-sweet nature of this
particular "success" story. The penicillin almost, but not quite, cured the
policeman's infection before the supply ran out; however, it must have given them
hope for the future which was shortly to be confirmed by independant clinical
trials particularly those carried out on wounded soldiers in the North Africa
Campaign of World War II (Pulvertaft, 1943). None of those involved in these
early studies could have realised that by 1985 (in that year alone) 2,200 tonnes of
penicillin were manufactured for human and veterinary use with a further 12,000
tonnes produced to provide the starting point for the manufacture of the semi¬
synthetic penicillins and cephalosporins (Rolinson, 1988).
So began an era in medical practice which was to have profound effects
on enormous numbers of patients, both in terms of their morbidity and mortality.
Never before nor since can a simple group of drugs have had such a profound
impact on human disease; and continue to have that effect some fifty years later.
Garrod (1979) would perhaps dispute this, he felt that it was the
discovery of prontosil in 1935 by Domagk that was "the outstanding therapeutic
discovery of modern times". Donowitz and Mandell (1988) would disagree
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stating that the accolade should go to the Beta-lactam drugs. They quote
McDermott & Rogers (1982) who took the rather dramatic view that if one could
cure all the cancers in the USA it would increase the life expectancy of the
average American by two years while the introduction of antimicrobials had
already raised the life expectancy by 10 years. "The agent most responsible for
this remarkable effect is penicillin, the prototypic Beta-lactam antibiotic".
At this time we read of many new and important therapeutic
breakthroughs which help and enhance the lives of many patients. These might
include agents such as the Beta-blockers and H2 antagonists. Many of these
drugs at best ameliorate or slow down the disease process but very few tackle the
disease in such a way as to cure it completely. This differs from the effects of
antimicrobial agents in that in many cases they will completely cure the patient of
their infection; and with their prophylactic use may prevent the infection from
ever occurring.
The problem that faces us now is one that has existed all along - even
before physicians or surgeons used the Bcta-lactams, or any other antimicrobials,
as therapeutic agents - namely bacterial resistance. Unfortunately many medical
practitioners now take the abilities of antimicrobial agents for granted. Let us
hope that the increasing problems of bacterial resistance to these agents never
allow the clock to be turned back to the situation that prevailed in the "Septic"
ward of the John Radcliffe Infirmarv in Februarv 1941.
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In a useful contribution entitled "Observations on Spiralling Empiricism:
Its Causes, Allure and Perils with particular reference to Antibiotic Therapy", Kim
& Gallis (1989) wrote: "Fleming, Domagk and Florey could not have anticipated
the proliferation of antibiotics that would follow their discoveries, nor would have
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understood the profligate and injudicious use of these agents in modern
therapeutics!"
Perhaps the real problem is a lack of basic understanding of the nature of
the host - parasite relationship. "The search for essential, basic knowledge is
tedious, difficult and time consuming, whereas the appeal of quick rewards is
tough to resist. We are disheartened and diverted by the easy and quick marketing
successes of practices that lack this essential, basic knowledge", Kornberg (1989).
Many have forgotten the earthy origins of the antimicrobial agents and
that the mechanisms to overcome their effects have consequently evolved over a
period of millions of years prior to their therapeutic use by man (Pollock, 1967;
Bassett, 1980). It is worthwhile examining more closely the complicated and
fascinating interaction that has taken place between the host (man) and the
parasite (bacteria) during the last fifty years or so since that first therapeutic use of
antimicrobial agents.
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HOST EVOLUTION : ADVANCES IN THERAPY AND THEIR
IMPLICATIONS ON MICROBIOLOGICAL CONTROL
In the years since the Second World War many huge advances in most
areas of medical practice have taken place. Perhaps the most remarkable have
been developments in the technology which have made it possible to sustain, and
indeed prolong, life and restore function for critically ill and injured patients.
These advances, coupled with those in anaesthesia and blood transfusion have
been the necessary basis for success of a number of the more aggressive forms of
therapy e.g. radical surgery, cardiac surgery and organ transplantation.
EVOLUTION OF CRITICAL CARE
It was the polio epidemics of the early 1950's which led to the
introduction of mechanical respiratory support (Bower et al., 1950: Lassen, 1953;
Ibsen, 1954). This was followed by the early respiratory intensive care units in
Oxford, Toronto and Baltimore (Barber et al., 1959; Safar et al., 1961).
Since then, as new techniques have been developed, (see Table 1 )
critical care and specialist care units have evolved to support the postoperative
care of surgical, cardiac, neurosurgical, trauma and burns patients as well as
patients with acute respiratory, neurological, gastrointestinal, renal and metabolic
crises. Further specialised units have appeared in the obstetric, paediatric and
neonatal areas.
Critical care medicine has become synonymous with "cutting edge, high
tech" medicine with : haemodynamic monitoring ; sophisticated forms of
mechanical ventilatory support ; metabolic monitoring; fluid and electrolyte
therapy ; total parenteral nutrition ; haemodialysis or continuous arteriovenous
haemofiltration ; intracranial pressure monitoring with ventilatory and
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pharmacological intervention for the prevention and treatment of cerebral oedema;
innovative surgical therapies for trauma, burns, intra-abdominal catastrophies,
intracranial haemorrhage and acute heart failure, plus a huge arsenal of potent
drugs, particularly antimicrobials, Maki (1989).
Table 1. Evolution of Intensive Support
Technique or device Reference
Resuscitation
Internal cardiac massage Igelsrud,1901
(quoted by Weil et al.,1989)
Open chest massage and defibrillation Beck et al. ,1947
Transthoracic pacing Zo 11,195 2
External defibrillation Zoll et a/.,1956
Closed chest cardio-pulmonary
resuscitation




Bower et al. ,1950
Blood gas electrodes Severinghaus & Bradley, 1958
Blood gas laboratory Udhoji et al., 1963
Cuffed endotracheal tubes Pontoppidian et al. ,1977
7
Table 1 (contd.)


















Dudrick et al., 1968


















Hufnagel & Harvey, 1954
Gibbon,1954
Sones et al. ,1959
Starr & Edward, 1961
Barnard, 1967
Kantrowitz et al. ,1968
Favaloro,1968
This new technology has had two main effects in terms of the host-
parasite relationship. Firstly these invasive devices (endotracheal tubes; urethral
and intravascular catheters; intraventricular catheters and surgical wound drains)
have negated one of the most important of the host defences i.e. the mechanical
defences - the skin and mucous membranes.
Secondly these therapies allow progressively iller and iller patients to
survive for longer periods often with multiple organ failure and consequently
defects in their humoral and cellular defence mechanisms.
Therefore it is not surprising that these patients have a significantly
higher incidence of hospital acquired (nosocomial) infection, Donowitz et al.
(1982).
9
Critical carc patients are particularly vulnerable to septicaemias (often
associated with intravascular devices), pneumonias (often related to intubation and
mechanical ventilation) and intra-abdominal infections (following trauma or
surgery). Infection is the most common cause of death in patients who survive
major trauma or full thickness burns and is the most common identified cause of
multiple organ failure. (Fry et al., 1980; Pine et al., 1983; Marshall & Dimick,
1983).
All these host factors interact with the parasite and, as we shall see, has
had an effect on the evolution of the micro-organisms causing infections in these
patients.
EVOLUTION OF THERAPY FOR HAEMATOLOGICAL MALIGNANCIES
AND SOLID TUMOURS
The other group of patients who provide the clinical microbiologist with
continuing problems of hospital acquired infections are those undergoing therapy
for haematological malignancies and some solid tumours. It is now possible to
cure some patients with 14 previously fatal malignancies, McCredie (1985).
1. Acute lymphocytic leukaemia
2. Acute non-lymphocytic leukaemia
3. Hodgkins disease
4. Diffuse histiocytic lymphoma








12. Small cell carcinoma of the lung
13. Adenocarcinoma of the breast
14. Rhabdomyosarcoma in children
This has resulted from the use of antitumour drugs, ionising radiation,
immunosuppressive agents and bone marrow transplantation. Chemotherapy
alone over the last 35 years has probably cured between 15 - 25% of patients with
acute myeloblastic leukaemia and up to 55% of good risk patients with acute
lymphoblastic leukaemia (Powles, 1986). This means that most patients with
acute leukaemia still die of their disease. Therefore alternative, more radical
forms of therapy such as bone marrow transplantation (BMT) have evolved.
BMT is used to "rescue" the patient from the intensive "supra-lethal" treatment
necessary to kill all his tumour cells but which consequently kills his own bone
marrow.
Successful BMT had to await several developments. The most important
was the elucidation of the major histocompatibility loci (Epstein et al., 1968)
necessary for the rational choice of an appropriate donor. Although preliminary
work had taken place ten or so years before (Kurnick et al., 1958; Thomas et al.,
1957; Thomas et al., 1959; Uphoff, 1958) other developments were necessary
including the support of patients through several weeks of pancytopenia. These
included the development of increasingly powerful antimicrobial and antiviral
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agents together with the haematological techniques allowing the harvesting of
platelets and granulocytes from normal donors (Thomas et al., 1975).
Therefore application of BMT as a treatment of human disease started in
earnest in Seattle in the early 1970's (Thomas et al., 1977). Subsequently these
other treatments were aided by the use of longterm, tunnelled intravascular
catheters (Hickman, 1979).
Therefore these patients have compromised mechanical defences not only
because of the use of these intravascular catheters but also as the result of
decreased mucosal integrity as a direct effect of the chemotherapy.
However, by far the more important effect of the therapy is on the host's
cellular and humoral immune defences. In the case of the BMT patient profound
neutropenia (<100 per pL) occurs in the early post transplant period. Septicaemia
by Gram negative bacilli is the most commonly observed infection at this time
(Winston et al., 1979b).
Immunosuppressive chemotherapy
This exerts a profound, often complex, effect on host resistance to
infection. High dose corticosteroid treatment significantly increases the risk of
infection since it has multiple effects on the immune response including actions
on neutrophils, lymphocytes and macrophages.
Cyclophosphamide and azathioprine increase the risk of infection
primarily by causing neutropenia.These immunosuppressive drugs are widely
used to treat immunologically mediated diseases such as systemic lupus
erythematosus, polyarteritis and Goodpastures syndrome. Similarly
corticosteroids are used in conditions such as rheumatoid arthritis, hepatitis and
nephritis. But the patients at greatest risk from intercurrent infection "are patients
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with haematological or other forms of malignancy and recipients of organ or bone
marrow transplants", Cohen (1988).
Therefore it is clear that infection is an enormous problem in such
patients, indeed in the mid 1970's infection was the commonest cause of death in
patients with haematological malignancy (Chang et al., 1976). This has however
been significantly reduced with the early use of antimicrobials in febrile
neutropenic patients (Pizzo et al., 1982); the use of more aggressive diagnostic
techniques (Burt et al., 1981) and the general improvement in intensive therapy.
Therefore, there are two types of compromised hosts which have severe
implications for microbiological control and antibacterial chemotherapy: firstly
there are those patients with severely impaired mechanical defences with or
without a degree of impaired immune function (dependant on the type and
severity of their underlying condition) - the intensive therapy patient.
Secondly there are those patients with severely impaired immune
function (often with profound neutropenia) with a degree of mechanical defence
impairment - the bone marrow transplant or oncology patient.
EVOLUTION OF ANTIMICROBIAL AGENTS
The evolution that has taken place in antimicrobial chemotherapy is best
seen in figure 1.
The evolution of the Beta-lactam drugs will be dealt with in more detail
later (see fig.2).
Essentially the pharmaceutical companies have been driven to produce
newer agents as often bacterial resistance mechanisms have rendered the original
agents less effective. Therefore ever more powerful agents with often very broad
13
spectra of activity (e.g. imipenem and the quinolones) have been produced. Their
evolution, of course, has been inextricably interwoven with the resistance
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MECHANISMS OF RESISTANCE TO ANTIMICROBIAL AGENTS
The mechanisms of resistance to antimicrobial agents can be divided into 3 major
types:
1. Alteration of the target
2. Inactivation of the drug (detoxifying enzyme )
3. Decreased uptake of the drug
They have been nicely summarised in a Table (Table 2) by Jacoby & Archer
(1991)
Table 2 Major Mechanisms of Resistance to Antimicrobial Agents



































Altered cell-wall stem peptide
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Table 2 (contd.)









Erythromycin New transport system
Tetracycline New transport system
(After Jacoby & Archer ,1991)
EVOLUTION OF BACTERIAL RESISTANCE MECHANISMS
Amyes (1989) stated: "Since the mid 1930's, clinically important bacteria
have been subjected to successive onslaughts of antibacterial drugs. However, in
response, the bacterial populations have overcome these attacks rapidly by the
selection of resistant variants or by their ability to acquire novel genetic material.
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Indeed, the development of new antibacterial drugs has been dominated by the
bacterium's ability to resist the previous-generation of drugs".
For instance when penicillin was first used in 1941, less than 1% of all
strains of Staphylococcus aureus were already resistant to its action; however, by
1946 under the selective pressure of this antibiotic's extensive use, the proportion
of penicillin resistant strains had risen to 14%. By 1947, 88% were resistant and
at the present time more than 90% of all strains of Staphylococcus aureus are
resistant,(Lewis, 1989).
It would seem that microbes have co-existed with antimicrobials for
some time. Sneath (1962) revived some spores of Bacillus licheniformis which
had been dormant in dried soil stuck to the roots of plant specimens preserved
untouched in the British Museum since 1689. Pollock (1967) examined these
strains and found them to produce a penicillinase.
Smith (1967) described a strain of Escherichia coli that had been stored




1. intrinsically resistant to an antimicrobial.
2. may undergo chromosomal mutation to become resistant e.g.streptomycin
or rifampicin.
or
3. may become resistant via the acquisition of new genetic material.
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It would seem that prior to the therapeutic use of antimicrobial agents
resistant bacteria were rare but with the use of these agents both in medical and
veterinary practice, the situation has dramatically changed.
Plasmids as transmissible agents of resistance (R plasmids) were
discovered in Japan in 1959 (Watanabe, 1963) and by the late 1960's were
accepted as the major cause of antimicrobial resistance in clinical isolates.
Hedges and Jacob (1974) demonstrated that the plasmid-borne resistance genes
were, in fact, more mobile that their plasmid hosts. Many were located on
transposons capable of migrating between replicons within the same bacterial cell.
This considerably improves their survival potential. Since the early discovery of
transposons, almost all plasmid-borne genes have been found to be located on
plasmids.
Jacoby (1985) pointed out the considerable advantages of having
resistance genes carried on plasmids.
(i) Some chromosomal resistance mutations retard growth or diminish
virulence whereas plasmid resistance does not.
(ii) A chromosomal mutation may revert, but the frequency at which a
plasmid may be lost when it no longer confers a selective advantage is
much higher.
(iii) Plasmid determined resistance can be amplified e.g. by gene duplication.
(iv) It can be carried on a segment of DNA that can transpose from one
replicon to another allowing greater flexibility in resistance dissemination.
(v) Resistance to multiple antibiotics can be packaged on a single plasmid.
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(vi) Plasmid determined resistance can be spread to new hosts often, into
different species of bacteria.
Thus we can see the range of mechanisms at the disposal of microbes which allow
them to adapt and evolve in the presence of antimicrobial agents.
This thesis will deal with Beta-lactam resistance manifested by Beta-
lactamases; therefore, it is important to examine the close relationship between the
development of new Beta-lactams and the evolution of the new Beta-lactamases.
Wiedemann et al. (1989) divided this into 4 periods:
1. 1942-60 : Development of penicillin. Increase of penicillin - resistant
Staphylococcus aureus strains caused by plasmid-mediated penicillinases.
Development of methicillin and oxacillin.
2. 1960-72 : Development of aminopenicillins e.g. ampicillin. Increase of
ampicillin-resistant coliforms resulting from plasmid-encoded penicillinases like
TEM-1.Development of first generation cephalosporins e.g.cephazolin.
3. 1972-80 : Development of second generation cephalosporins e.g.
cefuroxime and cefoxitin. Selection of mutants that overproduce chromosomally-
mediated cephalosporinases.Induction of chromosomally mediated enzymes.
4. 1980-> : Development of third generation cephalosporins e.g. cefotaxime
and ceftazidime. Development of mutated plasmid-mediated Beta-lactamases
such as TEM-3 to TEM-7 and SHV-2 and SHV-3, plasmid-coded broad spectrum
Beta-lactamases.
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EVOLUTION OF INFECTING ORGANISMS
The kinds of organisms that cause severe infections in hospitalized
patients are clearly linked with :
1. The evolution in the type of patients themselves which is related to their
host-defence mechanisms and therapies they undergo.
2. The use of antimicrobial agents (and their evolution into even more
powerful agents).
3. The evolution of bacterial resistance mechanisms to these antimicrobial
agents.
In the pre-antibiotic and early antibiotic era significant infections were
caused by the virulent pyogenic cocci (such as Staphylococcus aureus, the
pneumococcus and Streptococcus pyogenes). These infections often occurred in
patients with reasonably complete host defence mechanisms (Abraham et ai,
1941; Garrod, 1979; McDermott & Rogers 1982).
With the availability of ampicillin and methicillin derivatives, infections
tended, in the 1960's and 1970's to shift to Gram negative coliforms and
organisms such as Pseudomonas aeruginosa. This change resulted from natural
resistance to these compounds or the acquisition of a resistance mechanism. At
the same time the development of modern therapies has led to patients who are
more and more compromised both in terms of their immune and mechanical
defence mechanisms.
Maki (1989) has slated that the intensive therapy unit has become a
milieu within the hospital uniquely conducive to the occurrence of epidemic
nosocomial infection, especially infection caused by antibiotic resistant pathogens.
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"Intensive antimicrobial therapy, used in most intensive therapy units, grossly
distorts the patient's microflora and fosters colonisation and ultimately infection".
At present Gram negative organisms such as multiply resistant enterobactcriaceae
e.g. Serratia, Klebsiella, Enterobacter, Pseudomonas or Acinetobacter are still
significant problems; however, there is an increase in organisms such as
methicillin-resistant Staphylococcus aureus (MRSA), coagulase negative
staphylococci and enterococci. Yeasts such as Candida albicans may also cause
problems.
Resistant nosocomial organisms from colonised and infected patients are
transmitted between patients in the unit most frequently by the hands of the
medical personnel and may be perpetuated by contaminated equipment such as
bedpans, respiratory apparatus, pressure transducers and endoscopes.
Craven et al. (1988) studied the risk factors for nosocomial infection in
ICU patients. They found that surgical ITU patients had a considerably higher
incidence of nosocomial infection as compared to medical ITU patients. These
infections were caused by enterococci, multiply resistant enterobacteriaceae,
(.Klebsiella, Enterobacter, and Serratia rather than E.coli) Pseudomonas
aeruginosa and Candida. These pathogens are almost always selected out by
antibiotic pressure.
Their surgical patients had significantly more antimicrobial therapy than
their medical ITU patients. These workers (Craven et al., 1988) also showed
convincingly by multivariate analysis that invasive devices are at least as
important in increasing the susceptibility to nosocomial infection as is the
underlying disease. But that while invasive devices are powerful predictors of
vulnerability to nosocomial infection, underlying diseases are much more
important predictors of fatality.
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A similar story emerges from oncology and bone marrow transplantation
patients. Just as Donowitz et al. (1982) noted the shift of infecting organisms in
the ITU from Gram negative to Gram positive and yeasts. Lowder et al. (1982)
and Young (1985) have noted a similar shift to often less virulent but multiply
resistant Gram positive organisms such Staphylococcus epidermidis and "JK"
Corynebacteria. This shift was associated with the increasing use of indwelling
central venous catheters. (Lowder et al., 1982 ; Catovsky and Hoffbrand, 1989).
Pneumococcal infections are also common in patients with splenectomy and post
bone marrow transplantation (Winston et al., 1989a).
OVERALL PERSPECTIVE
In ending this section I will use a table (Table 3) from a recent review by
Selwyn (1991). Like most of Selwyn's tables it has its good points and... its bad! It
is useful for its historical nature - it shows the evolution of hospital-acquired
(nosocomial) infections from the 18th century to the present day.
Table 3. The evolution of hospital acquired ( nosocomial) infection
Date Dominant hospital Organism
infections
->1800 Hospital fever (typhus) Rickettsia
Dysentery Shigella
The itch (scabies) Sarcoptes










c. 1940-> Staph, sepsis (skin, breast, Staphylococcus aureus
wounds etc. ('hospital staph.')






c.1965 Virus hepatitis Hepatitis B virus
('Australia antigen')
1970s-> ( Anaerobic infections ) 2 Bacteroides spp. etc.
Legionnaires disease 3 Legionella spp.
Food poisoning 4 Salmonella spp. etc.





* But fungus-like on RNA sequencing.
Increase more apparent than real.
3 N.B.Stafford (1985).
N.B.Stanley Royd, Wakefield (1984).
5 Minimal risk of transmission in hospital.
(After Selwyn ,1991)
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It is fine until "c.1955 - opportunistic infections (esp Gram-negatives)"
where he correctly points out the importance of Pseudomonas and other
multiresistant enterobacteria as nosocomial pathogens. He does mention the
importance of yeasts and fungi but not the increasing problems with the Gram
positive multiresistant bacteria such as the coagulase negative staphylococci
(CNS), MRSA and JK diphtheroids (although he does mention them in the
accompanying text). He does however discuss problems with other
microorganisms such as Hepatitis B virus, the Herpes viruses and the "fungus¬
like" protozoan Pneumocystis carinii (though this organism is almost certainly
endogenously acquired). It is particularly useful to mention the viruses and
protozoa in order not to forget their increasing role in infections of the
immunocompromised. This thesis will deal exclusively with the bacterial
pathogens and it is timely to remember that they are not the only ones.
Where Selwyn is not so good is by describing as "dominant hospital
infections" of the "1970s ...." the following epidemic infections that may be
acquired in hospital: Legionnaires' disease (1985 outbreak in Stafford) and food
poisoning (1984 outbreak of foodborne salmonellosis at Stanley Rovd,
Wakefield).
These infections are not the endemic problems that the clinical
microbiologist sees day in and day out as the major causes of infection in his
hospital and therefore should not be included.
He, under the same heading, also mentions anaerobic infections caused
by Bacteroides spp. These infections do occur in hospitals - often as a result of
surgery on, e.g., the large bowel - but they are relatively uncommon since the
advent of prophylaxis and treatment with metronidazole* He himself states that
they are "more apparent than real".
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*(Anaerobic bacteria were the cause of only 140 of 2578 cases of nosocomially
acquired bacteraemia, i.e. 5.6%, over a 20 year period in St Thomas's hospital,
Eykyn et al., 1990).
For good measure he adds HIV infection (AIDS) as a "dominant hospital
infection" since 1981. This, as he himself states, is not often acquired by
transmission within the hospital and it is therefore clearly not a "nosocomial"
infection. It is a particular problem in specific areas of the UK: in some large
cities but not all. However it is again useful in the context of this thesis to mention
HIV infection since it has led to an evolution of infection. These
immunocompromised patients suffer a variety of infections not only bacterial (e.g.
salmonella, mycobacterial); but viral e.g. cytomegalovirus, herpesvirus; protozoal
e.g. Toxoplasma gondii, cryptosporidiae, Pneumocystis carinii; and fungal e.g.
Cryptococcus neoformans , Candida albicans .
But returning to the bacteria...
Table 4. Evolution of the Host-Parasite Relationship
PARASITE HOST
SITUATION PRE-ANTIBIOTICS
Highly Virulent Good Defences
e.g. STAPH AUREUS NON-COMPROMISED
CURRENT SITUATION
Less Virulent Poor Defences
with multiple antimicrobial resistance (both mechanical and immune)
e.g. STAPH. EPIDERMIDIS COMPROMISED
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In terms of the host - parasite relationship clear changes have taken place
over the last 50 years as each strand (of e.g. therapy and resistance) has evolved.




"Purge me with hyssop, and I shall be clean"
Psalm 51,verse 7.
"Quinsye and Swelling of the Throte"
"For the quinsy and swelling vnder the eares. Take the musherom that
groweth vpon an elder tree"
Boke ofChyldren
Thomas Phayre,1545.
Both these are quoted as examples of the use of moulds and fungi as
empirical treatment of infections by Selwyn (1980).
The reference to hyssop may be relevant since the first description of
Penicillium notatum was made following its isolation from a hyssop plant
(Westling,1911).
In the case of Thomas Phayre, the fungus was taken in the form of a
warm infusion and apparently had good results against diseases most usually
caused by the penicillin-sensitive haemolytic streptococci.
For the medical historian, the history of the therapeutic use of moulds, the
discovery of penicillin and the subsequent development and evolution of the Beta-
lactam drugs is fascinating.
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For an account of the early work on the antibacterial action of Penicillium
species by workers such as Burdon-Sanderson, Lister, Roberts, Tyndall,
Duchesne etc, I refer the reader to Selwyn (1980).
For an insight into the discovery of penicillin by Fleming and the early
work on its isolation, purification and clinical use; I refer the reader to the two
excellent biographies of Florey and Fleming by MacFarlane (1979 & 1984), a
review by Abraham (1983) and the book chapter by Selwyn (1980).
THE EVOLUTION OF THE BETA-LACTAMS
The dramatic growth of the Beta-lactam drugs of the early 1950's can be
seen in fig.2 (Rolinson, 1988).
The rapid emergence of penicillin-resistant Staphylococcus aureus under
the selective pressure of the use of penicillin in the late 1940's and the subsequent
importance of the penicillinase-producing Gram negative bacteria provided the
stimulus for the pharmaceutical companies to develop the Beta-lactam drugs.
During the 1950's two crucial occurrences provided the starting points for the
dramatic surge in the clinical usefulness of the Beta-lactams as antimicrobial
agents. First was the discovery of methods for obtaining 6-aminopenicillanic acid
in quantity. Secondly the discovery of Cephalosporin C and its nucleus, 7-
aminocephalosporanic acid (7-ACA) (See figs.3 & 4).
6 APA and the semisynthetic penicillins
In the late 1950's Beecham Research Laboratories developed the
technology to produce large quantities of 6-APA (Batchelor et al., 1959). This
opened the way to the modification of the penicillin nucleus (6 APA) by the
addition of novel side chains by chemical means through the 6-amino group.
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Two significant derivatives of 6 APA were quickly to appear: methicillin
and ampicillin. Methicillin - methicillin, cloxacillin and
flucloxacillin were a major advance since they are stable to the Beta-lactamases
produced by Staphylococcus aureus. They have remained the anti-staphylococcal
drugs of choice, in most situations, until the recent problems with epidemic
methicillin-resistant Staphylococcus aureus (EMRSA). Ampicillin - with its
wider spectrum of activity against Gram negative organisms coupled with its oral
absorption led to it becoming one of the most widely used antibiotics. Derivatives
such as the ureidopenicillins (e.g. piperacillin and azlocillin) have proved useful.
As amoxycillin,and with the addition of a Beta-lactamase inhibitor( clavulanic
acid) the spectrum of activity of ampicillin has been resuscitated ( for the moment
at least).
Intrinsically, penicillins lack sufficient flexibility because they possess
only one position available for fundamental group development (C-6).
Consequently, the penicillins have not enjoyed the variety nor the success of the
cephalosporins - which will be discussed in the next section.
The discovery and development of the cephalosporins
Cephalosporin C was discovered by Newton & Abraham in 1953
(Newton & Abraham, 1955) while they were studying the antibiotics of a strain of
Cephalosporium acremonium that had been isolated by Guiseppe Brotzu from the
sea near a sewage outfall at Cagliari in Sardinia.
The importance of cephalosporin C was not only that it was effective
against both penicillin-sensitive and penicillin-resistant staphylococci but also
because it had a wide spectrum of antibacterial activity.
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Unlike the penicillin nucleus, the cephalosporin nucleus contains several
positions at which chemical modifications can be attempted (see fig.4) and
therefore many thousands of cephalosporin antibiotics have been produced by
various pharmaceutical companies world-wide (Williams & Williams, 1980).
For a fuller account of the early history and evolution of the penicillins
and cephalosporins please see Abraham (1983) and Rolinson (1988).
Further important milestones in the Beta-lactam story include the
discovery of:
1. cephamycins from Streptomyces (Daoust etal., 1973)
2. carbapenems from Streptomyces (Kropp el al., 1980)
3. clavams from Streptomyces (Reading & Cole, 1977)
4. monobactams from bacteria ( Nocardia) (Aoki etal.,1916)
New Beta-lactam drugs have continued to be discovered and synthesized.
Not only do they have a remarkable diversity of spectrum with a range from
narrow (e.g. benzylpenicillin) to extremely broad (e.g. imipenem) but they all
share a relative freedom from side effects.
The latest cephalosporin modifications have resulted in drugs with
differing pharmacokinetic properties so that some drugs need only be given once
or twice per day (e.g. ceftriaxone).
CLASSIFICATION OF THE BETA-LACTAMS
By the mid 1980's more than 50 different Beta-lactam drugs were in
clinical use or at an advanced stage of evaluation. Many have similar names with
either similar or differing properties. Rolinson (1986) therefore thought it useful
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to publish a register of all Beta-lactams with their name, structure and both their
antibacterial spectra and pharmacokinetic properties.
The easiest way to classify Beta-lactams is into chemically related
groups. The basic Beta-lactam structure consists of a four membered ring fused to
a second ring. Biochemical modifications have been made in attempts to increase
penetration through bacterial cell walls, to decrease susceptibility to Beta-
lactamases or to increase binding to PBP's (Donowitz & Mandell, 1988).
Penams : The four membered Beta-lactam ring (azetidinone ring) is
fused with the sulphur containing thiazolidine ring. Examples are
benzylpenicillin, ampicillin, flucloxacillin, the ureidopenicillins and temocillin.
Penems : The penem nucleus is the unsaturated analogue of the penam
ring system.
Carbapenems : The carbapenems result from the replacement of the
sulphur atom of the penem nucleus by a (CH2) group. This type of Beta-lactam
includes the thienamycin and olivanic acid families. Imipenem is an example.
The small size and compact structure of these agents allow them to pass easily
through Gram negative cell walls. Marked resistance to hydrolysis by Beta-
lactamases is provided by the trans configuration of this group, which contrasts
with the cis configuration of other Beta-lactams (Birnbaum et al., 1985).
Clavams : The sulphur atom in the five membered ring is replaced by an
oxygen.An example is clavulanic acid a potent suicide inhibitor of certain types of
Beta-lactamase.
Cephems : A cephem is the bicyclic ring system obtained by the fusion
of a azetidinone (Beta-lactam) ring with a dihydrothiazine ring. Numerous
cephalosporins have been developed from this nucleus.
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The cephamycins have a methoxy group at the C-7 position of the 7-
ACA nucleus which increases Beta-lactamase stability (an example is cefoxitin).
The amino-thiazol substituted cephalosporins (e.g. ceftazidime,
cefotaxime and cefuroxime) give a combination of increased activity and
increased Beta-lactamase stability.
Oxacephems : The sulphur in the dihydrothiazine ring is substituted by
an oxygen resulting in an increased spectrum against Gram negative species. The
most notable member of this group is latamoxef (moxalactam).
Monobactams : The monobactams (azetidinone derivatives) are a novel
group of compounds in which the bicyclic structure characteristic of other Beta-
lactams is absent but the core configuration is that of a "naked" Beta-lactam ring.
Since the 1-sulphonic acid group lowers the energy requirements for interaction of
the Beta-lactam with PBPs, it is said to "activate" the molecule (Cimarusti &
Sykes, 1984). Examples are aztreonam, carumonam and tigemonam.
Further details of the structure-activity relationship of the Beta-lactam
drugs can be found in Dunn (1982), Hoover (1983) and Neu (1986a).
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RESISTANCE TO THE BETA-LACTAM ANTIBIOTICS
Resistance to these antimicrobial agents can occur by at least three routes:
Inactivation : This is by far the most common cause of resistance - the
production of a Beta-lactamase which hydrolyses the Beta-lactam to a biologically
inert product.
Alterations in the permeability of the drug : In Gram negative bacteria
resistance can also result from a decrease in the rate of penetration of the
antibiotic through the outer membrane to the penicillin binding proteins (PBP's) in
the cytoplasmic membrane. This resistance mechanism is unlikely to give high
levels of resistance without the concomitant effect of limiting the uptake of
nutrients and thereby seriously impairing the growth of the bacteria. This form of
resistance has not been reported in Gram positive bacteria as they lack an outer
membrane.
Alteration of the target : The third form of resistance to the Beta-lactam
antibiotics is via alterations in the properties of the physiological targets of these
antibiotics - the penicillin binding proteins.
"Each of these 3 factors are interdependant on the others", (Sanders &
Wiedemann, 1988)
This thesis will concentrate on the resistance due to the Bcta-lactamases,
particularly in Gram negative bacteria. However the importance of the other two
mechanisms of resistance should not be overlooked.
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The role of permeability changes in resistance has been reviewed recently
by Nikaida (1989) and the role of alterations in the penicillin binding proteins has




If the first serious therapeutic use of the Beta-lactam drugs took place on
the 12 February 1941, "penicillinase" was born on 28 December 1940 (Hamilton-
Miller, 1979). One may view the chronology of these milestones as a little ironic.
Abraham and Chain (1940) described the extraction of a substance from
B.coli (E.coli) which destroyed the growth inhibiting property of penicillin. They
concluded that this substance was an enzyme and named it "penicillinase".
They also observed the following:
1. The enzyme was found in a penicillin resistant Gram negative rod
contaminating their Penicillium cultures.
2. They also found it in a culture of penicillin sensitive Micrococcus
lysodeikticus and concluded that:
3. "The presence or absence of the enzyme in a bacterium may not be the
sole factor determining its sensitivity to penicillin". They also postulated that:
4. Because various species of bacteria contain penicillinase, it "may have a
function in their metabolism".
Only a few years later it was shown that penicillinase was responsible for
clinical resistance in Staphylococcus aureus (Kirby, 1944; Gots, 1945). From
then until the 1960's most attention focused on staphylococcal penicillinase as the
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prevalence of penicillin resistant staphylococci quickly reached epidemic
proportions in hospitals where penicillin was widely used.
It was shortly realised that Beta-lactamases from different sources had
different properties. Brodersen (1947) showed that the enzyme from a
"paracolon" organism has different properties from the Beta-lactamase of Bacillus
subtilis. Abraham (1951) in the first major review of Beta- lactamases recognised
that there was likely to be a wide variety of different Beta-lactamases. This had to
remain unproven until the introduction of the new substrates - i.e. the
semisynthetic penicillins - in the early 1960's. Smith and Hamilton-Miller (1963)
pointed out "major qualitative differences" between the penicillinases of Gram
positive origin and those of Gram negative origin. They also speculated that
"each individual species of penicillinase-producing Gram negative bacteria may
produce a 'species specific' penicillinase "
This was to be (to some extent) confirmed by Matthew and Harris (1976)
using the technique of isoelectric focusing.
As the first semisynthetic cephalosporins appeared it soon became
obvious that although they were virtually unaffected by staphylococcal enzymes,
they were rapidly destroyed by the Beta-lactamases from many Gram negative
bacteria (Jago et al., 1963; Hamilton-Miller et al., 1965).
At the same time a discovery was made that was to have a profound
effect on the spread of Beta-lactam resistance and was the spur to the production
of the next generation of Beta-lactam drugs by the pharmaceutical houses. Datta
and Kontomichalou (1965) first described resistance to Beta-lactam drugs
mediated by R factors in Gram negative bacteria.This, of course, was invariably
associated with specific Beta-lactamases.
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Since then we have seen the concomitant evolution of the newer Beta-
lactam antimicrobials (see later) and the "counter" evolution of the new Beta-
lactamases. Classification schemes of these Beta-lactamases have necessarily
evolved as these Beta-lactamases have been characterised. These will be
described later.
ACTION OF BETA-LACTAMASE
Beta-lactam drugs provide a substrate for a number of hydrolytic
enzymes but the most important of these are the Beta-lactamases (Sykes, 1982).
Beta-lactamases hydrolyse the cyclic amide bond (see 1, fig.5 ) of
susceptible Beta-lactams to give antibiotic inactive products. For penicillins these
are relatively stable penicilloates but for cephalosporins are the relatively unstable
cephalosporates.The pattern of fragmentation is dependent on the nature of the C-
3 substituent.
The second type of enzymic degradation of Beta-lactams involves the
removal of the acyl-side chains (see 2, fig.5 ) by amino acid acylases (often
referred to as penicillin acylases or amidases). These enzymes are believed to
have little role in antimicrobial resistance but are of immense commercial value in
cleaving penicillins in the production of semisynthetic derivatives (Batchelor et
al., 1959).
Beta-lactamases (E) function by first binding the Beta-lactam substrate
(S) in a noncovalent Michaelis complex (E.S). Then the enzyme and substrate
may dissociate or commit themselves to the hydrolytic reaction by forming an
acyl enzyme via an active site serine hydroxyl (E-S). Deacylation of this covalent
complex with release of ring opened products (P) completes the mechanistic

















Interaction of cephalosporins {top) and penicillins (bottom) with hydrolysing enzymes.
(After Sykes, 1982)
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A third type of enzymic degradation involves the acetyl group of the
cephalosporins containing the acetoxymethyl function at C-3 which is removed by
esterases (see 3, fig.5 ). Such cleavage produces components of reduced
antibacterial activity. The presence of esterases in mammalian tissue has however
been exploited with inactive prodrug esters such as talampicillin,which is cleaved
in vivo to release the active drug - ampicillin.
Mammalian kidney has been found to produce dehydropeptidases (Kropp
et al., 1980) that specifically inactivate the carbapenems. This has necessitated the
addition of a renal dipeptidase inhibitor (cilastatin) with imipenem in
pharmaceutical preparations.
Figure 6
The mechanism of action of the (3-lactamase
k\




For the years following the paper by Abraham and Chain (1940)
"penicillinase" became the accepted term for this group of enzymes. In 1965 the
Enzyme Commission gave penicillinase the official name "penicillin amide Beta-
lactam hydrolase", E.C.3.5.2.6 (Enzyme Nomenclature, 1965). This name was
very similar to that given to acylase (E.C.3.5.1.11) namely
"penicillinamidohydrolase" (Hamilton-Miller, 1979).
With the rush of new substrates in the 1960's and the discovery that some
Beta-lactamases hydrolysed cephalosporins, the term "cephalosporinase" was
coined. Therefore in 1972 the Enzyme Commission introduced
"cephalosporinase" as E.C.3.4.2.8. However they continued to confuse the
situation by introducing the terms "Beta-lactamase I" for penicillinases and "Beta-
lactamases II" for cephalosporinases. Thankfully few workers entertained the use
of these terms (Hamilton-Miller, 1979). The Enzyme Commission finally
grouped Beta-lactamases under one heading (E.C.3.5.2.6.) in 1984 (Enzyme
Nomenclature, 1984).
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THE CLASSIFICATION OF BETA-LACTAMASES
The method used to classify is that which ends up classifying in the most
useful classification for the classifier. This is exactly what has taken place with
the classification of the Beta-lactamases.




The molecular biologists themselves can be further subdivided into two:
i.e. sequencers and crystallographers ; and perhaps a third group of geneticists.
The microbiologists may have a tinge of the biochemist, the molecular biologist
or the geneticist. Each one may have particular interests in the chromosomal or
plasmid mediated Beta-lactamases or similarly may be more interested in Beta-
lactamases from Gram positive than from Gram negative organisms. The above
classification is of course far from complete and new subdivisions may be
required in the future!




3. relative activity towards different Beta-lactams (substrate profile)
4. interaction with inhibitors and inactivators
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5. nature of the active site
6. amino acid sequence
7. three dimensional structure ( Ambler, 1980)
and to this list we should add :
8. the genetic location of the Beta- lactamase genes i.e. plasmid or
chromosomal
EARLY CLASSIFICATION SCHEMES
The first attempts at classification were made in the early 1960's, just
after the introduction of ampicillin: Ayliffe (1963) described two "penicillinases"
and Fleming et al. (1963) studied a Beta-lactamase mainly active against
cephalosporins. These enzymes, and the most clinically important ones that
followed, were produced by Gram negative bacteria. Classification schemes
have, because of this clinical importance, essentially disregarded Gram positive
Beta-lactamases. However, molecular biologists have been mainly interested in
the Beta-lactamases from Gram positive bacteria which were either never a
clinical problem (e.g. Bacillus licheniformis) or no longer the major clinical
problem (e.g. Staphylococcus aureus with the advent of methicillin and its
derivatives).
Sawai et al. (1968) divided Beta-lactamases on the basis of the enzyme's
"substrate profile" i.e. its spectrum of hydrolytic activity against a range of Beta-
lactam substrates.
Group I: comprised of typical cephalosporinases.
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Group 2: comprised of cephalosporinases that also had penicillinase activity
(broad spectrum enzymes).
Group 3: comprised of penicillinases.
Jack and Richmond (1970) produced a similar classification employing
this biochemical parameter but divided the cephalosporinases into two categories
i.e.:
Group 1: comprised of the broad spectrum enzymes.
Group 2: comprised of the penicillinases.
Group 3: comprised of the cephalosporinases with little or no activity against
penicillins.
Group 4: comprised of cephalosporinases with some hydrolytic activity
against the penicillins.
With inclusion of additional parameters such as reaction against antisera;
enzyme inhibition with pCMB and cloxacillin; and electrophoretic mobility, they
identified at least 8 different Beta-lactamases types.
In 1973, Richmond and Sykes produced a more definite classification:
Class I: comprises the enzymes predominantly active against
cephalosporins.
Class II: comprises the enzymes predominantly active against penicillins.
Class III: comprises the enzymes with approximately equal activity against
penicillins and cephalosporins but that are sensitive to inhibition by cloxacillin
and resistant to inhibition by pCMB.
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Class IV: comprises the enzymes of similar substrate profile to the enzymes
of Class III but that are resistant to the inhibition by cloxacillin and sensitive to the
inhibition by pCMB. (Some enzymes in this class have the capacity to hydrolyse
cloxacillin).
Class V: comprises the enzymes that have a "penicillinase" profile including
activity against cloxacillin and that are resistant to pCMB.
Class I enzymes were also subdivided as in Table 5.
Table 5. Classification of chromosomal cephalosporinases
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Taken from Sanders (1987)
Class I enzymes : are characteristically chromosomally mediated and are either
constitutive or inducible. Typical examples are produced by strains of E.coli,
Enterobacter spp., Citrobacter spp., indole positive Proteus spp., Pseudomonas
spp. and Serratia spp.
Class II enzymes: these are chromosomally mediated with predominant
penicillinase activity. They are rare but have been noted in Proteusmirabilis .
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Class III enzymes: these are plasmid mediated TEM and SHV types. The TEM
enzymes are the most commonly encountered plasmid mediated Beta-lactamases
among clinically resistant isolates (to penicillins and cephalosporins) world-wide.
Class IV enzymes: the most important enzymes of this group are those produced
by Klebsiella spp.
Class V enzymes: are a heterogeneous group of plasmid mediated Beta-
lactamases and include the oxacillin hydrolysing enzymes such as OXA-I, OXA-2
and OXA-3 and the Pseudomonas "specific" enzymes (carbenicillinases) i.e. PSE-
1,2,3,4.
Neu (1986b) added a Class VI - found in Bactericides spp. which
hydrolyse cephalosporins better than penicillins and is inhibited by cloxacillin,
carbenicillin, clavulanate but not cefoxitin.
Table 6 shows the early and continuing confusion resulting from multiple
classification schemes (Table 4 of Richmond & Sykes ,1973)
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Table 6.
Correlation of the Jack & Richmond (1970) Classification with the Scheme
used in Richmond & Sykes (1973) and in Richmond et al. (1971)
Classification in Jack & Richmond (1970) Classification in R&S (1973) and in
Table 3 of Richmond etal. (1971)









Nevertheless this scheme has been widely used since, until an update was
proposed by Bush (1988) and delineated by her ( Bush, 1989 a,b,c).
It is interesting to note two statements made in this paper (Richmond &
Sykes,1973): "Against this diffuse background, there have been a number of
attempts to group the enzymes in various categories since there appears to be an
instinctive feeling among workers in this field that the evolutionary pattern of a
group of organisms will have given rise to a number of different categories of
Beta-lactamase which should be reflected in their detailed properties, even if the
evolutionary source of all the molecules is ultimately the same. This may,
however, be pure illusion. In the last analysis the only information that gives any
reliable indication as to the absolute similarity of the proteins is their polypeptide
sequences, and we are still some way from obtaining this information for more
than one of the enzymes concerned. But a number of arbitrary tests have been
used to aid classification; the only rationale behind the choice of those used being
that they do in fact give some sort of pattern within the whole range encountered
so far". Perhaps the first allusion to the need for a more definitive classification
based on molecular structure?
"One must admit, however, that the complexity of Beta-lactamase
classification will soon require the full treatment by the formal techniques of
numerical taxonomy".
Sykes and Matthew (1976) modified the classification of Gram negative
Beta-lactamases by essentially subdividing them into: those normally mediated by
the bacterial chromosome; or by a transmissible R plasmid; and by inclusion of
the enzyme's isoelectric point (pi) as obtained by the newly applied technique of
isoelectric focusing described by Matthew et a/.(1975).The other parameters
employed were:
1. Relative rate of hydrolysis (substrate profile)
2. Inhibition by pCMB and cloxacillin
3. Inducible or constitutive
4. Molecular weight





c) broad spectrum enzymes
R Plasmid mediated
a) those that do not hydrolyse methicillin or isoxazolyl Beta-lactams
b) those that do hydrolyse methicillin and isoxazolyl Beta-lactams
The importance of this paper is two fold. Firstly it splits Beta-lactamases
into chromosomally mediated and plasmid mediated enzymes. At that time
plasmid mediated Beta-lactamases were of considerable clinical importance as the
mediators of Beta-lactam resistance and novel enzymes were about to appear
rapidly. Secondly the use of analytical isoelectric focusing was:
i) going to be the most important method used to distinguish novel plasmid
mediated Beta-lactamases (until the appearance of 3GC plasmid mediated Beta-
lactamases with similar isoelectric points to previously known enzymes, in the
mid 1980's).
ii) going to be the "splitters" dream but the "lumpers" nightmare in the
classification of these enzymes because many new plasmid mediated enzymes
required classification and it had shown that chromosomal Beta-lactamases are
probably genus, species, and subspecies specific (Matthew & Harris, 1976).
As the plasmid mediated group of Beta-lactamases grew in terms of its
size and importance it became clear that Group III and IV of the Richmond and
Sykes classification provided insufficient criteria for such a large and diverse
group of enzymes.
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Several different classification and nomenclature schemes for plasmid
mediated Beta-lactamases therefore were published. However,this then led to
considerable confusion (Mederios, 1984). This is best exemplified by Table II of
that paper ( Table 7).
Table 7.
Nomenclature of plasmid-determined Beta-lactamases (Mederios, 1984)




TEM-1 Type la TEM-1,typel Ilia
TEM-2 Type lb Ilia
SHV-1 TEM-1,type2 IV
HMS-1
OXA-1 Type II Va
OXA-2 Type III Vb
OXA-3 V




Meanwhile others who were more interested in chromosomally mediated
Beta-lactamases were equally confused. Mitsuhashi and Inoue (1981) split
chromosomal enzymes into two groups i.e. cephalosporinases and cefuroximases.
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The Richmond & Sykes class la, lb, Ic and Id enzymes were easily
confused with the Mitsuhashi la and lb plasmid mediated Beta-lactamases and the
Bacillus cereus type I enzyme (Sanders 1987).





4. broad spectrum Beta-lactamases
As can be seen all the above classification systems firstly rely heavily on
biochemical "substrate profiles" coupled with the effects of inhibitors and
secondly (particularly in the case of plasmid mediated Beta-lactamases) on the
isoelectric points of the enzymes.
These biochemical classifications have important drawbacks:
1. Substrate profile
This is usually expressed as the rate of hydrolysis or Vmax which is
related, as a percentage, to that of a standard substrate e.g. penicillin ,
cephaloridine or in the case of weak enzymes , nitrocephin. This allows the
enzymes to be categorised simply as cephalosporinases or penicillinases or more
specifically as e.g. carbenicillinases. However this takes no account of the
enzymes affinity for the substrate (Km). Listing hydrolysis data without including
the Km value has been criticised on many occasions (Amyes, 1987; Bush &
Sykes, 1986; Livermore, 1987). It has also been noted that individual rates of
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hydrolysis for the same enzyme may vary widely between one laboratory and
another.
2. Isoelectric point
Since its description in 1975 (Matthew et al., 1975) pi has "become one
of the most critical assays used to verify the identity of Beta-lactamases (Bush,
1988). However with the recent explosion of "extended broad spectrum" (EBS)
plasmid mediated Beta-lactamases, often with identical or similar pi's, it has
become clear that the only conclusive method to identify and, therefore, classify
them is by analysis of their amino acid sequence. This is exemplified by five
recently described enzymes which have isoelectric points of 5.55 + 0.05 (Quinn et
al., 1989)
3. Structural relationships
Biochemical classification systems do not consider the structural
relationships between Beta-lactamases which are central to enabling meaningful
structure-activity correlations. Such information will be of considerable
assistance in the future design and synthesis of new Beta-lactam compounds
(Baurenfeind, 1986). An understanding and comparison of the primary,
secondary and tertiary structure of Beta-lactamases is crucial to the fascinating
study into the evolution of these proteins.
Another more minor criticism of the previous classifications has been that
they do not include Beta-lactamases produced by Gram positive species (Bush,
1988).
In summary the biochemical classifications of the Beta-lactamases can be
viewed as minor variations (often confusing) of a central theme which has
obvious drawbacks.
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Therefore in 1980, Ambler proposed a scheme in which Beta-lactamases
are classified by the molecular characteristics of the proteins, or the genes coding
for them.
This, perhaps cynically, may be viewed as:
(i) finally clarifying the classification of Beta-lactamases.
or
(ii) confusing the situation even further.
Ambler (1980) himself apologised for imposing a new nomenclature.
However, as I hope the following text will show, it was an important
breakthrough and greatly aided our understanding of Beta-lactamases.
STRUCTURAL CLASSIFICATION FOR BETA LACTAMASES
The central protagonists in the Beta-lactamase story have always
accepted that the knowledge of the primary, secondary and tertiary structures of
these proteins would be crucial to their understanding of their evolution and
function and would therefore provide their ultimate classification. (See previous
quote from Richmond & Sykes, 1973).
The molecular biologists have always been in the vanguard of such
thought. Pollock (1967) in the conclusion of his paper entitled "Origin and
Function of Penicillinase: A problem in Biochemical Evolution" stated:
"All these scrappy and indecisive points, the indirect and circumstantial
evidence, and the speculative and perhaps tenditious arguments may seem rather
naive and primitive attempts for tackling so difficult and huge a problem as
biochemical evolution, albeit of a single enzyme type. But here and there a few
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indications and direction pointers have emerged, most of them leading towards a
demand for greater information on the amino acid sequences of more and more
enzymes".
Twenty-one years later Bush (1988) wrote: "Within the last decade a
combination of efforts by protein biochemists and molecular biologists has made
the subject of Beta-lactamase taxonomy more scientific and less empirical". A
year later Bush (1989a) went on to state: "All major Beta-lactamases will
eventually be sequenced, thus allowing meaningful correlations between structure
and function to be made". But she went on, in true biochemical style, to say:
"However, the biological activity associated with the enzyme should be
emphasised as the most relevant attribute to a novel Beta-lactamase".
In 1980, Ambler on the basis of the amino acid sequences of
Staphylococcus aureus PCI, Bacillus licheniformis 749/C, Bacillus cereus 569/H
(Beta-lactamase type I) and E. coli plasmid mediated TEM-2, proposed that they
all belonged to one homology group which he called Class A. On the basis of
differences in mechanism and size, coupled with "apparent lack of sequence
homology" with the metalloenzyme B.cereus Beta-lactamase type II he also
proposed the Class B group. This was to be confirmed later by full sequencing
(Hussain etal., 1985).
With the significant advances in molecular techniques of cloning;
probing; amino acid and nucleotide sequencing that has taken place in the last
decade - enough Beta-lactamase sequences have been elucidated to allow, at least,




These enzymes all have a serine residue at their active sites and have
molecular weights of around 29,000. They have significant amino acid homology
and are either penicillinases or broad spectrum Beta-lactamases. Class A enzymes
also show considerable homology with some D-alanine carboxypeptidases
(PBP's) which will be discussed further later.
Based on the sequences of 18 Beta-lactamases of the Class A group,
Huletsky et al. (1990) have contributed a phylogenic tree by the progressive
alignment method (see fig. 7 ). Their data "suggested that the Beta-lactamases of
Gram positive Streptomyces, Staphylococcus and Bacillus spp. appeared early in
evolution, followed by the PSE and CARB enzymes of Pseudomonas species and,
more recently by the SHV type and TEM type enzymes found in enteric bacteria".
Recently, Ambler et al. (1991) have proposed a standardised numbering
system for the amino acid sequences of the Class A Beta-lactamases (ABL
numbers - Class A Beta-Lactamase ). This should allow for a more meaningful
comparison of homologous residues within different Class A enzyme sequences.
Class B (metalloenzvmes)
This includes the metalloenzymes of Bacillus cereus II a
cephalosporinase which requires a metal cofactor - normally Znll (Davies &
Abraham,1974). Recently, Thomson & Malamy (1990) and Rasmussen et al.

















































Cladogram of Class A B-lactamases (after Huletsky etal., 1990).
The cladogram was constructed with the progressive method of Feng & Doolittle (1987).
Branch length values represent relative phylogenetic distances.
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Although these enzymes show only 33% and 32% sequence similarity
with the sequence of Bacillus cereus II, the Zn ligand binding and Cys residues
are precisely conserved and the amino acids in the vicinity of these sites are highly
conserved > 80% when the two proteins are compared.
The other metalloenzymes e.g. from Flavobacterium odoratum (Sato et
al., 1985); Aeromonas sobria and Aeromonas hydrophila (Iaconis & Sanders,
1990); Legionella gormanii (Fujii et al., 1986); Xanthomonas maltophilia - LI
AA.
(Saino et al., 1982 and Bicknell et al., 1985) and Pseudomonas aerginosa,
GN17203 (Watanabe et al., 1991) may yet be included in this group.
Class C
This group was proposed by Jaurin and Grundstrom (1981) though
Ambler had speculated on its necessity (Ambler, 1980). They analysed the amp C
Beta-lactamase of E. coli K12 and showed no significant homologies with Class
A enzymes or with D-alanine carboxypeptidase. Confirmation of this group was
shown by Knott-Hunziker et al.( 1982a); Joris et al. (1986) and Lindberg &
Normark (1986).
The molecular weights of these enzymes were found to be around 39,000
as opposed to those of Class A enzymes at around 29,000.
Recently it has been proposed that a novel plasmid-mediated Beta-
lactamase (MIR-1), which confers a broad spectrum of resistance (including 3rd
generation cephalosporins and cefoxitin but which is not inhibited by sulbactam or
clavulanic acid) is a Class C Beta-lactamase (Papanicolaou et al., 1990). Their
evidence for this is that the provisional sequence of 150bp of the MIR-1 gene is
90% identical to the sequence of ampC from Enterobacter cloacae but only 71%
identical to that of E. coli. The latter was used to explain why a probe for E.coli
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ampC gene had failed to hybridise with MIR-1. TEM-1 and SHV-1 probes also
failed to hybridise with MIR-1.
Although these workers felt that this was the first documented example of
a plasmid-mediated "chromosomal" cephalosporinase it is likely that this is not
the case. Woodford et al. (1990) previously described in E. coli a plasmid
mediated enzyme resembling a chromosomally mediated Beta-lactamase of
Enterobacter cloacae which conferred resistance against all penicillins, 1st, 2nd,
3rd generation cephalosporins and to clavulanic acid. This enzyme, named BIL-
1, would seem to be a Class C Beta lactamase but as in the case of MIR-1, a full
nucleotide sequence of the gene is awaited.
Nevertheless as Papanicolaou et a/.(1990) stated "The presence of such a
resistance determinant on a plasmid raises concern for rapid dissemination among
Gram negative bacilli and the possible loss of effectiveness of the alpha-methoxy
Beta-lactams".
Class D
OXA-1 and OXA-2 enzymes share greater than 48% homology but show
no significant homology with the TEM enzymes nor with the Class A or Class C
Beta-lactamases except at the region adjacent to the active site. No homology
exists between the OXA and Class B Beta-lactamases. Ouellette et a/.(1987)
therefore proposed that the OXA-1 and OXA-2 be designated as Class D.
The nucleotide sequence of PSE-2 Beta-lactamase was determined by
Huovinen et al.(1988) and was found to have distinct homology with the
sequence of OXA-2 as previously deduced by Dale et al. (1985). He therefore
suggested that, since neither of these enzymes exhibited structural similarities with
TEM-1 or ampC Beta-lactamases, they should be put in a new Class D. Jacoby
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(1988) demonstrated that the amino acid sequences of OXA-1, OXA-2 and PSE-
1, PSE-2 showed greater homology between each other than with TEM-1.
Levesque (1988) has also reported that the sequence of OXA-5 shows greater
homology with the PSE and OXA enzymes than with TEM-1.
Although hybridisation studies have illustrated that PSE-4 shows
homology with the PSE enzymes, the nucleotide sequence of this gene has shown
a 50% homology with TEM-1, (Boissinot & Levesque, 1990). Consequently it
has been placed in Class A.
?Class E
It has been suggested by Sanders (1989) that the L-l metalloenzyme
described in a strain of Xanthomonas maltophilia (Saino et al., 1982; Bicknell et
al., 1985) should be designated into a new Class E since its N-terminal amino acid
sequence and biochemical properties show no similarity to these of Bacillus
cereus II metalloenzyme of Class B (Bicknell et al., 1985).
This is highly speculative and we will await the full nucleotide sequence
of the gene encoding this enzyme before confirming this new class.
We await even more keenly the sequence of the gene encoding the
plasmid mediated Beta- lactamase which confers imipenem resistance in a strain











Bacillus cereus type I
Bacillus cereus type III
Klebsiella pneumonia K1 (SC10436)
Klebsiella pneumonia (LEN-1)









Wang & Novick (1987)
Houba et al. (1989)
Ambler (1980)
Neugebauer et al. (1981)
Ambler (1980)
Sloma & Gross (1983)
Wang et al. (1985)
Madonna et al. (1987)
Madgwick <z/.(1987)
Hussain et al. (1987)
Joris et al. (1987)
Arakawa et al. (1986)
Emanuel et al. (1986)
Arakawa et al. (1989)
De Meester et al. (1987)
Dehottay etal. (1987)
Reynes et al. (quoted by Eluletsky et al.
1990)
Forsman et al. (1990)
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De Meester et al. (1987)
Lenzini et al. (1988)
Forsman et al. (1990)
Forsman et al. (1990)
Forsman et al. (1990)
Campbell et al. (1989)
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Beta-lactamase Reference
CLASS A Plasmid mediated
TEM-1 Sutcliffe (1978)
TEM-2 Ambler & Scott (1978)
Barthelemy etal. (1985)
Chen & Clowes (1987
TEM-3 Sougakoff etal. (1988)
TEM-4 Sougakoff etal. (1989)
TEM-5 Sougakoff etal. (1989)
TEM-6 Goussard etal. (1989)
Mabilat & Courvalin (1990)
TEM-7 Collatz et al. (1989)
TEM-8 Mabilat et al. (1989)
Mabilat & Courvalin (1990)
TEM-9 Mabilat et al. (1990)
TEM-10 to TEM-19 Mabilat & Courvalin (1990)
ROB-1 Juteau & Levesque (1990)
Livrelli et al. (1991)
SHV-1 Barthelemy etal. (1988a)
Mercier & Levesque (1990)
SHV-2 Barthelemy etal. (1988b)
Huletsky et al (1990)
Garbarg - Chenon et al. (1990)
SHV-3 Nicolas et al. (1989)











Bacillus cereus type II
Bacteroides fragilis (TAL 3636)
Bacteroides fragilis (TAL 2480)
CLASS C Chromosomal
Escherichia coli (K12)





Billot-Klein et al. (1990)
Shaes et al. (1990)
Boissinot & Levesque (1990)
Lachapelle & Levesque (unpublished
data)(quoted by Huletsky et al. 1990)
Bejaoui & Levesque (unpublished data)
(quoted by Huletsky et al. (1990)
Ambler (1980)
Hussain et al. (1985)
Rasmussen et al. (1990)
Thompson & Malamy (1990)
Knott-Hunziker et al. (1982b)
Knott-Hunziker et al. (1982b)
Lindberg & Normark (1986)
Joris et al. (1984)
Galleni et al. (1988)




CLASS C Plasmid mediated
MIR-1 Papanicolaou etal. (1990)
BIL-1 Woodford et al. (1990)
CLASS D Plasmid mediated
OXA-1 Ouellette etal. (1987)
OXA-2 Dale et al. (1985)
OXA-5 Levesque (1988)
PSE-1 Jacoby (1988)
PSE-2 Houvinen et al. (1988)
CLASS E Chromosomal
Xanthomonas maltophilia LI Bicknell etal. (1985)
(suggested by Sanders, 1989)
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THE SUPERFAMILY OF ACTIVE SERINE ENZYMES:
THE PENICILLIN-RECOGNISING ENZYMES
Gene sequencing has also been used to elucidate the structure of the DD-
peptidases/PBP's (Duez et al., 1987; Broome - Smith et al., 1983; Todd et al.,
1986; Broome - Smith et al., 1985; Asoh et al., 1986 ; Nakamura et al., 1983).
Thus these can be compared with the gene sequences known for Beta-
lactamases together with the secondary and tertiary structures and the active site
environment that has been determined for some of these proteins (Kelly et
al., 1986; Samraoui et al., 1986; Knox et al., 1976; Herzberg & Moult, 1987;
Dideberg etal., 1987; Kelly etal., 1987).
The active-site-serine Beta-lactamases are defensive enzymes; they
hydrolyse the Beta-lactams into inactive metabolites. The active-site-serine DD
peptidases which are involved in bacterial cell wall metabolism, catalyse the
attack of the C-terminal D-alanyl-D-alanine peptide bond in peptidoglycan
precursors. They are inactivated by the Beta-lactam antibiotics whose endocyclic
amide linkage is equivalent to the scissile peptide bond in the peptidoglycan
precursors.
Therefore these two groups of enzymes not only bind similar ligands but
they also operate by a common acyl enzyme mechanism.
Crucial to this mechanism is the transfer of the electrophilic group R-
C=0 of the scissile (peptide, amide) bond to the hydroxyl group of the active-site-
serine residue. The ester-linked acyl-enzymes formed by the reaction with the
DD peptidases are usually very long lived. In contrast those found in the reaction
between the Beta-lactams and the Beta-lactamases are usually very short lived.
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Consequently the Beta-lactam antibiotics are substrates of the Beta-
lactamases and inactivators of the DD peptidases which therefore behave as
penicillin-binding proteins (PPBs) (Cartwright & Waley, 1983; Ghuysen et al.,
1984; Frere & Joris, 1985).
Joris et al. (1988) employed the Streptomyces R61 DD
peptidase/penicillin binding protein as a reference and compared the Beta-
lactamases of Classes A and C; the OXA-2 (as an example of Class D); the low
Mr DD peptidases/PBP's (PBP5 ofE.coli and B.subtilis) and the penicillin binding
domains of the high Mr PBP's of E.coli (PBP1A, PBP1B, PBP2 and PBP3) by
homology searches and amino acid alignments.They produced a tentative family
tree of the penicillin - recognising enzymes ( see fig.8 ).
They stated: "Though the evolutionary distance may vary considerably,
all these penicillin-interactive proteins and domains appear to be members of a
single superfamily of active-site-serine enzymes distinct from the classical trypsin
, ^
or subtil^i families. The amino acid alignments reveal several conserved boxes
that consist of strict identities or homologous amino acids".
Boxes II, III, IV, V, and VI occupy critical positions in the 3D structure
of Staphylococcus aureus and Streptomyces albus G Beta-lactamases. These
workers found that amino acid replacements in each of these boxes affect or
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EVOLUTION AND ORIGIN OF BETA-LACTAMASES
Pollock (1967) described experiments he carried out on the spores of
Bacillus licheniformis which had "lain dormant in the dried soil stuck to the roots
of some plant specimens preserved untouched in the British Museum since 1689".
Sneath (1962) had revived the organisms and Pollock examined the
penicillinases produced by them. They all fell "clearly" into one of the two
groups of penicillinases that existed in the 1960's, both in their substrate profiles
and their immunological reactions. Pollock took this to indicate that no
evolutionary change had occurred in 270 years - an equivalent of 100 million
years of human generation time. In other words long enough "for evolution to
have occured if cell generations were the main operative factor".
In the summary of the paper he concluded: "Consideration of the
evolutionary origin of penicillinase remains highly speculative, though it is clear
that the various forms of the enzyme, as we now know then, pre-existed the
therapeutic penicillin era, the only effect of which, in this context, has been to
increase by natural selection the proportion of bacteria producing them.
Search for a possible penicillinase-ancestor is focused on the only other
known class of protein that must, on a priori reasoning, be capable of specific
combination with penicillin - that is, one or other of the enzymes involved in
biosynthesis of the mucopeptide of the bacterial cell wall, a reaction known to be
specifically inhibited by this antibiotic".
However, Pollock's work was inconclusive and 20 years later, Joris et al.
(1988) have provided some evidence to support this hypothesis. (See previous
section).
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Ghuysen(1988) reiterated that all the active-site-serine, penicillin-
interactive proteins are related in an evolutionary sense and form a superfamily of
enzymes. This he felt was an example of divergent evolution. Depending on the
evolutionary distance, they had acquired: different amino acid sequences; distinct
functionalities; and specificities. Yet they had conserved the same pattern of
polypeptide scaffolding. Divergent evolution means, of course, that these
enzymes have a common ancestor. He made the following points to back up this
theory:
1. The DD peptidases/PBP's are important or even essential bacterial
enzymes, whereas the Beta-lactamases are dispensable unless Beta-lactam
antibiotics are present in the environment.
2. Streptomyces are soil bacteria and one may assume that they were among
the first bacteria to be exposed to Beta-lactam molecules.
3. Streptomyces are the only known bacteria that spontaneously excrete some
low molecular weight DD-peptidases/PBP's during growth.
4. The exocellular DD-peptidase/PBP of Streptomyces R61 occupies an
important position in the family tree of interactive penicillin proteins where it
serves as a bridge between the Beta-lactamases of Class A and the Beta-
lactamases Class C (see fig.8 ).
Ghuysen therefore concluded:"On this basis, one may propose a possible
mechanism for the emergence of Beta-lactamases. The primary response of soil
Streptomyces to exposure to Beta-lactam compounds produced by other micro¬
organisms was to develop an excretion mechanism permitting release of a
membrane bound PBP into the environment and immobilisation of the Beta-
lactam molecules in the form of stable acyl enzymes. Further improvements of
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this detoxication mechanism was the conversion of this water soluble Beta-
lactam-binding enzyme into a Beta-lactam-hydrolysing enzyme by remodelling of
the active site".
This is certainly an attractive and very plausible theory for the origin of
Beta-lactamases. The importance of comparing secondary and tertiary structures
rather than just primary amino acid structure when looking at the evolution of
proteins was stressed by Kelly et al. (1986). "Ancestral origin is difficult or
impossible to establish with certainty. Amino acid sequences change rather
rapidly on the genetic time scale, and they are therefore intrinsically less
informational than the more time-stable three-dimensional foldings that are
maintained in accordance with external entropic and energetic limitations. The
DD peptidase (Streptomyces R61) and Beta-lactamase {Bacillus licheniformis) are
from different species and lack close relatedness in their overall primary
structures. Yet they share the same basic catalytic mechanism, they recognise the
same Beta-lactam compounds, they contain several conserved amino acids in their
active sites, and they exhibit clear similarity in their 3 dimensional structures (see
fig 9). The analogous positioning of secondary structure elements even well away
from the active site, suggests that these enzymes may be another example of
divergent evolution where structural changes required for their distinctive
functions appeared only in the relatively compact catalytic area".
Richmond (1988) widened this hypothesis. He noted that many
organisms have been shown to produce very small amounts of monobactams and
he wondered whether these molecules were widely distributed in bacteria as
"endogenous regulators of peptidoglycan biosynthesis". Presumably he is also
implying, since he feels that peptidoglycan biosynthesis is an extremely
complicated and organised system "where things have to be switched on precisely
and switched off precisely..." that the regulatory effect of the Beta-lactams is itself
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SecondarystructureelementsinB.lich niformis-la a ase(l ft)ndStreptomyc sR61DD-p ptidase(righ ). CylindersarhelicndribbonsreB-stran s. TheknownsitefB-lactambindingitDD-peptidasei dic tedy( f rK llyt.,1986).
regulated by the Beta-lactamases (However there is no experimental evidence to
suggest that this hypothesis is correct).
Therefore perhaps our use of Beta-lactams therapeutically, is analogous
to our use of the morphine-like drugs which are very similar to the naturally
occurring "painkillers" - the endorphins.
The subsequent evolution from a common ancestor is best seen in the
unrooted phylogenetic study of Class A Beta-lactamases by Huletsky et al.,
(1990) (see fig. 7 ).
They observed two major groups of proteins, the Beta-lactamases of
Gram positive bacteria, including BCE5H, BCE5B, BLIP, BCEZ, CACAOI, PCI,
SABLA and ALBUS that presumably appeared early in evolution, followed by
the Beta-lactamases of Gram negative bacteria such as CARB-3, CARB-4, PSE-
4, LEN-1, OHIO-1, SHV-1, SHV-2, TEM-1, and TEM-3. The Gram negative
bacteria were further subdivided into two main groups: the PSE and CARB
enzymes of Pseudomonas spp. followed by the SHV and TEM type enzymes.
In the Gram positive group of bacteria they noted SABLA and ALBUS
Beta-lactamases from Streptomyces spp. at the bottom of the phylogenetic tree
followed by the well known PCI enzyme of Staphylococcus aureus. Surprisingly
close to the PCI enzyme branch was the plasmid mediated ROB-1 Beta-lactamase
from Haemophilus influenzae a Gram negative rod. Presumably this had been
acquired by horizontal gene transfer from a Gram positive organism. This was
followed by the Beta-lactamase from Streptomyces cacaoi. Finally, at the top of
the Gram positive group branch of the tree they found the Beta-lactamases of
Bacillus spp. indicating a more recent derivation of these enzymes.
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In the Gram negative group the PSE and CARB enzymes presumably
branched off early, starting with CARB-4. Next they noted the recent divergence
of the SHV family. LEN-1, the chromosomal Beta-lactamase from Klebsiella
spp. appeared first followed by OHIO-1. SHV-1 and SHV-2 were separated by a
very short evolutionary distance indicating that SHV-2 is a very recent derivative
of SHV-1. The more recent Class A Beta-lactamases found in the cledogram are
the TEM enzymes commonly found in enteric bacteria that are highly related to
SHV-type Beta-lactamases. A very short evolutionary distance also separated
TEM-1 from TEM-3 because of only 3 amino acid substitutions.
These data support the hypothesis proposed in the 1960's by Naomi Datta
that the TEM-1 Beta-lactamase evolved from the chromosomal Beta-lactamase of
Klebsiella pneumoniae. This was also proposed by Arakawa et al. (1986) and
Arakawa et al. (1989).
Interestingly the structural subgroupings delineated by Huletsky et al.
(1990) seem to be directly related to the biochemical properties of these enzymes.
The SHV and TEM enzymes are members of the broad spectrum enzymes of
Class 2b and 2b'; PSE and CARB enzvmes are Class 2c; and the Beta-lactamases7 j 7
of the Gram positive bacteria are penicillinase enzymes of Class 2a of Bush's
classification system (Bush, 1989 a,b,c).
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THE BIOCHEMISTS STRIKE BACK: THE BUSH CLASSIFICATION
In 1986, Bush and Sykes published a much needed set of guidlines in the
hope of standardising the study of Beta-lactamases. They felt this was necessary
because of the plethora of new Beta-lactamases and the, correctly perceived, need
for a more detailed knowledge of their kinetic parameters rather than the simple
substrate profiles that had sufficed in the past. The hope was that with
standardised methodology more meaningful "structure - activity relationships and
mechanistic interpretations" could take place.
The requirements included:
1. ideally a homogeneous enzyme preparation (95% pure)
OR at least
2. a single Beta-lactamase activity on IEF
3. a specific activity ( pmol substrate hydrolysed per minute per mg of
protein) for partially pure enzyme, OR a K cat value for a homogenous
enzyme with a standard substrate
4. hydrolysis data - K m and Vmax values to cephaloridine and penicillin or
nitrocephin (if only weak activity is detected )
5. inhibition studies - with well characterised inhibitors such as : clavulanic
acid , sulbactam , cloxacillin and aztreonam; EDTA, pCMB , and boronic
acids - carried out under defined conditions
6. induction studies - using antibiotic levels likely to be encountered
extracellularly.
The logical step was then to create a new classification for the Beta-
lactamases employing the data derived from such a standard methodology and
incorporating it with the structural data (if available) from the same enzymes.
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After all, in structure - activity relationships there must be data relating to the
biochemical activity of the enzyme.
Therefore Bush (1988) proposed a scheme which incorporated both
biochemical and molecular aspects and divided the enzymes into 3 classes,
Subsequently Bush (1989a,b,c) expanded this classification into 4 groups
to include most Beta-lactamases known at that time. The parameters employed
were:
(i) genetic location - chromosomal or plasmid




(vi) molecular class (if known)
The general outline of this scheme is shown in Table 9.
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Table 9. General classification scheme for bacterial ^-lactamases
Group Subtitle Preferred Inhibited by: Representative enzyme(s)
substrates
CAa EDTA
1 CEP-N cephalosporins No No Chromosomal enzymes
from Gram negative
bacteria
2a PEN-Y penicillins Yes No Gram positive
penicillinases
2b BDS-Y cephs & pens Yes No TEM-l.TEM-2
2b' EBS-Y cephs,cefotaxime Yes No TEM-3,TEM-5
2c CAR-Y
& penicillins
pens,carbenicillin Yes No PSE-l,PSE-3,PSE-4
2d CLX-Y pens,cloxacillin Yesb No OXA-l,PSE-2
2e CEP-Y cephalosporins Yes No Proteus vulgaris
3 MET-N variable No Yes Xanthomonas maltophilia
LI, Bacillus cereus II
4 PEN-N penicillins No ?c Pseudomonas cepacia
lOpM clavulanic acid ; Inhibition by clavulanic acid may occur at higher concentrations for some
c
members of the group.; Variable. (Taken from Bush , 1989a ).
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It is clear that this scheme will serve to differentiate the Beta-lactamases
that have been described to date and will provide the necessary framework for the
classification of additional enzymes as they become described. It will also serve
as the corollary to the structural information elucidated from the Ambler
classification of these enzymes.
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THE PAYNE-AMYES CLASSIFICATION OF THE PLASMID-MEDIATED
EXTENDED-SPECTRUM BETA-LACTAMASES
These authors provide us with the most recent subclassification of beta-
lactamases (Payne & Amyes, 1991) They feel that since there are now, at least,
27 reports of transferable genes encoding resistance to the broad spectrum
cephalosporins - there needs to be a classification scheme. They acknowledge
that a structurally based scheme is important, but some way off as all the genes
need to be sequenced. Therefore they have classified these enzymes into 4 groups
based on their relative efficiencies of hydrolysis to cefotaxime and ceftazidime.
Group 1
Enzymes that hydrolyse cefotaxime and ceftazidime with poor efficiency,
cefotaxime > ceftazidime, paradoxically since all the group 1 enzymes confer
greater resistance to ceftazidime than cefotaxime. This may be explained by their
different permeability characteristics (Nikaido, 1990).
Group 2
3GC enzymes that hydrolyse ceftazidime more efficiently than cefotaxime.
Group 3
3a. TEM - derived
3b. SHV - derived
3c. unknown derivation
Most enzymes in this group confer a greater resistance to ceftazidime.
Group 4
This group contains Beta-lactamases that confer resistance to all generations of
cephalosporins and clavulanic acid eg BIL-1 (Woodford et ai, 1990) and
MIR-1 (Papanicolaou etal., 1990).
It would seem likely that there should now be a Group 5 to include the
plasmid mediated imipenemase described by Watanabe et al. (1991).
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NEW FORMS OF RESISTANCE TO THE BROAD SPECTRUM BETA-
LACTAM ANTIBIOTICS IN GRAM NEGATIVE BACTERIA
I have previously briefly alluded to the evolution of this form of bacterial
resistance (Weidemann etal., 1989).
The broad spectrum cephalosporins, carbapenems and monobactams
were developed essentially to deal with the Beta-lactamase producing Gram
negatives that were resistant to ampillicin and the ureidopenicillins (Jacoby &
Archer, 1991). Bacteria have met this challenge in several ways.
Chromosomally-mediated resistance to the broad spectrum Beta-Iactamases
By the mid 1980's clinical microbiology laboratories began to report
resistance to these new extended spectrum Beta-lactams in Gram negative
bacteria. This was due to hyperproduction of the chromosomal class I (AmpC)
Beta-lactamases in these species. Hyperproduction of these enzymes can occur in
one of two ways.
(i) In species such as Enterobacter, Pseudomonas, Serratia, Citrobacter,
indole positive Proteus and Providencia hyperproduction can arise transiently as a
result of induction. (Sanders & Sanders, 1988).
(ii) In the same species hyperproduction can occur on a permanent basis via
mutation of the regulatory gene - the production of stably derepressed mutants
(SDM).
SDM can be produced at a frequency of between 10"5 and 10~10
depending on the species, strain and selection conditions (Philiipon, 1987;
Weidemann, 1986).These mutants have the same broad spectrum of resistance as
strains which produce high levels of cephalosporinase after induction and
consequently, confer resistance to all generation of cephalosporins (Curtis et al.,
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1986). The importance of inducible Beta-lactamases and SDM is reviewed by
Sanders & Sanders (1988).
Livermore (1987) has characterised the Beta-lactam drugs into either
labile or stable substrates and strong or weak inducers of the chromosomal Beta-
lactamases. This is shown in Table 10.
Table 10. Chromosomal cephalosporinases : expression and resistance
Compound Behaviour Susceptibility Selection pressure
for SDM
I SDM B











B = basal p-lactamase production
I = inducible (5-lactamase production
SDM = p-lactamase stably derepressed production
(After Livermore ,1987)
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Livermore's thesis being ,that it is the labile and weak inducers that
provide strong selection pressure for SDM. Since they are resistant, these mutants
have an advantage over the inducible cells when challenged with labile, weak
inducers e.g. the newer cephalosporins. They easily overrun the population both in
vitro and in vivo and once selected they continue to manufacture large quantities
of enzyme even when the inducer is absent.
However, the turnover numbers (kcat) for cefuroxime, most third-
generation cephalosporins, monobactams and carboxypenicillins are extremely
low, therefore they are "stable" poor substrates - so why are the organisms
producing these chromosomal Beta-lactamases resistant?
The resistance is explained by two broad models. The arguments raged
through the early 1980's as to which of these theories was correct.
"Trapping" or "sponge" theory
Then & Angehrn (1982) and Gutmann & Williamson (1983) proposed
that the low Km of these enzymes (i.e. their high affinity for the 3GC substrates)
"trapped" and inactivated these antibiotics in non-covalent E.S complexes or
covalent E-S complexes (see fig. 6 ). Covalent "trapping" is often suggested in the
cases of aztreonam and moxalactam (though the debate still rages even in the case
of these drugs: Hewinson el al., 1989; Livermore, 1989). Non-covalent "trapping"
is viewed as reversible while covalent "trapping" is irreversible.
Efficient-hydrolysis model
It is now felt that the major factor in 3GC resistance is Beta-lactamase
hydrolysis of these "stable" substrates. Vu and Nikaido (1985) proposed that the
assays of in vitro hydrolysis were misleading. Firstly the enzyme concentrations
are 100 - 10,000 - fold lower than those in the periplasm resulting in the
significance of slow hydrolysis being underestimated and secondly the high
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enzyme-antibiotic affinity ensures that the drug turnover remains fully efficient
even at very low drug concentrations.
Clearly slow entry of the drug into the bacterial cell is a fundamental
assumption of both models. It is suggested therefore that the Beta-lactamase
molecules are able to prevent the periplasmic drug concentration rising to toxic
levels since the rate of drug influx through the outer membranes is extremely
slow. If such a barrier did not exist the enzyme would rapidly be overwhelmed.
Livermore (personal communication) perhaps sums this up well with the
analogy of a few soldiers guarding a narrow pass against a much larger army.
Which is the most important - the soldiers or the narrowness of the pass?
Clearly an understanding of the genetic control of the chromosomal Beta-
lactamases is required in order to circumvent the clinical problems that result from
induction and the selection of SDM. This is as yet poorly understood and I refer
the reader to the following : Kobayashi et al., 1982; Lindberg et al.,
1988; Korfmann & Sanders, 1989; Oliva et al., 1989; Everett et al., 1990; Normark
et al., 1990.
Plasmid-mediated resistance to the broad spectrum Beta-lactamases
(extended broad spectrum, EBS)
In 1979, Matthew el al. described the properties of 11 plasmid mediated
Beta-lactamases which were easily differentiated by their isoelectric points on
IEF. In epidemiological studies it became clear that TEM-1 was the commonest
plasmid-encoded Beta-lactamase (60% of all plasmid mediated Beta-lactam
resistance in E.coli) (Simpson et al., 1980; Roy et al., 1983; Medeiros, 1984).
SHV-1 is also frequent in Klebsiella pneumoniae and PSE-1 is common in
Pseudomonas aeruginosa (Medeiros, 1989)
The success of these enzymes seems firstly to be due to the fact that the
resistance genes are located on transposons and secondly because they are
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extremely efficient at hydrolysing penicillins and many first generation
cephalosporins (but not second or third generation) (Payne & Amyes, 1991).
The first report of transferable cefotaxime resistance came in 1983 from
West Germany (Knothe et al., 1983) in three strains of Klebsiella pneumoniae and
one of Serratia marcescens. This enzyme was found to be a modification of the
ubiquitous klebsiella enzyme SHV-1 and was called SHV-2 (Kliebe et al., 1985).
Subsequently, Payne et al.{1989 & 1990) have shown that the earliest EBS
enzyme originated from an English strain in 1982. Since their discovery in 1983
there has been a large number of publications from every continent describing
"novel" EBS Beta-lactamases.
Nearly all of these new enzymes appear to be modifications of either the
TEM or SHV groups of Beta-lactamases (Philippon et al.,1989). See Table.ll.
Therefore the bacteria have evolved not in this case by mutation of the
gene controlling the production of the Bcta-lactamase but by mutation of the
structural gene itself.
Many have shown that EBS can be easily obtained spontaneously from
TEM-1/2 or SHV-1 in vitro (See Payne & Amyes, 1991).
There now has been at least 27 reports of transferable genes encoding
3GC resistance. One particularly worrying aspect of these new resistances has
been that the organisms were resistant not only to Beta-lactams but also other
classes of antimicrobials e.g. aminoglycosides, tetracyclines, sulphonamides,
quinolones, chloramphenicol and trimethoprim. (Sirot et al., 1988).
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Table 11. Differences in amino acid substitutions among sequenced broad
spectrum ^-lactamases and related enzymes. Italicized amino acids indicate
differences from the first enzyme in the series
Amino acid substitution a
Enzyme 37 102 162 235 236 237 261
TEM-1 Gin Glu Arg Ala Gly Glu Thr
TEM-2 Lys Glu Arg Ala Gly Glu Thr
TEM-3 Lys Lys Arg Ala Ser Glu Thr
TEM-4 b Gin Lys Arg Ala Ser Glu Met
TEM-5 Gin Glu Ser Thr Gly Lys Thr
TEM-7 Lys Glu Ser Ala Gly Glu Thr
SHV-1 Gin Asp Arg Ala Gly Glu Leu
SHV-2 Gin Asp Arg Ala Ser Glu Leu
a
Amino acid positions are numbered according to Sutcliffe (1978).
Also, substitution of Phe at position 19 for Leu.
After Philippon, Labia & Jacoby (1989)
Other factors that are important about EBS Bcta-lactamases arc:
(i) they are well inhibited by existing Beta-lactamase inhibitors such as
clavulanic acid, sulbactam and tazobactam (Bush & Singer, 1989;
Gutmann etal., 1989).
(ii) they have greater affinities than their parent enzymes for both the
inhibitors and substrates but their total activities are several orders of
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magnitude lower than that of the older TEM enzymes when measured
against penicillin and cephaloridine. Their kcat values against the 3GC's as
substrates are also low. Thus, although they have a wider spectrum of
hydrolytic activity they are "functionally lazy offspring of the classical
Beta-lactamases", Bush (1989d).
(iii) the majority of these new Beta-lactamases have been reported to be
produced by less than ten clinical isolates. This suggests that they are not
spreading as one particular "epidemic" enzyme i.e. no one particular
enzyme has been able to predominate and spread in the manner of TEM-1
(Payne & Amyes, 1991). Only one enzyme (TEM-3) has been responsible
for nearly 500 clinical isolates in French hospitals (Sirot et al., 1988) but
with no worldwide or even countrywide pandemic.
Therefore it has been suggested that these enzymes at present are more of
an inconvenience than a major threat (Payne & Amyes, 1991). However as they
themselves said: "these are still early days and our controlled use of later
cephalosporins will probably determine whether we can keep these enzymes as a
minor inconvenience rather than let them emerge as a major threat".
Only the future will reveal whether other recently described novel transferable
broad spectrum Beta-lactam resistance - such as BIL-1 (Woodford et al., 1990),
MIR-1 (Papanicolaou et al., 1990) and the plasmid mediated imipenemase of
Watanabe et al., (1991) - will pose an even greater threat and perhaps return us to




Acinetobacters are short, plump Gram negative rods that are often
coccoid in the stationary phase. The cells commonly occur in pairs or chains and
they can be difficult to destain. Although they have no flagella and are considered
to be non-motile, "twitching" and "gliding" motility has been described on semi¬
solid media (Barker & Maxted, 1975; Henrichsen, 1975). Many strains are
capsulated. All acinetobacter are non-fastidious strict aerobes which are catalase
positive and oxidase negative. Most will grow on simple media with a single
carbon and energy source between 20 and 30°C. The GC content is 38-45 mol%.
(Towner et al, 1991).
TAXONOMY
The only word that can accurately be used to describe the taxonomy of
Acinetobacter is confused. Only recently, has some sense finally prevailed with
the development of a reasonable taxonomic scheme (Bouvet & Grimont, 1986 ;
Grimont & Bouvet, 1991).
Historical perspective
Excellent reviews by Baumann et al. (1968), Henriksen (1973 & 1976) and Juni
(1978) provide us with much information on the long and varied history of these
organisms.
In 1911, Beijerinck isolated an organism from the soil, this he named
Micrococcus calco-aceticus, but he did not describe it. This organism was stored,
however, and subsequently re-examined and found to be very similar to
organisms that in the intervening years were described as: Bacterium anitratum,
Moraxella glucidolytica and Neisseria winogradski (Henriksen, 1973).
90
Henriksen (1937) described Alcaligenes haemolysans,a similar but
strongly haemolytic organism, which differed from the above by not producing
acid from sugars.
In 1939, De Bord introduced a new "tribe" name for the Neisseria - like
bacteria - Mimeae, since they "mimicked" Neisseria. The type species was named
Mima polymorpha and De Bord (1942) subsequently described two other genera -
Herellea vaginicola and Colloides anoxydana. Mima polymorpha was not
described in significant detail for the Code of Nomenclature, and Andureau
(1940) described more closely a similar organism under the name of Moraxella
IwoffiL H. vaginicola has subsequently been confused with B. anilratum,
however, Henriksen (1973) feels that they differ markedly and were not likely to
be the same organism. Its name {H.vaginicola) was subsequently rejected
(Judicial Commission, 1971).
Colloides anoxydana was found to be biochemically identical to
Citrobacter therefore this name too suffered the same fate as De Bord's other two
proposed species.
Schaub & Hauber (1948) described an organism which they called
Bacterium anitratum, Piechaud et al. (1951) described a similar organism as
Moraxella Iwoffii var glucidolytica (after, elevated to M. glucidolytica). Brisou
and Morichau- Beauchant (1952) showed that these two organisms were identical.
Lemoigne et al. (1952) further confused the issue by describing an
identical organism as Neisseria winogradski .
In 1954, Brisou proposed the inclusion of B.anitratum in the genus
Achromobacter for the non-motile species of Acinetobacter. At this time it
included both the oxidase-positive (Moraxella) and the oxidase negative strains.
Shortly after this Acinetobacter flirted briefly with several other bacterial
genera. Lautrop (1961) suggested transfer of B.anitratum to the genus Cytophaga
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but this was based solely on, supposed, "gliding and creeping motion" of the cells
of B.anitratum. Lautrop (1965) himself changed his mind shortly after.
Seeliger et al. (1968) assumed that the organism, previously very briefly
described by von Lingelsheim (1906) as Diplococcus mucosus, was identical to
B.anitratum/M.glucocidolytica. They consequently proposed transfer of these
species into a new genus Lingelsheima.
Henricksen (1973) disagreed strongly stating that the original von
Lingelsheim strains had not survived to allow their proper characterisation and
that their original description was too vague.
Delineation of the genus
The genus Acinetobacter was again exhumed by Baumann et al. (1968) who
showed by nutritional studies that the oxidase-negative strains clearly differed
- fosifiVe
from the oxidase'strains within the genus Moraxella.
In 1971 the subcommittee of the Taxonomy of Moraxella and Allied
Bacteria proposed that the genus Acinetobacter should include only the oxidase-
negative strains. It was classified in the family Neisseriaceae and originally as
only one species : A.calcoaceticus.
The genus was well delineated by the transformation studies of Juni
(1972). DNA from oxidase-negative strains of Moraxella {Acinetobacter spp) was
found to transform a competent strain (strain BD413 trpE 27) of that group, but
DNA from oxidase-positive strains failed to transform this strain.
Acinetobacter strains were therefore seen as a natural group distinct from
the genera Moraxella and Neisseria. Grimont and Bouvet (1991) gave the current
definition of the genus Acinetobacter (which was adapted from Juni, 1984) as:
"strictly aerobic, non motile, oxidase negative coccobacilli; Gram-negative, but
sometimes difficult to destain; grows well on complex media between 20 and
30°C without growth factor requirements; nitrates are rarely reduced; extracted
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DNA is able to transform strain BD413 trpE 27; the G and C content of the DNA
is between 39 and 47mol/%
Van Landschoot et al.(1986) described the genus Acinetobacter as a
discrete phylogenetic branch in superfamily II of the Proteobacteria. The closest
genera being: Moraxella, Pseudomonas (fluorescent group), and Xatithomonas
(Woese et al., 1985 and Van Landschoot el al., 1986).
Recently, Rossau et al. (1991) have proposed a new bacterial family: the
Moraxellaceae fam. nov. to accommodate the genera: Moraxella, Acinetobacter
and Psychrobacter. Thus finally removing these genera from the family
Neisseriaceae. Henricksen (1976) felt this split was necessary but perhaps felt that
Acinetobacter should form a family of its own: the Acinetobacteriaceae!
Delineation of species within the genus
Only two species (A.calcoaceticus and A.lwoffii are on the Approved
Lists of Bacterial Names (Skerman et al., 1980) and only one species
(A.calcoaceticus) is described in Bergey's Manual of Systematic Bacteriology
(Juni, 1984). However the studies of Baumann et al. (1968) and Johnson et al.
(1970) have shown that the genus is clearly heterogeneous both biochemically and
genetically.
Using DNA hybridisation techniques, Bouvet and Grimont (1986)
identified 12 hybridisation (genomic) groups. Ten genomic species could be
identified by phenotypic tests (including carbon source utilisation).
Subsequent work (using genetic transformation, DNA hybridisation and
RNA sequence comparisons) has resulted in the identification of 17 genomic
species and 19 biotypes. The major genomic species comprises A.baumannii (9
biotypes), Acinetobacter sp. 3 (6 biotypes) , A.haemolyticus, A.johnsonii, A.junii,
A.lwoffii, (emended) A.calcoaceticus (emended) Acinetobacter sp. 6 and
Acinetobacter sp. 11 (Grimont & Bouvet, 1991).
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Work carried out simultaneously by others (Tjernberg & Ursing, 1989;
Nishimura et al. 1988b) have corroborated the groupings outlined by Grimont &
Bouvet (1986) and Bouvet & Grimont (1991). Phenotypic group 5 has
subsequently been named as Acinetobacter radioresistans (Nishimura et al.,
1988a)
Thus, hopefully, a satisfactory classification of the genus Acinetobacter is
now at the disposal of microbiologists (Towner et al., 1991).
THE ECOLOGICAL SIGNIFICANCE OF THE NEW TAXONOMIC
CHANGES
The whole question of the role of Acinetobacter in human infection and the
epidemiology of these infections has clearly been hampered by the taxonomic
confusion. In conjunction with the new changes described, Grimont and Bouvet
(1991) have outlined the different habitats of the new species.
(i) A.calcoaceticus sensu stricto
This organism is seldom associated with human infection and its normal habitat is
in the soil - where it was originally described by Beijerinck (1911).
(ii) A.baumannii
Has so far only been isolated from humans. It is the most commonly isolated
Acinetobacter in cases of nosocomial infection (Bergogne- Berezin & Joly -
Guillou, 1991a). Bouvet & Grimont (1987) found that it comprised of 244 of 291
isolates from 264 cases (84%). The authors made a very important point when
they stated that "no habitat other than man is known for this species. Thus, its
presence on inanimate objects in the hospital environment can be interpreted as
contamination from an infected patient". (Grimont & Bouvet, 1991).
94
(iii) Acinetobacter sp 3
Unlike the French studies this species formed the largest group of clinical isolates
studied by Tjemberg & Ursing (1989). It has been found in both soil and clinical
samples.
(iv) A.haemolyticus
Is only occasionally isolated from patients and the hospital environment.
(v) A.junii
Is found both in the environment and in clinical samples.
(vi) A.johnsonii
This species can be found in the environment (soil, activated sludge), animal
products (chicken, raw milk), the skin of normal people and only rarely from
clinical specimens. It is commonly found on the skin (hands) of nurses but also on
the skin of non-hospital workers (Bouvet & Grimont, 1987). Since this species is
unable to grow at 37°C its isolation from clinical specimens should be treated
with suspicion since hand-borne contamination is most likely. Grimont & Bouvet
(1991) pointed out that "In an epidemiological investigation, the presence of
Acinetobacter strains on the hands of personnel is meaningless unless the
identification procedure differentiates A.baumannii from A.johnsonii and the other
species".
vii) A.lwoffti
Has been isolated from human cases (3-6% of total isolates), from the hands of
non infected personnel, eviserated chickens and activated sludge (Bouvet &
Grimont, 1987; Duncan etal., 1988).
viii) A.radioresistens
Originally found in association with cotton it has also been isolated from patients
(Tjernberg & Ursing, 1989).
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Concluding, Grimont & Bouvet (1991) made the following important
statement: "Accurate identification to the species level of a clinical isolate
belonging to the genus Acinetobacter is essential since:
(i) identification is a primary epidemiological marker
(ii) habitats may differ between species
(iii) the antibiotic susceptibility of A.baumannii compared with other species is
quite different (Freney etal. 1989)".
CLINICAL PROBLEMS POSED BY ACINETOBACTER
These have been well reviewed by Bergogne - Berezin et al. (1987).
Acinetobacter spp. is a good example of the new group of organisms, previously
thought to be of low grade pathogenicity, which have become increasingly
important as causes of nosocomial infection, especially in the intensive therapy
situation.
The significant problems posed by this species are partly related to its
high rates of resistance to most antimicrobial agents. Towner et al. (1991)
describe Acinetobacters as exhibiting "one of the most impressive patterns of
antibiotic resistance found in nosocomial bacteria". Acinetobacter are often
resistant to most members of the Beta-lactam and aminoglycoside classes.
Bergogne- Berezin & Joly- Guillou (1991b) described resistance of 84% to the
Beta-lactams, 64% to the aminoglycosides, 65% to co-trimoxazole and 63% to
perfloxacin. The latter resistance to the fluoroquinolones was particularly
worrying since they were initially sensitive. They mentioned that in many cases
the only effective treatment was imipenem but resistance to even this powerful
agent is appearing. In this series 5.5% of their isolates were resistant to all
available anitmicrobial agents (Bergogne- Berezin & Joly - Guillou, 1991).
Major Infections caused by Acinetobacter




Nosocomial urinary tract infections (Hoffmann et al., 1982)
Others include : meningitis; skin and wound infections; burn wound
infections; and bacteriuria (Bergogne - Berezin et al., 1987)
HOSPITAL EPIDEMIOLOGY OF ACINETOBACTER INFECTION
This has suffered from the taxonomic problems and the lack of reliable
typing schemes. Noble (1991) has recently reviewed this subject.
Normal carriage
Acinetobacter spp. (presumably A.baumannii) are normal inhabitants of
the human skin and are found in at least 25% of the normal population in the
groins, axillae, toewebs and antecubetal fossae, (Taplin et al., 1963 ; Noble,1991).
This fact has always led to a debate as to whether isolation of these organisms
from blood or wound swabs etc. was indicative of infec tion or mere
contamination.
Role of contaminated equipment and fomites in Acinetobacter infections
A recurrent theme of Acinetobacter nosocomial infection is contaminated
equipment (see Table 12 ).
Table 12. Contaminated equipment and fluids in Acinetobacter infections.
Equipment Reference
Resuscitators in a baby ITU Stone & Das (1986)
Wright respirometers Cunha et al. (1980)
Cold water room humidifiers Smith & Massanari (1977)
Water reservoir in mist tents Snydman et al. (1977)
Bed mattresses Sheretz & Sullivan (1985)
CAPD bags Abrutyn etal.(1978)
Intrathecal methotrexate / needles Kelkar et al. (1989)
Parenteral nutrition fluid Ng et al. (1989)
Intra-arterial pressure transducers This thesis
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Acinetobacters are known to survive drying better than most other Gram
negative bacteria - once dried they may persist for at least 7 days. (Buxton et al.,
1978). Therefore airborne spread with contamination of equipment and other
patients may play an important role in the natural history of nosocomial infections
caused by Acinetobacter. However, as with other nosocomial pathogens,
transmission occurs most frequently, directly by the hands of the medical/nursing
personnel and indirectly via contaminated equipment.
TYPING SCHEMES FOR ACINETOBACTER
These have recently been comprehensively reviewed by Bouvet (1991).
(See Table 13 ).
Table 13. Typing schemes for Acinetobacter.
Typing scheme References
Biotyping Towner & Chopade (1987)
Plasmid profile & plasmid
fingerprinting
Cell envelope protein patterns
Serotyping
Phage typing
Buisson et al. (1990)
Vieu et al. (1979)
Vieu et al. (1980)




Dijkshoorn et al. (1987 a, b &1989)
Crombach et al. (1989)
Bouvet et al. (1990)
Gerner-Smidt (1989)




Antimicrobial resistance patterns Castle et al. (1978)
French et al. (1980)
Gerner-Smidt et al. (1985)
Buisson et al. (1990)
Low-frequency-cleavage restriction Allardet-Servent etal. (1989)
endonuclease analysis
Electrophoretic analysis of isoenzymes Picard et al. (1989)
He emphasised that the initial step in the typing of Acinetobacter should
be the establishment of which particular species of this genus are "of clinical and
epidemiological relevance". Therefore the first step in typing should be the
identification of the organism to the species level. He felt that identification to the
species level and biotyping using physiological and nutritional properties were
"easy and accurate methods for screening strains". He also felt that the
investigation of small outbreaks within specific ward areas caused by
A.baumannii could easily be carried out by using, in addition, cell envelope
protein profile typing. But the latter technique was perhaps too laborious for large
scale epidemiological studies.
He concluded that: analysis following treatment with low-frequency-
cleavage restriction endonucleases, electrophoretic analysis of isoenzymes, or
restriction endonuclease analysis of rRNA genes - currently being evaluated - may
prove extremely useful epidemiological tools in the future.
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THE EVOLUTION OF ANTIMICROBIAL DRUG RESISTANCE IN
ACINETOBACTER
I do not intend to discuss this in detail here, since it has been extensively
and comprehensively reviewed (including some of the work presented in this
thesis) by Professeur E. Bergogne- Berezin (Bergogne- Berezin & Joly- Guillou,
1985; Joly- Guillou et al., 1987 ; Bergogne- Berezin & Joly Guillou, 1991a).
She concluded that although much work had been carried out on the
resistance mechanisms of Acinetobacter spp., a great deal remains to be
investigated. This includes the resistance that has emerged to the fluorquinolones
and imipenem. "Problems of outer membrane permeability are suspected, but not
yet demonstrated" (Bergogne-Berezin & Joly -Guillou, 1991a).
The role of Acinetobacter spp. as a reservoir of resistance genes within
hospitals also requires careful study in the future.
This thesis will look particularly at the nature and role of the (presumed)





The majority of the clinical isolates of Gram negative aerobic bacilli
studied in this thesis were collected from the patients in the Royal Infirmary of
Edinburgh (RIE) during the period of January 1986 to December 1987.
The following Acinetobacter spp. were obtained from the blood culture
collection of the RIE Bacteriology laboratory 75, 5B86, 6B101, 6B230, 6B253,
6B299, 6B324, 6B410 and 7B52. Strains H246, 247, 248, 284, 285 and 286 were
kindly donated by the Bacteriology Laboratory of the City Hospital, Edinburgh.
Strains H201 through to H243 were kindly donated by the Bacteriology
Department of the University of Dundee, Ninewells Hospital.
All strains were maintained at -70°C in nutrient broth with 10% glycerol
v/v. Identification of all strains was carried out with the API 20E or API 20NE
system (API System, S.A. France). Details of the individual strains are given in
the appendix. The standard bacterial strains used in this thesis are listed in Table
14 Details of the strains producing standard beta-lactamases are shown in Table
15.
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Table 14. Standard Bacterial Strains








pro- his' tip' lac' Bachmann (1972)
E.coli
Table lS.Standard (3-lactamase producing strains
Bacterial strain (3-lactamase Plasmid Original
produced reference
E.coli J53-2 TEM-1 R6K Hedges etal.
2316E (1974)
E.coli J53-2 TEM-2 RP4 Hedges etal.
2137E (1974)
E.coli J53-2 SHV-1 R1010-6 Petrocheilou et al.
2141E (1977)
E.coli J53-2 OXA-1 R455 Dale & Smith
(1974)
E.coli J53-2 OXA-2 R46-Ts Dale & Smith
(1974)
Ent. cloacae P99 Fleming et al.
(1963)
Kl.pneumoniae Kl Marshall et al.
1082E (1972)
Kl pneumoniae K14 Matthew & Harris
(1976)
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INFORMATION STORAGE AND RETRIEVAL
Hood isolates (prefixed by H)
Information concerning each bacterial strain was stored in the database
program of dBASE III (Ashton-Tate, Milton Keynes). This system was used for
the identification and removal from the survey of repeat isolates from individual
patients.
Cefuroxime resistance survey
A hospital wide survey was performed of the incidence of cefuroxime
resistance within the population of non-pseudomonal aerobic Gram negative
bacilli reported from the clinical bacteriology laboratory, RIE from April 1986
until March 1991. This was obtained from the computer records held in archive
disks of a Digital Equipment Corporation (DEC) FDr 11/44 computer which ran
as Digital Standard Mumps (DSM) version 4.1. In-house programs were written
by Karen Wilson (CSU Lothian Health Board) and A. Bruce Harris (MLSO 3
Dept of Bacteriology) to retrieve the appropriate data. Hard copy was produced to
ensure all patient and isolate duplicates were removed.
Antimicrobial usage
This hospital-wide survey of all antimicrobial usage in RIE for the




This hospital wide survey of patient admissions and discharges was
obtained from Mr N Pettinger, RIE.
MATERIALS
Antimicrobial Agents
The antimicrobial agents and their suppliers are listed in Table 16.
Table 16. Antimicrobial agents
Compound Supplier
Ampicillin SmithKline Beecham Pharmaceuticals
Aztreonam E.R.Squibb &Sons
Benzylpenicillin Glaxo Laboratories Ltd.
Carbenicillin SmithKline Beecham Pharmaceuticals
Cefotaxime Roussel Laboratories Ltd.
Cefoxitin Merck Sharp &Dohme Ltd.
Ceftazidime Glaxo Group Research Ltd.
Ceftriaxone Roche Products Ltd.
Cefuroxime Glaxo Laboratories Ltd.
Cephaloridine Glaxo Group Research Ltd.
Cephradine E.R.Squibb &Sons
Ciprofloxacin Bayer (UK) Ltd.
Clavulanic acid SmithKline Beecham Pharmaceuticals
Gentamicin Nicholas Laboratories
Imipenem Merck Sharp &Dohme Ltd.
Netilmicin Schering Plough Ltd




Sodium phosphate and Tris-HCl buffers were prepared as described in
Data for Biochemical Research (Oxford University Press, 1974). Other specialist
buffers are described with the appropriate method.
Media
Sterilisation ofMedia
All growth media, both agar and broth, were sterilised by autoclaving at
151bs/in ^ for 15 minutes.
Complex media
The following complex media were used: Nutrient broth No 2 (CM67),
Diagnostic Sensitivity Test Agar (DSTA) (CM261), MacConkey agar (CM7)
(Oxoid, Basingstoke, Hants).
Minimal medium (DM agar)
Double strength minimal salts medium was prepared as described by
Davis and Mingioli (1950) (Table 17 ).Fifty ml of double strength DM was then
supplemented with appropriate amounts of the required amino acid stock solutions
to achieve the final concentrations as shown in Table 18 .
Table 17. Preparation of double strength Davis & Mingioli basal medium






After appropriate quantities of antibiotics were added 2.5ml of 20%
glucose solution was added and the volume made up to 60ml with sterile distilled
water. This solution was mixed and added to 40ml of molten Bacteriological
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Agar No 1 (lg of agar/40ml of distilled water) and, after gentle mixing, the plates
were poured.
Table 18. Amino acid solutions




L-histidine (BDH) 5 50
L-methionine (BDH) 5 50
L-proline (BDH) 5 50
L-tryptophan (Sigma) 2 50
METHODS
Antibacterial drug susceptibilities
Minimum Inhibitory Concentration (MIC) Determination on SolidMedia
Serial dilutions of an overnight, nutrient broth culture was made in single
strength DM to 10~4 . Approximately 1 of this was inoculated onto the surface
of DSTA plates, containing the appropriate concentrations of antimicrobial,
employing a Denley A 400 Multipoint inoculator. The inoculum suspension
contained approximately 10 5 colony forming units per ml (cfu/ml).
Each plate was also inoculated with two control organisms E. coli NCTC
10418 and Ps. aeruginosa NCTC 10662. A DSTA plate containing no
antimicrobial agents was also inoculated as a positive control. Plates were
incubated for 18h at 37°C. The MIC was expressed as the first concentration
inhibiting all visible growth.
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Conjugation experiments
In the mating experiments 0.1ml of an overnight culture of the donor
strain was mixed with 1ml of an overnight culture of the recipient strain in 4.5ml
of nutrient broth, as described previously by Amyes and Gould (1984). This
mixture was then incubated at 37 °C for 6h.
E. coli J62-2 transconjugants of the clinical Acinetobacter spp. isolated
were selected for on DM agar supplemented by histidine (50mg/L), tryptophan
(50mg/L) and proline (50mg/L) and containing rifampicin (25pg/ml) and
aztreonam (|pg/ml).
Beta-lactamase Preparation
Large scale preparation ofcrude cell extracts
Cells were grown in 4.5ml of nutrient broth overnight at 37°C and used
to inoculate a 1 L culture of nutrient broth and this was shaken (200 osc/mm) at
37°C for 18h. Cells were harvested at 5000g for 15 min at 4°C (Sorvall RC-5B
Refrigerated Superspeed Centrifuge, Du Pont Instruments) and the pellet was
washed in 500ml of 25mmol/L sodium phosphate buffer (pH 7.0) and re-
centrifuged at 5000g for 15 min. The pellet was then resuspended in 3ml of
sodium phosphate buffer (pH 7.0) and the cells were disrupted by ultrasonication
with constant cooling (8pM, lmin x 3, MSE Soniprep 150, MSE
Instruments,Crawley).
The cell debris was removed by centrifugation at 38,000g for 15 min at
4°C (Sorvall).The supernatant, crude Beta-lactamase preparation, could then be
stored at -20 °C until required.
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Small scale preparation ofcrude cell extracts
Small quantities of Beta-lactamases were prepared by the method
described by Livermore et al. (1984).Cultures were grown on 2ml nutrient agar
slopes which were incubated for 18h at 37°C. A cell suspension was obtained by
the addition of 1ml of sodium phosphate buffer (pH 7.0, 25 mM) to the agar
surface coupled with gentle agitation. The cells were then disrupted at 4°C by
ultrasonication (8pM, 30s, Soniprep). The cell lysate was cleared employing a
MSE Microcentaur centrifuge (ll,500g, lOmin, 4°C). The cleared lysate was
stored at -20 °C until required.
Assessment of Beta lactamase activity of Beta lactamase preparations
Thirty pL of the beta-lactamase extract was mixed with 100 pL of a
nitrocephin solution (50 mg/L) in a microlitre tray. The time taken in seconds for
the mixture to change from yellow to red was taken as an indication of the Beta-
lactamase activity of the enzyme preparation. The amount of Beta-lactamase
added to an IEF gel in (pL) was equal to the time taken (in seconds) for this
colour change to take place. In each gel up to lOOpL was employed as the sample
volume.
Beta-lactamase Enzyme Induction
The method employed was that described by Minami et al. (1980).
Cefoxitin, a well documented inducer of Beta-lactamase production, was added to
the growing culture at one quarter of the MIC value for that particular strain.Beta-
lactamase enzymes were extracted as previously described for large-scale
preparation of crude enzyme extracts.
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Conventional analytical isoelectric focusing of Beta-lactamases
Gelpreparation
Beta-lactamases were identified (if possible) by analytical isoelectric
focusing as described by Matthews et al. (1975). The extracts were focused on a
thin layer polyacrylamide gel containing carrier ampholines (pH 3.5 - 10.6, LKB).
The composition of the gel is shown in Table 19 .
Table 19. Composition of a conventional IEF gel
Material Supplier Volume Final
employed (ml) concentration
5% TEMED* in distilled water. Sigma 0.2 0.25mg/L
40% ampholines w/v (various LKB 2.0 2% w/v
pH ranges).
Aerylamide (lOOg) plus BDH 9.0 acrylamide: 75g/L
methylene bisacrylamide (2.7g) bisacrylamide: 2g/L
in 300ml distilled water.
Distilled water. 25.0
Riboflavin (20mg/L). Sigma 4.0 2mg/L
* TEMED : tetramethyl-ethylenediamine
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Running conditions
Samples of the enzymes (up to 100p,L) were applied, about 2cm from the
anode, onto the gel surface. The amount added in (p.L) being equal to the time
taken (in seconds) for a mixture of 30p,L of Beta-lactamase preparation and
100[xL of nitrocephin solution (50mg/L) to change from yellow to red.
Isoelectric focusing was performed at 4°C at 1W (constant), 550V
(limiting) and 20 mA (limiting) for 18h. Five |aL of isoelectric point (pi) standard
markers (BDH) were also spotted on the gel in order to quantify the pi gradient
Staining
Polyacrylamide gels were stained by repeatedly overlaying the surface
with a sheet of Whatman No 54 paper which had been dipped in nitrocephin
solution (500mg/L). The focused bands of Beta-lactamase activity appeared red
on a yellow background.
Photography
Serial photographs of the IEF gels were taken after treatment with the
nitrocephin solution. Kodak Ortholith film (35mm) with transmitted hight and a
Wratten 58 green filter was used initially. Subsequently a polaroid film system
with a green filter was employed.
SDS-free PAGE
The apparatus and discontinuous buffer system employed was essentially
that described by Laemmli (1970) except that it did not contained SDS.
Buffers
(i) electrode buffer:
0.025M Tris, 0.192M Glvcine7 j
ill
(ii) Separating gel buffer: (double strength)
0.75M Tris/HCl, pH 8.8
(iii) Stacking gel buffer: (double strength)
0.25M Tris/HCl, pH 6.8
(iv) Sample buffer: (double strength)





A separating gel of 12% acrylamide with a stacking gel of 4%
acrylamide were employed. The gel mixtures were prepared as in Tables 20 and
21.
Table 20. Composition of discontinuous buffer separating gel
Solutions Volume (ml) per gel
Distilled water 5.2
0.75M Tris/HCl,pH 8.8 17.5
40% acrylamide (stock) * 10.5
Ammonium persulphate (15mg/ml) 1.75
TEMED 0.05
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Table 21. Preparation of stacking gel
Solution Volume (ml) per gel
Distilled water 3.5
0.25M Tris/HCl pH 6.8






40% acrylamide stock solution *
40g acrylamide and 1.08g methylbisacrylamide dissolved in a total volume of
100ml of distilled water.
Sample preparation
An equal volume of sample was added to double strength sample buffer
which contained:





See appropriate results section.
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Molecular size (M r) Estimation by gel filtration
This was carried out by employing the method of Andrews (1964).
Preparation ofG-75 andSephacryl S-300 columns
The media (Sephadex G-75 or Sephacryl S-300, Pharmacia) was swollen
with the appropriate volume of 25mM sodium phosphate buffer (pH 7.0) at
100°C for lh. The slurry was allowed to cool and then carefully poured into a
Pharmacia gel filtration column (2cm^ x 90cm). When the column was full, the
top was connected and the flow commenced in an upward direction with a LKB
peristaltic pump. The gel was then allowed to equilibrate for 48h with 25mM
sodium phosphate buffer (pH 7.0). Following this equilibration period a flow rate
of 15ml/h was attained by adjusting the speed of the peristaltic pump.
Calibration ofG-75 andSephacryl S-300 columns
(i) G-75
Prior to the estimation of a Beta-lactamase of unknown M r it was
calibrated with proteins of known molecular size (see Table 22 ).
Table 22. Protein standards (lOmg in 1ml buffer)applied to G-75




After the application of the standard proteins, 100 fractions were collected
by an Ultrorack fraction collector(LKB). The fraction size was set to
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collect 2ml of eluate. The absorbance of each fraction was measured at
280nm to give an estimate of its protein concentration. The position of the
peaks of the protein markers was then established by plotting the OD of
the fractions against the fraction number (Waddell, 1956). A standard
curve ofM r versus fraction number could then be drawn.
(ii) Sephacryl S-300
This column was calibrated with the following protein standards (see
Table 23).
Table 23. Protein standards (10mg in 1ml buffer) applied to S-300




Determination of theMr ofBeta-lactamases
lml of crude enzyme preparation, prepared as described previously,was
applied to the column. The settings of the peristaltic pump and fraction collector
were maintained at the same parameters as those employed during the calibration
procedure. One hundred fractions of 2ml volumes were eluted from the column
after the application of the sample.
The Beta-lactamase peak was first identified by each fraction for activity
with the chromogenic cephalosporin, nitrocephin. Thirty pL of each fraction were
added to lOOpL of nitrocephin solution (50mg/L) in a microtitre plate. Those
which showed a rapid colour change (<120s) from yellow to red indicated the
presence of beta-lactamase activity.
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These fractions were then further assayed by the spectrophotometry
method O'Callaghan et a/.(1972) to determine the peak beta-lactamase activity. If
the activity appeared in the void volume of the G-75 column another 1ml of crude
preparation was added to a similar column containing Sephacryl S-300 and the
peak fractions determined as before. The Mr was then determined from the
standard curve.
Fractions containing significant Beta-lactamase activity were pooled and
used for the spectrophotometry analyses described in the next section and were
also used to load the isoelectric focusing gels.
Spectrophotometry Assay of Beta-lactamase Activity
The basic method employed for spectrophotometric assay was that of
O'Callaghan et a/.(1972). For all spectrophotometric assays either a Pyc Unicam
SP1800 uv/vis spectrophotometer or a Perkin Elmer Lambda 2 Spectrometer was
employed. Both instruments had themostatically controlled cell carriers and all
measurements were performed at 37 °C.
Penicillin and cephalosporin substrates were prepared at lO'^M and
10'^M respectively in 25mM sodium phosphate buffer (pH 7.0).
Test and blank cuvettes were prepared and equilibrated at 37°C. The test
cuvette contained 0.3ml substrate and 2.6ml sodium phosphate buffer (25mM, pH
7.0). The blank cuvette contained 2.9ml buffer. Beta-lactamase (0.1ml) was added
to each cuvette and monitoring of the decrease in optical density (OD) at the
appropriate X max, was begun immediately. Kinetic measurements were
performed on Beta-lactamases which had been partially purified by gel filtration.
The initial linear part of the reaction curve was used to obtain a value for
change in OD minute "1.
The rate (R) of the reaction was calculated according to the equation
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R= AOD x N x (enzyme dilution)
ODj x time
where R = p. moles of substrate hydrolysed minute ~1 ml enzyme
AOD = change in optical density
N = p. moles substrate in cuvette (0.3 for cephalosporins, 3.0 for
penicillins)
OD i - optical density of intact substrate.
Specific Activities
Rates for individual Beta-lactamases were calculated at 10'^M for
penicillins and lO'^M for cephalosporins. Protein concentrations were determined
by the method of Waddell (1956) and specific activities were expressed as pico-
moles of substrate hydrolysed per minute per mg of protein ( p moles/ min/mg).
If no activity was detectable at a concentration of 10'^M against the
following substrates: aztreonam, ceftazidime, cefotaxime and cefuroxime, they
were repeated at a concentration of lO'^M. This was carried out employing the
following method. Each test cuvette contained 2.6ml sodium phosphate buffer
(25mM, pH 7.0), 0.3ml of substrate (10"^M) and 0.1ml of test Beta-lactamase.
Each blank cuvette contained 2.9ml of buffer and 0.1ml of test Beta-lactamase.
Each reaction mixture was diluted 1:100 prior to measurement of the OD at the
appropriate wavelength. The reaction mixtures were then incubated at 37°C in a
waterbath and the OD of 1:100 dilutions made at intervals up to 18h later.
Determination of Michaelis Menton Kinetics
The Km and Vmax values were obtained by measuring the rate of
hydrolysis at limiting substrate concentrations and plotting the reciprocal of the
substrate concentration against the reciprocal of the rate by the Lineweaver - Burk
(1934) method.
The Vmax values were normalised with respect to nitrocephin i.e.,
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relative Vmax = Vmax (per txL enzyme) of substrate _ x 100
Vmax (per pL enzyme) of nitrocephin
Measuring Beta-lactamase inhibition
The ID50 value is defined as the amount of inhibitor required to reduce
the hydrolytic activity of an enzyme by 50%. The ID50 values for the Beta-
lactamase enzymes were determined by spectrophotometric assay described above
(O'Callaghan et al.\91T). Firstly, the rate of hydrolysis of nitrocephin (at lO'^M)
by the Beta-lactamase was measured. This procedure was then repeated in the
presence of 10"^M of the potential inhibitor and then with increasing
concentrations of this inhibitor until inhibition approached 100%.
Percentage inhibition was then plotted against log concentration of
inhibitor. The concentration of the inhibitor which gave 50% inhibition was
calculated from the graph.
Inhibition Studies with Clavulanic acid
In these studies the enzyme and clavulanic acid were pre-incubated
together for 5 minutes prior to the addition of the nitrocephin substrate.
Method for the preparation of the cell membrane fraction of Acinetobacter
baumannii (Strain H68)
This was carried out by the methods described previously by Hills and
Fewson (1983) and Allison et al. (1985 a and b).
Growth ofbacteria
A loopful of stock culture was used to inoculate 50ml of complex media,
the composition of which is shown in Table 24. This culture was incubated,
statically at 30°C overnight. The resultant culture was then used to inoculate
400ml of complex media which was incubated overnight at 30°C with shaking
(120 rev/min). This in turn was used to inoculate 4L of complex media in a 10L
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fermenter (Braun Biostat V; F.T. Scientific Instruments, Tewkesbury, Glos., UK).
The fermenter was operated at 30°C with an aeration rate of 4L of sterile air/min
with stirring set at of 2.5 (approx 350 rev/min). After 18h growth the bacteria
were harvested.
Table 24. Composition ofComplex media
Ingredient Manufacturer Quantity dissolved in
IL(g)











(NH4)2S04 BDH (Analar) 1.0
MgS047h20 BDH (Analar) 0.4
The pH was adjusted to 7.0 using 5M NaOH, then made up to 1L with distilled water. It was sterilised by
autoclaving at 151bs/in^ for 15 min. Polypropylene glycol was added to a concentration of 0.005% when
the above media was used in the fcrmenter.
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Harvesting
The cells were harvested by centrifugation (MSE 18) at 6000g for 20 min
at 4°C, washed by resuspension in ice-cold phosphate buffer (pH 7.5, 40mM) and
recentrifuged at 12,000g for 30 min at 4 °C.
Disruption
The cells were disrupted either by passage through a French pressure cell
or by ultrasonication.
i) French pressure cell
20g of wet cells were resuspended in 20ml of ice-cold phosphate buffer
and disrupted by four passages through a cooled French pressure cell
(95MPa). The broken cell suspension was centrifuged (MSE18) at
12,000g for 30 min at 4 °C and resuspended in ice-cold phosphate buffer.
ii) Ultrasonication
The cells were resuspended in 25ml of ice-cold phosphate buffer to give
an A500 of 100-200. This suspension was disrupted (with cooling) by 5
cycles of ultrasonication each of 30sec at SOW. The broken cell
suspension was treated by centrifugation of 12,000g for 30 min at 4 °C.
The resulting preparations produced by both methods were stored
overnight at 4 °C.
Preparation ofwashed cell membranes
The suspensions obtained from the previous steps were centrifuged
(Beckman L5-65) at 113,000g for 150 min at 4°C ,then the precipitate was
resuspended in ice-cold phosphate buffer and recentrifuged. This procedure was
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repeated once more (giving 3 high-speed spins in total) and the resultant pellet
was regarded as washed cell membranes.
Estimation ofBeta-lactamase activity
The Beta-lactamase activity at various points of the purification
procedure was assayed by the spectrophotometric method previously described,
employing nitrocephin as the substrate.
Protein assay




SCREEN FOR CEFUROXIME RESISTANCE
During the two year period between January 1986 and December 1987
inclusive, 400 strains of Gram negative aerobic bacilli, that were oxidasemegative,
and showed resistance on disc testing by the Stokes' Method to cefuroxime (30pg)
were collected. All strains were identified by API 20E or API 20NE. These
strains were given "H" numbers and are listed in Appendix I. Three hundred and
fifty one strains originated from the RIE, 43 from the Bacteriology Laboratory,
Ninewells Hospital, Dundee and 6 from the Bacteriology Laboratory, City
Hospital, Edinburgh.
The original aims were threefold. Firstly to compare the cefuroxime
resistance in these strains to their sensitivity/resistance to eleven other
antimicrobial agents by carrying out MIC estimations.
Secondly to elucidate the role of Beta-lactamases in the resistance of
these strains to cefuroxime.
Thirdly to attempt to relate the cefuroxime resistance to particular ward
areas of the RIE.
MIC ESTIMATIONS
These were carried out on all 400 strains. The antimicrobials were:
Ampicillin as an example of a common penicillin
Cephradine as an example of a first generation cephalosporin
Cefuroxime as an example of a second generation cephalosporin
Cefoxitin as an example of a second generation cephalosporin
Cefotaxime as an example of a third generation cephalosporin
Ceftazidime as an example of a third generation cephalosporin
Ceftriaxone as an example of a third generation cephalosporin
Aztreonam as an example of a monobactam
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Imipenem as an example of a carbapenem
Ciprofloxacin as an example of a quinolone
Gentamicin as an example of an aminoglycoside
Netilmicin as an example of an aminoglycoside
The MIC50, MIC90, MIC range and the percentage resistance
(employing break points as described by the Working Party of the BSAC, 1991)
to each of the 12 antimicrobials is seen in Table 25.
The following should be noted:
i) The overall resistance to cefuroxime was around 68.5% and cefoxitin
resistance was very similar, at 69%.
ii) Resistance to ampicillin and cephradine was almost complete at 96% and
92%,)respectively.
iii) The third generation cephalosporins cefotaxime and ceftriaxone had
similar resistance figures of 57.8% and 54%Jrespectively5whereas the
22.3% resistance of ceftazidine was significantly better in this population.
iv) Surprisingly perhaps aztreonam had a lower rate of resistance than the 3rd
generation cephalosporins -19%.
v) This was comparable with the resistance of 21% and 17.8% to the
aminoglycosides gentamicin and netilmicin, respectively.
vi) As one would expect the resistance to the two newest drugs: (neither on
the market at the time) imipenem and ciprofloxacin were the lowest at
2.8% and 3% respectively.
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percentager sistanc breakpoint(mg/L) minimuminhibitoryconcentrati n( g/L)
AMP CED CXM CTR CAZ GENT
ampicillin cephradine cefuroxime ceftriaxone ceftazidime gentamicin
CFX AZ CTX IMI CIP NET
cefoxitin aztreonam cefotaxime imipenem ciprofloxacin netilmicin
CEFUROXIME-RESISTANT STRAINS (MIC > 32mg/L)
Out of the 400 initial strains a group of 200 strains was delineated. These
were all clearly resistant to cefuroxime (MIC>32mg/L) and excluded any strains
that had originated from outside the RIE and any strains of Pseudomonas or
Xanthomonas (see Appendix II).
Their MIC50, MIC90, MIC range and percentage resistance (to a specific
breakpoint) is given to the twelve antimicrobials in Table 26.
Therefore as one might have expected the resistance to ampicillin and
cephradine in this population of cefuroxime resistance strains was almost 100%.
Cefoxitin, the other second generation cephalosporin, was much the same as
cefuroxime resistance at 84%. Aztreonam, cefotaxime and ceftriaxone all had
significantly better levels of resistance at 25.5%, 24% and 29% respectively. The
resistance to ceftazidime was slightly greater, at 35% reflecting the removal of
ceftazidime-sensitive strains of Pseudomonas spp. from the original 400 strains.
Imipenem and ciprofloxacin, again, came out best with resistance of only
1% and 2% of strains^respectively.
The aminoglycosides showed similar resistance rates (to each other) of
26.5% for gentamicin and 19.5% for netilmicin. Table 27 shows the proportion of
different bacterial species within this group of 200 strains.
The resistances to the 12 antimicrobials in the five major species are
shown in Tables 28 to 32.
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minimuminhibitoryco centrati n( g/L)
AMP= CED CXM= CTR CAZ GENT=
ampicillin cephradine cefuroxime ceftriaxone ceftazidime gentamicin
CFX AZ CTX IMI CIP NET
cefoxitin aztreonam cefotaxime imipenem ciprofloxacin netilmicin
The following are worth noting:
1. All species were essentially resistant to ampiciliin, cephradine and
cefuroxime.
2. Cefoxitin: resistance to this antibiotic varied from 97.7% in Acinetobacter,
86% in Enterobacters to 50%*in Serratias.
3. Aztreonam : in Enterobacters and Serratias this was a useful drug with
only 4% and 4.2% resistance respectively. However in Acinetobacter
there was resistance in 97.7% of the strains tested.
4. Cefotaxime and Ceftriaxone : in Enterobacters resistance was 85% and
80%. In Acinetobacters both were 97.7% (as with aztreonam). There was
a lower resistance in Serratias at 29.2% and 37.5%, though this was
significantly higher than aztreonam (4.2%).
5. There was generally a lower resistance to ceftazidime than to cefotaxime
and ceftriaxone, 41% in Enterobacters ; 41.9% in Acinetobacters and 0%
inSerratias. This was better than aztreonam in Acinetobacter and Serratia
but worse than aztreonam in Enterobacters .
6. Imipenem was by far the most active Beta-lactam with only 1% resistance
in Enlerobacters; none in either Acinetobacters or in Serratias. All the
Klebsiellas and Citrobacters had MIC's within the sensitive range too.
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BETA-LACTAMASES PRODUCED BY THE CEFUROXIME-RESISTANT
POPULATION
The Beta-lactamases produced by the 200 strains were identified by
analytical isoelectric focusing (IEF) of small-scale crude enzyme extracts.
Comparisons with standard marker enzymes enabled identification of the
Beta lactamases as to whether they were of plasmid-mediated or probable
chromosomal origin. The Beta-lactamases detected in these strains are listed in
Appendix III.
Distribution of Beta-lactamases
The distribution of these enzymes within different bacterial species is
shown in Table 33.
Enterobacter spp.
Forty-eight strains produced an enzyme of typically chromosomal origin.
Four strains produced the plasmid-mediated enzyme TEM-1. Forty-eight strains
produced a typically chromosomal enzyme and TEM-1. The 96 chromosomal
enzymes produced by the Enterobacters are for convenience described as either
having a pi the same as P99, >P99 or <P99. In fact at least 5 distinct pi's for
Enterobacter chromosomal enzymes were seen. In two strains, two typically
chromosomal enzymes were seen (P99 and >P99). This has previously been
noted by Medeiros (1987 ). Fifty-two Enterobacter strains produced the TEM-1
plasmid mediated Beta-lactamase.
Acinetobacter spp.
All 43 strains produced a typically chromosomal enzyme. No plasmid
mediated enzymes were detected. Only one strain (H126) produced a
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Beta-lactamase on isoelectric focusing with a discernable pi. The rest produced a
blur of activity near the cathode.
Serratia spp.
Twenty-three strains produced a typical chromosomal enzyme and only
one strain produced the plasmid mediated TEM-1, alone.
Klebsiella spp.
Of the 11 strains, eight produced a typical chromosomal enzyme while
two produced a typical chromosomal enzyme and TEM-1. Only one produced
TEM-1 alone.
Citrobacter spp.
Seven produced a typical chromosomal enzyme and two produced the
TEM-1 Beta-lactamase alone.
Morganella spp.
Three produced chromosomal enzymes alone while one produced a
chromosomal enzyme and the TEM-1 Beta-lactamase.
Proteus/Providencia spp.
All three produced chromosomal enzymes alone.
Escherichia coli
All three produced chromosomal enzymes alone.
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Hafnia alvei
One strain produced a chromosomal enzyme and the TEM-1 Beta-lactamase.
One strain produced a chromosomal enzyme and the SHV-1 Beta-lactamase.
Erwinia spp.
One strain produced a chromosomal enzyme alone.
Therefore in summary 192 strains produced a typical chromosomal Beta-
lactamase. Of these 192 strains, 139 produced a typical chromosomal enzyme
alone; 52 produced a typical chromosomal enzyme plus the TEM-1 Beta-
lactamase and one produced a typical chromosomal enzyme and the SHV-1 Beta-
lactamase. Eight strains produced a TEM-1 Beta-lactamase alone.
It is therefore most likely that the resistance to cefuroxime in most of
these strains resulted from the presence of a "typical" chromosomal Beta-
lactamase. However conjugation experiments should be performed on all these
strains to at least partially corroborate this statement.
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TRANSFERABLE THIRD GENERATION CEPHALOSPORIN RESISTANCE
In collaboration with Dr D J Payne 54 of 79 strains (from the original
collection of 400 strains - excluding Acinetobacter spp) which had MIC's to
ceftazidime, cefotaxime or ceftriaxone of >4mg/L were investigated for the
presence of transferable 3GC resistance. The Beta-lactamases produced by these
54 strains were examined by analytical isoelectric focusing and they were tested
for transferable 3GC resistance by conjugation experiments as described in the
Materials and Methods.
There was no evidence that any of the 54 strains conferred transferable
3GC resistance to either ceftazidime or cefotaxime. There was no evidence of
any of the recently reported TEM or SHV derived Beta-lactamases which confer
3GC resistance in these strains.
Consequently the 3GC resistance conferred by the strains in this survey most
probably resulted from the production of "typical" chromosomal
cephalosporinases.
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CEFUROXIME RESISTANCE WITHIN DIFFERENT AREAS OF THE
ROYAL INFIRMARY OF EDINBURGH
One of the original aims of this thesis was to attempt to relate the
resistance levels of cefuroxime to particular units within the RIE. Anecdotal
evidence suggested that resistance to cephalosporins was higher in certain ward
areas and it seemed lower in areas where aminoglycosides were still used
frequently. None of these "observations" were based in hard scientific evidence.
Therefore initially it was thought that the results from the survey of 400
strains of "supposed" cefuroxime resistance might shed some light on this
problem. However it became quite clear that these 400 strains (subsequently
more clearly defined as 200 strains with cefuroxime resistance of > 32mg/L)
could not be used to investigate the relationship between ward area and
cefuroxime resistance, for two main reasons.
Firstly the numbers were too small to attain statistical significance and
secondlv the 200 strains did not show a true reflection of the numbers of resistant
organisms in any given area. This was due to sampling error. Of the three main
laboratory groupings within the department, only one area consistently kept
cefuroxime-resistant strains that could be included in the study. This was revealed
by running a computer program over a period of 1 year (1986-1987) which picked
/res/STanT
out the number of cefuroxime/strains (duplicates excluded) that were reported by
the laboratory during that period by ward area. This was expressed as a
percentage resistance.
Another program was devised which gave the number of organisms -
duplicates excluded - that were reported as cefuroxime-sensitive. The organisms
included in this computer search were Gram negative, aerobic, oxidase-negative
bacilli escluding Pseudomonas spp.
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This initial computer search not only showed the sampling error within
the original 400 (and 200) survey strains but also provided the first clear evidence
of differences in resistance between areas within the RIE.
It was therefore decided to look at both cefuroxime and gentamicin
resistances within 18 distinct patient areas of the RIE over a longer time period.
These ward areas could also be grouped under three major headings - namely the
Surgical hospital, the Medical hospital and the Intensive therapy areas.
The following should be noted:
(i) the isolates were collected between 1 April 1986 and 31 March
1989
(ii) all patient duplicates were removed
(iii) cefuroxime and gentamicin sensitivities were estimated by
laboratory staff using the modified Stokes' method (Pearson &
Whitehead, 1974). The cefuroxime disc contained 30 pg and
gentamicin contained 10 gg of each drugjrespectively
(iv) strains were designated as either Sensitive or Resistant
(v) any group of resistant isolates that appeared to be of the same
resistance phenotype and part of an epidemiologically distinct
outbreak were counted as a single isolate
(vi) for logistical reasons it was not possible to check by hand the
numbers of sensitive isolates for duplicate patients missed by the
computer search. Therefore the numbers of sensitive isolates may
be an overestimate. However this meant that the final figures of
gentamicin and cefuroxime resistance is (if anything) an
underestimate
Table 34 shows the resistance figures for the initial 3 year period (1986-1989) for
both cefuroxime and gentamicin. These are shown both as an overall resistance
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rate for the hospital and also broken down into rates for the Surgical, Medical and
Intensive care areas.
Table 34 Cefuroxime and gentamicin resistance rates within the general
hospital population isolated between 1986-1989.
Area Proportion resistant Percentage resistance(%)
CEFUROXIME
RESISTANCE
Surgical hospital 511/4600 11.1
Medical hospital 289/2577 11.1




Surgical hospital 88/4635 1.9
Medical hospital 78/2512 3.1
ITU areas 40/894 4.5
Overall 206/8041 2.6
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The overall resistance to cefuroxime in the hospital was 13.1%
(1070/8153); in the Surgical hospital 11.1% (511/4600); in the Medical hospital
11.1% (289/2577) and in the Intensive therapy areas 27.7% (270/976).
The resistances within the Surgical and Medical hospitals are almost
identical but within the ITU's it is more than twice these rates.
The overall gentamicin resistance in the hospital was 2.6% (206/8041); in
the Surgical hospital 1.9% (88/4635); in the Medical hospital 3.1% (78/2512) and
in the Intensive therapy areas 4.5% (40/894). Therefore the gentamicin
resistances were very much the same in each area, if slightly higher within the
ITU areas.
However the rate of gentamicin resistance was, in all areas, significantly
lower than the cefuroxime resistance.
To estimate the validity of these resistance patterns obtained by the
Stokes' method, we decided to compare them with the resistance patterns in the
blood culture isolates, the same organism types and from the same ward areas.
The blood culture isolates had their MIC's to cefuroxime and gentamicin
estimated and those with MIC's of > 32mg/L for cefuroxime and > 4mg/L for
gentamicin were considered resistant to these agents. This work was carried out
by Mr R Paton. Table 35 shows a comparison of the resistance rates between the
blood culture and general isolates (1986-1989) by hospital area for both
cefuroxime and gentamicin.
The resistance to cefuroxime within the two groups of isolates (general
and blood culture) is remarkably similar.
The resistance to gentamicin within the two groups of isolates was also
similar, particularly within the ITU area.
Within the Medical and Surgical hospitals the blood culture isolates were a little
more resistant than in the general population of isolates but within the ITU areas
the resistance in the blood culture and general isolates were similar.
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Table 35 Comparison of the resistance rates between the general and blood
culture isolates (1986-1989) by hospital area for both cefuroxime and
gentamicin




Percentage resistant(%) Percentage resistant(%)
n=8153 n=460
11.1 10.7
Medical hospital 11.1 11.2





Percentage resistant(%) Percentage resistant(%)
n=8014 n=460
1.9 3.3
Medical hospital 5.1 5.4
ITU areas 4.5 3.8
Overall 2.6 4.6
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Therefore it seems that the cefuroxime and gentamicin resistance figures
obtained by Stokes' method are valid.
Tables 36-38 show the cefuroxime resistance within the general isolates
from 18 separate ward areas (units) over the 3 year period. Tables 39-41 show, in
a similar manner, the gentamicin resistance in the same units over the same time
period.
These resistances were related, as far as was possible, with what, as
clinical microbiologists, we believed to have been the pattern of antibacterial
usage within each unit.
This was based essentially on our knowledge of the particular antibiotic
policies that we had discussed with each individual unit. This was certainly the
case with the prophylactic regimes for the Surgical hospital and the initial blind
therapy employed by the haematologists within their population of neutropenic
patients. However we had no hard data on the actual usage within these areas
over that time period. Therefore the statements in Tables 36-41 listed under
"Antimicrobial use" should be viewed with some circumspection.
In trying to relate the gentamicin resistance to a particular area without
the aid of the actual aminoglycoside use, it was decided that it could at least be
related indirectly to that use. This was attempted by running another computer
search which counted the number of different patients within each unit who had at
least one aminoglycoside assay (duplicates and multiples excluded).
These are enumerated in Tables 39-41 and are also expressed as a
percentage of the total aminoglycoside assays over the 3 year time period.
Cefuroxime resistance within the surgical hospital
The overall rate of cefuroxime resistance was 11.1% but the range varied
from 4.7% to 20.9%. The general units 1 (14%) and 2 (12.7%) had similar rates
of resistance whereas general unit 3 (7%) was significantly lower.
146













































































































It was known that units 1 and 2 preferred cefotaxime for prophylaxis
whereas unit 3 preferred an aminoglycoside. However the number of patients
having aminoglycoside assays carried out in unit 1 (75) and unit 3 (68) was not
appreciably different.
The vascular surgery unit (4) had a much higher rate of cefuroxime
resistance at 20.9%. It was known that every vascular patient was given
cefuroxime prophylactically.
Unit 5 (urology) was perceived as a unit likely to have resistant Gram
negative aerobes and to be a heavy user of antimicrobials. Therefore it was not
surprising that the cefuroxime resistance was higher than in the general surgical
units at 15.9%.
Gynaecology (unit 6) had the lowest rate of resistance at 4.7%. This unit
contained patients who mostly had simple uncomplicated operations and it had the
highest bed occupancy rate for the hospital.
Orthopaedics (unit 7) with a resistance rate of 11.7% was perhaps lower
than expected since cefuroxime was one of the orthopaedic surgeons favourite
drugs because of its antistaphylococcal activity coupled with a broader cover than
flucloxacillin.
Cefuroxime resistance within the medical hospital
Overall resistance was 11.1% with a range from 7.6% to 18.5%.
The actual antimicrobial usage within the general medical units (9, 11
and 12) was particularly sketchy, however it was known that (at that time) within
units 10 and 13 (general / haematology) there was considerable use of netilmicin
and azlocillin. This combination formed the blind treatment of choice for pyrexial
neutropenic patients.
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Unit 8, the renal ward which included patients with infections related to
chronic ambulatory peritoneal dialysis (GAPD), was known to heavily use
antimicrobials. This unit had the highest rate of resistance at 18.5%.
The general medical units 9 (8.4%), 11 (8.5%) and 12 (7.6%) had similar
rates of resistance to cefuroxime.
Interestingly the general/haematology units (10 and 13) had higher rates
of resistance at 12.2 and 13.2% respectively.
Cefuroxime resistance within the ITU areas
This area had an overall resistance rate of 27.7% with a range from
16.9% to 38.0%.
As expected the cefuroxime resistance within these patients was
significantly higher than in the rest of the hospital.
The following was known about antimicrobial use in these units.
In the cardiothoracic ITU (14) all patients received cefuroxime as
prophylaxis prior to and during surgery and this was continued until all invasive
lines were removed.
In the general ITU (unit 15) the illest patients in the hospital were treated.
Cefuroxime was, at times, the commonest drug (in the widest sense) prescribed in
this area.
In the head injury unit (16) the most injudicious antimicrobial therapy
within the hospital took place. There was also a subset of severely injured
patients on assisted ventilation.
The renal ITU (17) and special care baby unit (18) were the two biggest
individual users of the aminoglycosides.
Cefuroxime resistance within the ITU areas seemed to follow the
perceived pattern of prescribing. Resistance was highest in the general ITU (15)
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at 38% with 34.9% resistance in the cardiothoracic ITU (14) and 24.6% in the
Head injury unit (16).
Resistance was much lower in the two units where aminoglycoside use
was higher i.e. 22% (Renal ITU, 17) and 16.9% (SCBU, 18).
Gentamicin resistance within the surgical hospital
The overall resistance to gentamicin was 1.9% with a range of 0.7% to
5.0%.
The resistance was highest in the urology unit (5) at 5% which had the
third highest number of patients (149) on aminoglycosides in the hospital.
The rates of resistance were similar in general surgical unit 2 (1.6%), 3
(1.4%), vascular unit 4 (1.4%) and orthopaedics (1.2%).
General surgical unit 1 had a higher rate of resistance at 2.6% than the
other general surgical units but it had a similar number of patients with
aminoglycoside assays as unit 3 (75 and 68 respectively) which was thought to
use aminoglycosides more than the others.
Gynaecology had the lowest rate of resistance at 0.7%.
Gentamicin resistance within the medical hospital
The overall gentamicin resistance in this area was 2.6% with a range
from 1.0% to 6.1%.
The general medical units 11 and 12 had similar rates of resistance at
1.9% and 1.0% respectively. This differed from a rate of 3.1% in the other
general medical unit 9. This led to a reassessment of the original data since the
difference appeared to be inexplicably large. The resistant patient numbers were
scrutinised revealing that in the male ward of this unit, during the summer of
1986, there had been 7 who had been colonised/infected (predominantly catheter
urines) with the same gentamicin resistant Enterobacter cloacae. A readjustment
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of the figures for unit 9 gave a more realistic gentamicin resistance rate of 1.7% -
very similar to the rates of the other medical units.
The general medical/haematology units (10 and 12) had significantly
greater resistance rates to gentamicin then the general units, at 3.1% and 4.3%
respectively. Unit 13 had, at least, 164 patients during this time period on
aminoglycosides. • .
The highest rate of gentamicin was in the Renal/CAPD unit (8) which
had an estimated 117 patients on aminoglycosides and a rate of 6.1%.
Gentamicin resistance within the ITU Areas
The overall resistance to gentamicin was 4.5% with a range of 1.5% to
6.7%.
The highest resistance was found in the renal ITU (17) at 6.7% where
110 patients had aminoglycoside therapy (this undoubtedly represented in the
region of 30% of their patients).
The general ITU had a resistance of 5.8% with 94 patients having
received aminoglycosides. Again this represented about 25% of their patients.
The most interesting figure however was a rate of 4.1% in the SCBU
where over the 3 year period at least 638 babies had aminoglycoside assays. This
unit, on average, has 400-500 admissions per annum, therefore about 40% - 50%
of all babies received aminoglycosides in this unit. So they were the largest users
(in patient terms) of aminoglycosides in the hospital, yet their resistance rate was
low.
The above data clearly give much to discuss with the wide range of
cefuroxime resistance within various units of the hospital (which was not so
marked with the resistance to gentamicin) and the generally higher rate of
resistance to cefuroxime than to gentamicin. While most of the differences could
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be explained by anecdotal evidence it was clear that an attempt to relate the
differences to the actual antimicrobial use within these areas was important.
It was also felt important to continue to calculate the cefuroxime and
gentamicin resistances within these wards over a longer time period, not only to
achieve a larger series but to ascertain whether the resistances were changing over
time Therefore the series was extended from 1 April 1986 - 31 March 1989 to 1
April 1989 to 31 March 1991.
By the financial year April 1989 to March 1990 the pharmacy department
of the RIE had developed software which enabled the downloading of data which
revealed the actual antimicrobial usage in each ward area. Although these data in
themselves were important it was also clearly necessary to relate them to bed
occupancy within each area, over the same time period. These data were obtained
from the RIE bedstate figures.
The percentage resistance to cefuroxime and genlamicin are shown in
Tables 42-44 for each of the 17 units over both time periods (the antimicrobial
usage figures for urology were not available).
Table 45-47 show the total number of patients admitted to each unit, the
total amount of Beta-lactams used per patient, the total amount of 2nd and 3rd
generation cephalosporins used per patient, the total amount of cefuroxime used
per patient and the total cost of all antimicrobial agents per patient. This is related
to the cefuroxime resistance over the time period April 1989 to March 1990.
Table 48-50 shows the usage of the aminoglycosides in each of the units
related to patient admissions and the gentamicin resistance over the period April
1989 to March 1991.
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Table 48 Aminoglycoside use related to unit, patient throughput and












1. General 95.9 1512 0.06 0.5
2. General 27.1 1737 0.02 1.3
3. General 80.6 1557 0.05 2.0
4. Vascular 16.6 969 0.02 0.7
6. Orthopaedics 1.4 3443 0.0004 0.6
7. Gynaecology 6.1 3842 0.002 0.7
Table 49 Aminoglycoside use related to unit, patient throughput and












8. Renal/CAPD 43.5 376 0.12 2.0
9. General 12.7 1561 0.008 0.9
10. General/
Haematology
74.3 1650 0.04 2.1
11. General 9.9 1148 0.009 1.8
12. General 17.7 1485 0.01 1.0
13. General/
Haematology
133.0 1774 0.07 1.6
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Table 50 Aminoglycoside use related to unit, patient throughput and












14. Cardiothoracic 8.3 799 0.01 4.5
15. General 23.8 109 0.2 2.2
16. Head injury 30.9 950 0.03 3.6
17. Renal 9.7 85 0.1 5.9
18. SCBU 17.6 429 0.04 2.5
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CEFUROXIME RESISTANCE OVER 5 YEARS
Surgical hospital
1. The overall resistance rose between 1986-89 and 1989-91 from
11.1% to 15.0%
2. Of the seven units studied the resistance rose in five and remained
similar in two (unit 3, general surgery and unit 7, gynaecology)
3. The rise in resistance was most marked in orthopaedics (6), general
surgery (unit 1) and vascular (unit 4)
Medical hospital
1. The overall resistance rose from 11.2% (1986-89) to 12.7%
(1989-91)
2. Of the six units studied the resistance rose in five and fell in one
(general medical, unit 9)
3. The rise in resistance was most marked in Renal/CAPD (unit 8)
and general medical unit 11
ITU areas
1. The overall resistance rose from 27.7% in 1986-89 to 38.3% in
1989-91
2. It rose in all five units studied
3. The rise was most marked in the Head injury unit (16), the
cardiothoracic ITU (14) and the general ITU (15)
GENTAMICIN RESISTANCE OVER 5 YEARS
Surgical hospital
1. Overall resistance to gentamicin fell from 1.9% in 1986-89 to 1.
in 1989-91
2. The resistance fell in five of the seven units studied.
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Medical hospital
1. Overall resistance fell from 2.9% in 1986-89 to 1.5% in 1989-91
2. It fell in five of the six units and remained the same in the other
ITU
1. Overall resistance to gentamicin fell from 4.5% in 1986-89 to 3.3% in
1989-91
2. It fell in all the units studied apart from the Head injury unit (16)
STATISTICAL ANALYSES OF THE RESISTANCE RATES
The analyses were carried out by Dr A Bowman of the Department of
Statistics, University of Glasgow.
The resistance rates were plotted for each unit for each drug over the two
time scales. This was carried out on a logit scale:
logit (r) = log (r/(l-r))
where r is the rate = number resistant/number tested
The plots are shown in figure 10 where :
drug 1 = cefuroxime
drug 2 = gentamicin
group 1 = Surgical hospital
group 2 = Medical hospital
group 3 = ITU areas
Interpretation
Resistance rates over the two timeperiods
Differences between the two times were assessed by taking the difference
across time for each ward and checking whether these differences were
significantly different fi-mizero. The p-values are shown in Table 51
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Figure 10
drug 1 group 1
1.4 1.6
lm#
drug 1 group 2
1.4 1.6
IfT*





drug 2 group 1
drug 2 group 2
drug 2 group 3
1.4 1.6
in*
Plots (employing a logit scale)showing the statistical analysis of the resistance
rates: for each unit, for each drug, over the two time scales.





p values for the difference in resistance across time
Area Cefuroxime (1) Gentamicin (2)
surgical (1) 0.014 0.085
medical (2) 0.612 0.044
ITU (3) 0.028 0.654
The trend for drug 1 (cefuroxime) is increasing over time and the trend
for drug 2 (gentamicin) is decreasing. This is clearly significant (p<0.05) for the
cefuroxime resistance in the surgical wards and the Intensive care areas and for
gentamicin resistance in the medical units.
Resistance rates to each drug within ward areas
This was carried out using one-way analysis of variance for each drug
and time combination. The p-values are shown in Table 52.
Table 52
p values for differences in resistance rates to each
drug within the ward areas.
Time period Cefuroxime (1) Gentamicin (2)
1986-1989 (1) 0.003 0.077
1989-1991 (2) 0.007 0.002
There is therefore clear evidence of differences in each case although
gentamicin resistance over 1986-89 it is a little marginal.
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Differences in resistance rates to cefuroxime and gentamicin
The differences in resistance rates between cefuroxime and gentamicin is
very clear indeed. When a two sample t test was carried out for each group and
time combination the p values were all extremely small. From the figure it can be
seen that the values for the two drugs hardly overlap at all.
COMMENTS ON THE BETA-LACTAM USAGE FIGURES COMPARED TO THE
CEFUROXIME RESISTANCE
Surgical hospital
1. The highest usage was in the vascular unit (4) with 5.4g/patient and the
resistance was high at 26%. Next was the general surgical unit 1 with
4g/patient and a resistance of 20.5%.
2. The highest costs of antimicrobials per patient were also in these two units
(4 and 1).
3. Most of unit l's Beta-lactam use was in the form of 3rd generation
cephalosporins.
4. Most of the vascular unit's (4) use was of cefuroxime (2.2g of 5.9g).
5. The lowest resistance and lowest usage were in Gynaecology (7) with
1.6g/patient and 4.6%, respectively.
6. General surgery unit, 3 had a higher total usage (2.8g/patient) than unit 2
(1.8g/patient) yet the resistance to cefuroxime was 7.7% compared to
15.4%.
Medical hospital
1. The highest usage and rates of resistance were found in the Renal/CAPD
ward (8) with 5.2g/patient and resistance of 24%, respectively.
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2. In the general/haematology wards (10 and 13) both had high usage at 4.6
and 4.3g/patients respectively. They were also high users of 2nd/3rd
generation cephalosporins.
3. The figures for the subgroups of haematology patients within units 10 and
13 were considerably higher because of the dilution by the numbers of
ordinary general medical patients.
4. In terms of the total antimicrobial costs per patient the general
medical/haematology units (10 and 13) and the Renal/CAPD (8) were the
highest at £20.06, £24.17 and £23.29 respectively. This should be
compared with the costs per patient in the general medical wards of less
than £10.
ITU Areas
1. It is clear that large numbers of straight forward cases were diluting out the
problem cases (true ITU cases) in the cardiothoracic ITU (14) with
3.6g/patient and in the Head injury unit (16) at 3.2g/patient. This is to be
compared with the general ITU (15) patients at 19.9g/patient and the renal
ITU patients at 13.9g/patient.
2. The costs of antimicrobials per patient were also similarly diluted in these
areas with the cardiothoracic ITU at £13.80/patient and the Head injury
unit at £8.98/patient compared with £88.04/patient for the general ITU and
£69.92 for the renal ITU.
3. Despite this, the figures show the clear differences that exist between the
usage of Beta-lactams and the total cost of antimicrobial between a general
ITU patient and the general medical or surgical patient.
4. Please note the relatively large amount of Beta-lactam given to each baby
(1.2g/baby) in the SCBU while realising that they are 50 times smaller
than an adult. Yet the cefuroxime resistance is the lowest of all the ITU
areas at 21%.
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COMMENTS ON THE USAGE OF THE AMINOGLYCOSIDES
Surgical unit
1. The highest usage was within surgical unit 1 with 0.06g per patient,
followed by the surgical unit 3 (0j05g/patient).
2. However the gentamicin resistance was 0.5% in unit 1 but 2% in unit 3.
Medical unit
1. The highest usage was in the Renal/CAPD unit (8) with 0.12g/patient.
This amount, when compared to normal patients, should probably be even
higher since the dosage in the renal patients is necessarily reduced because
of their renal insufficiency.
2. The next highest users were the two general/haematology units (10 and 13)
with usage of 0.04g/patient and 0.07g/patienyespectively.
3. As was the case with Beta-lactam use, the use within the subgroup of
haematology patients will be considerably higher than this.
Intensive care areas
1. The highest usage was in the general ITU (15) with 0.2g/patient although
the gentamicin resistance was only 2.2%.
2. Next highest usage was in the Renal ITU (17) with a use of O.lg/patient.
This figure is perhaps relatively lower than it might have been since most
of the patients were in acute renal failure. The resistance to gentamicin
was highest here at 5.9%.
3. The figures of usage within the cardiothoracic ITU (14) and Head injury
unit (16) were falsely low because of a dilution out of the true ITU patients
by those patients who were straightforward operative cases or minor head
injuries.
4. The most remarkable figure was the usage within the SCBU (18) with
0.04g/patient. This in itself is four times more per patient than in e.g. the
cardiothoracic ITU. But it is even more significant when it is realised that
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the babies are on average at least 50 times lighter than an adult. Therefore
an equivalent adult usage figure would be about 2g/patient. Yet the
gentamicin resistance is low at only 2.5%.
STATISTICAL ANALYSIS OF THE ANTIMICROBIAL USAGE FIGURES
Scatter diagrams were constructed (data not shown) for the total Beta-
lactam used per patient, total 2nd and 3rd generation cephalosporins per patient,
total cefuroxime per patient and total antimicrobial costs per patient versus the
cefuroxime resistance over the period of 1989-91.
In only the case of the surgical wards did an elliptical distribution occur.
Similarly scatter diagrams were constructed for the aminoglycoside use
per patient versus the gentamicin resistance. No elliptical distributions were
found.
This apparent lack of correlation between antimicrobial use and
resistance is not surprising.
1. As has previously been pointed out, figures for antimicrobial use in the
haematology patients, in the cardiothoracic ITU and Head injury unit are
biased because of the dilution brought about by large numbers of problem-
free patients. This results in a lack of correlation between use and
resistance within the medical and ITU areas of the hospital.
2. Similar problems existed within the population of surgical patients. For
instance the gentamicin use in surgical units 1 and 3 were very similar at
0.06g/patient and 0.05g/patient.)respectively.yet their resistance rates to
gentamicin are clearly different at 0.5% and 2%/espectively.
The Beta-lactam usage in surgical unit 2 was 1.8g/per patient and in
surgical unit 3 was 2.8g/per patient yet the resistance to cefuroxime was
15.4% in unit 2 and about half that at 7.7% in unit 3.
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Perhaps the sort of surgery (and therefore the underlying conditions of the
patients) in each of these surgical units was different in some way which
then had an effect on their likelihood of acquiring a resistant coliform?
The underlying condition of the patient has already been shown to be an
important variable in the rate of resistance to both cefuroxime and
gentamicin by the fact that the rates of resistance were higher in the ITU
patients than in either those patients from a general surgical or general
medical wards.
3. The relatively low rates of resistance to both gentamicin and cefuroxime in
babies from the SCBU in the face of the relatively widespread use of both
these drugs (in terms of the number of babies treated) suggests that it
might be in the total amount of drugs that are used (per square metre, for
instance) that was important.
4. In any case the relationship between antimicrobial use and resistance is not
a simple one and requires a great deal more investigation of the other
possible variables to elucidate it.
5. The usage figures are only over a 12 month period and it is therefore
obviously important to obtain these over a much longer time period in
order to view the trends in antimicrobial prescribing which might then
allow us to explain why there has been a rise in resistance to ccfuroxime
but a decrease in the resistance to gentamicin.
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CHARACTERISATION OF ACINETOBACTER BETA-LACTAMASES
CONVENTIONAL ISOELECTRIC FOCUSING
Bush (1988) described isoelectric focusing as "one of the most critical
assays used to verify the identity of Beta-lactamases". Therefore IEF is a
reasonable technique to employ in the first instance to look for obvious
differences or similarities in the Beta-lactamases produced by these organisms.
Clearly it was important to determine which strains had Beta-lactamases
which were obviously plasmid mediated e.g. TEM-1, TEM-2, SHV-1 etc. From
the IEF screen it was found:
a) No strains carried a TEM-1 or a similar plasmid mediated Beta-
lactamase.
b) All 43 strains studies possessed a (presumed) chromosomal Beta-
lactamase which had a very basic pi.
c) Only one strain (HI26) out of the 43 strains focused in a
conventional sense with a pi of around 9.1.
d) The other 42 possessed ill-defined areas of activity often
associated with streaks from the anode to the cathode. This
made it extremely difficult to assess the pi of these enzymes.
e) It was also clear that the staining with nitrocephin was
comparatively slow compared to the rapid staining of control
enzymes such as TEM-1, P99 etc. This no doubt reflected the
poorer activity of the Acinetobacter enzymes.
The problem is graphically portrayed in figure 11 where in Track A a
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Conventional isoelectric focusing
Track A: Acinetobacter, H10 Track F:
Track B: Providencia, H25 Track G:
Track C: Acinetobacter, 6B101 Track H:
Track D: TEM-1 Track I:























Tracks A to F are Acinetobacter |3-lactamases on conventional isoelectric
focusing with a mixture of 3.5-10 and 9-11 ampholines
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lactamases, both plasmid mediated and chromosomal in origin, with pi values that
were easily assessed.
This obvious failure to focus properly in conventional polyacrylamide
IEF systems is further shown by employing a 1:1 mixture of 3.5 - 10.0 and 9-11
ampholines. (figure 12)
SDS-FREE PAGE
Therefore an attempt to discriminate between different Beta-lactamases
on the basis of their M r (molecular size) was made.
Conventionally, proteins can be separated by their molecular size on an
SDS - PAGE system. This involves denaturing the protein and linearising it with
the SDS. This linearised and negatively charged protein will then migrate in an
electrical field to a distance proportional to its length (if the right conditions are
attained, e.g. gel porosity, a plot of log^o Mr versus relative mobility (Rf) reveals
a straight line relationship). The protein is stained with either coosmassie blue or
silver nitrate.
Such a system, therefore, employs reducing conditions, these are
unsatisfactory when using crude preparations of Beta-lactamase since many other
proteins are inevitably present. In order to use crude sample preparations and to
retain the substrate nitrocephin as a rapid probe for the enzymes, it was therefore
necessary to employ non-denaturing conditions. This required a system that was
free from SDS. The protocol employed was as described in the Materials and
Methods.
Initial experimentation with this system was with twelve mini-
preparations of Acinetobacter Beta-lactamases run on 12% acrylamide gels with
normal polarity for short running times of up to 4 hours e.g. 250 V, 40 mA for 1 h
followed by 250 V, 70 mA for 3 h.
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The result was a broad band of Beta-lactamase activity detected in front
of the focused line of bromophenol blue. Similar results were obtained despite
running the gels at lower voltages for longer periods e.g. 40 V for 2 h followed by
30 V for 14 h.
Finally six Acinetobacter enzymes were run in a SDS-free, 12%
acrylamide gel with control Beta-lactamases i.e. TEM-1, TEM-2 and OXA-2 on
normal polarity at 30 V for 17 h followed by 40 V for 9 h.
The result is shown in figure 13 . Almost all the Beta-lactamase activity
detected was found on the anode side of the bromophenol blue line. The control
Beta-lactamases TEM-1 (track C), TEM-2 (track F) and OXA-2 (track F) could
all be visualised. The activity in track G, at the point of loading was thought to be
an artefact.
From these experiments it was decided to abandon SDS - free PAGE as a
means of discriminating between Acinetobacter Beta-lactamases. It was felt that
these enzymes were neither solubilising within the conventional IEF
polyacrylamide system nor in the SDS-free PAGE system. The reasons for this
apparent lack of solubilisation were therefore pursued. This followed two
separate lines of research, firstly into systems for solubilising the preparations and
secondly into estimations of the M r of these enzymes.
It should be noted however, that several of the assumptions made at this
stage concerning the SDS-free PAGE electrophoresis were misplaced as will be
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Track F TEM-2 + OXA-2
Track G Acinetobacter,H33
Track H Acinetobacter,HI 0
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ISOELECTRIC FOCUSING EMPLOYING A POLYACRYLAMIDE GEL
INCORPORATING UREA AND TRITON X-100
To investigate the hypothesis of poor solubilisation in conventional IEF
PAGE systems an IEF system incorporating urea and Triton X-100 was devised.
Clearly it was important that the denaturing conditions employed were
sufficient to enable solubilisation but not enough to destroy the biological activity
of the Beta-lactamase. This was crucial to enable the enzyme activity to be
probed, as before, with the chromogenic substrate, nitrocephin.
An IEF gel containing approximately 12% polyacrylamide (final
concentration) with 4M urea and 2.5% Triton X-100 was devised, its composition
is shown in Table 53.
Table 53
Composition of the IEF gel containing urea, Triton X-100 & polyacry lamide









in 100ml distilled water
BDH 15ml 80g/L (A)
9g/L(bis)
Riboflavin (20mg/L) Sigma 5ml 2mg/L







TEMED Sigma 0.05ml 0.9mg/L
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The concentration (%C) of bisacrylamide (crosslinker) was increased to
10% to increase the pore size of the gel (i.e. where %C - g crosslinker per 100 g
monomers).
Attempts to decrease the %T of the gel (i.e. %T = g monomers per 100
ml, where g monomers = g acrylamide + g crosslinker) resulted in gels that could
not be poured in a vertical plane due to their lack of physical strength.
The problems of employing urea in these systems were noted. The major
problem is the accummulation of cyanate ions in stock solutions as a result of
chemical isomerisation. The cyanate ions react with the amino groups to form
stable carbamylated derivatives resulting in an alteration of the charge of the
proteins.
If this reaction is incomplete several artefactual species of proteins, with
different charges, result. For this reason all urea solutions were made up fresh just
prior to use.
Preparation of gels
The gels were poured in the same vertical glass plate cassette as for
conventional IEF polyacrylamide gels.
The gel mixture was prepared by initially mixing lOg of urea in 10.2 ml
of 10% w/v Triton X-100 in a 60°C waterbath followed by 10 ml of distilled
water. To 15 ml of the stock acrylamide/bisacrylamide solution, 2.5 ml of a 50:50
mixture of pH 3.5 - 10.6 and pH 9 - 11 ampholines were added. The two
mixtures were then added to each other with gentle agitation followed by 5 ml of
riboflavin (20 mg/L) and 50 pi of TEMED. The mixture was thoroughly but
gently mixed and applied to the vertical glass plates. The gel was allowed to
stand overnight to achieve mechanical strength.
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Sample preparation
Initially mini-preparations of the Beta-lactamases were employed (as
described previously). Up to 100 pi were added for each sample depending on
the nitrocephin spot test. Five pi of isoelectric point (pi) standard markers were
also spotted onto the gel to quantify the pi gradient.
Running conditions
The gel was run at 1W (constant), 550 V (limiting) and 20 mA (limiting)
for 18 h at room temperature.
Results
Initial gel runs revealed no detectable Beta-lactamase activity after
staining with nitrocephin solution (500 mg/L)
It was therefore possible that the concentration of particularly, urea and
Triton X-100 in the gel might have been denaturing the enzyme to such an extent
that it was losing its biological activity. Controls were prepared of each enzyme
containing equivalent concentrations of urea and Triton X- 100. These were
probed for biological activity with the nitrocephin spot test over a time period of
up to 18 h. In all cases the biological activity of the enzyme remained unaffected.
Acinetobacter strains
At this point chronologically we narrowed our interest down to ten strains
of Acinetobacter from the survey. They had been selected on the basis of their
resistance to aztreonam and had MIC values of >4 mg/L (see Table 54)
All subsequent work with IEF gels, Mr estimates and biochemical
characterisation was carried out on 9 of these 10 strains. Conventional IEF on
polyacrylamide showed that strain HI51 as well as possessing a chromosomal
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Beta-lactamase also carried a TEM-2 plasmid-mediated Beta-lactamase.
Therefore it was excluded from further study.
Table 54
Ten strains of Acinetobacter studied: sources & MIC to aztreonam
Strain sub-species New species Source AZ
MIC
5B86 var.lwoffii A.lwoffii blood 16
6B230 var.anitratus A.junii blood 32
H17 var.anitratus A.baumannii urine 64
H26 var.anitratus A.baumannii sinus swab 32
H63 var.anitratus A.baumannii wound swab 128
H68 var.anitratus A.baumannii urine 64
H126 var.lwoffii A.junii wound swab >256
H141 var.anitratus A.baumannii wound swab 64
H151 var.lwoffii A.junii /A.lwoffii blood 8.0
H162 var.anitratus A.baumannii wound swab 64
Sample solubilisation
A possible explanation for the failure of the initial experimentation with
the urea/Triton polyacrylamide gels was that the sample itself required
solubilisation before being placed on the gel. Therefore a sample concentrate was
devised whose composition is shown in Table 55.
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Table 55 Composition of the sample concentrate
Material Supplier Volume
40% ampholines w/v LKB
pH 3.5-10 lOOpL
pH 9-11 lOOpL
Triton X-100 (10% w/v) BDH 200pL
(3-mercap toethano 1 Sigma lOOpL
Sample concentrate was added to each sample in the ratio of 1 pi of
sample concentrate for each 5 pi of Beta-lactamase in an Eppendorf tube. The
total sample volume was not more than 120 pi.
Results after sample solubilisation
After the above sample solubilisation, activity was again detected by
nitrocephin staining and, rather than ill-defined areas of activity, lines of focusing
were beginning to appear.
It was also noted that the time for the colour change to occur in the gel
(from yellow to red) was taking a considerably greater length of time compared to
conventional IEF gels. In fact staining took 30 - 60 minutes at 37°C. The gel
during that period was wrapped in "clingwrap" to prevent it drying out.
Sample solubilisation and saturation with urea
The next step was to increase the solubilisation of the sample. To do this
urea was added to the sample + sample concentrate in an Eppendorf until the
sample was saturated.
The excess urea was pelleted by centrifugation (30s at 2874 g, MSE
Microcentaur). After considerable experimentation, there appeared to be a critical
185
amount of urea required to give optimal "focusing". Too little resulted in poorer
focusing and too much affected the activity of the enzyme. The technique was
therefore very difficult to standardise.
This was especially true if ambient room temperatures fell below 10°C
when the urea began to precipitate out of solution.
After running some 12 individual gels, there appeared some degree of
similarity amongst 5 of the strains with clear differences within the other 4 strains.
These are shown in Figure 14.
From these gels a tentative classification of the Beta-lactamases was made (Table
56). HI7, H26, H63, H68 and HI41 all had what appeared as 3 predominant areas
of activity in each gel. Namely at pi 9.0, 8.8 and 7.8. These were all A.
baumannii strains. 6B230 focused best with bands around pi 7.8. It was felt that
all the other enzymes HI7, 26, 63, 68 and 141 might well, if given the same
conditions, focus in the same manner. 6B230 was a A junii strain. HI62 another
A. baumannii strain was very similar to the first group but also had pronounced
bands of activity at pi 9.3 and 9.5. The other strains 5B86 (A.lwoffii) and H126
{A.junii) produced completely different bands of activity at pi 7.2 and pi 7.5
respectively.
Although a tentative classification was possible, the technique was
clearly not optimal. There was still considerable distortion of the polyacrylamide
during focusing. The slow staining was also a problem with 50 mg of nitrocephin
being required to stain one gel properly.
It was clear that solubilility was still the major problem and the distortion
of the gels perhaps was due to sieving in the polyacrylamide - suggesting that the
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Tentative classification ofAcinetobacter chromosomal (^-lactamases
ACE group Strain (s) Pl(s)
la HI 7, H26, H63, H68 & 7.8, 8.8, 9.0
H141
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BETA-LACTAMASE MOLECULAR MASS DETERMINATIONS
This was carried out in conventional low pressure gel permeation
columns with large scale preparation of crude cell extracts.
Each enzyme was first applied to a calibrated G-75 Sephadex column.
All but two enzymes appeared in the void volume and in those the procedure was
repeated with a Sephacryl S- 300 column. The Mr of these enzymes is shown in
Table 57.
Table 57












It was therefore clear that only two enzymes HI26 and HI62 had an Mr
that one would expect of chromosomal Beta-lactamases in Gram negative aerobic
bacilli. Interestingly, the one with the lowest Mr (HI26) at 32.5 Kd was the only
enzyme which focused in a conventional IEF polyacrylamide gel. Seven of the
others had an Mr ranging from 580 Kd to >1000 Kd. These enzymes were clearly
different to any other Beta-lactamase so far described. This finding indeed
suggested that the polyacrylamide matrix was too tight for optimal separation of
these large enzymes. It also set the interesting question as to why these enzymes
appeared so large in low pressure gel permeation systems. Was it because they
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were attached to other cell membrane components? Or was it because they exist
in multi-subunit form?
AGAROSE UREA AND SORBITOL (AUS) GELS
It was not very easily to increase the porosity of the polyacrylamide gel
further. This would have required a lower concentration of acrylamide (we had
already increased the concentration of the crosslinker). A lower concentration of
acrylamide leads to a gel with poor mechanical stability - unsuitable for
production in a vertical cassette. Increasing the crosslinker was also likely to
increase the hydrophobicity of the gel. Therefore agarose, with a macroporous
structure that minimises molecular sieving effects, appeared to be the matrix of
choice, especially with proteins of the molecular size that we were wishing to
studv.
J
Vecoli et al. (1983) compared the use of an agarose gel IEF with that of a
conventional polyacrylamide gel IEF in characterising low molecular weight
Beta-lactamases. They showed good correlation with the isoelectric points in
most samples tested. Differences were found in only two cases. HMS-1
produced two highly resolvable enzyme bands in agarose gels rather than the
single faint band seen on a polyacrylamide gels. The PSE-1 enzyme showed a 0.2
pH unit shift between polyacrylamide and agarose (5.7 and 5.5 respectively).
Olsson & Laas (1981) described a method for isoelectric focusing in
agarose under denaturing conditions. They pointed out the following:
1. Agarose of standard quality cannot be used for IEF since it contains a high
content of charged groups, this gives rise to severe endosmosis and consequently
disruption of the gel. Agarose-IEF has an extremely low concentration of
negatively charged groups and the effect of these are counter-balanced by
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positively charged groups that are covalently bound to the matrix. This results in
a gel with very little endosmosis.
2. The presence of urea in an agarose gel disturbs the well organised structure
of the agarose matrix. This matrix is extensively hydrogen bonded and urea is a
typical H-bond breaking agent. This results in a much lower gelling temperature,
an increased time for gelling and a gel of lower mechanical strength.
3. Urea and ammonium cyanate form an equilibrium pair,Therefore there is
always a risk of carbamylation when using urea especially of the proteins under
study. "The risk is fairly low with fresh urea solutions at room temperature, but
increases as the temperature rises."
Olsson and Laas (1981) solved the problems of agarose/urea
incompatibility by:
(a) increasing the agarose concentration in the gel to 2% (for 8M urea)
(b) incorporating 10% sorbitol into the gel.
(c) scavanging the cyanate ions by employing 1% p-mercaptoethanol
in the agarose matrix.
(d) allowing the gel solution to set overnight at room temperature.
We therefore devised a gel containing agarose, urea, sorbitol and Triton
X-100 based on the polyacrylamide, urea, Triton X-100 gel previously described
,taking into account the findings of Olsson and Laas (1981). The composition of
this gel is shown in Table 58. It was found that a 1% agarose gel gave optimal
results, the higher (2%) concentration resulted in fracturing of the gel followed by
gel disintegration resulting from high field strength around the fractures.
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Table 58
Composition of AUS gel





Urea BDH lOg 4.3 mol/L
Distilled water 24.6ml
Agarose-IEF (VIII) Sigma 377mg 1%
D-sorbitol BDH 4g 10%
Triton X-100 (10%w/v) BDH 10.2ml 2.5%
40% ampholines w/v
pH 3.5-10 BDH 2.5ml 2.0% w/v
P-mercaptoethanol Sigma 0.5ml 1%
AUS gel preparation
AUS gels were prepared by melting 377 mg of agarose (agarose for
isoelectric focusing) in 15 ml of distilled water in a microwave oven (550 W) for
30 - 40 seconds. This was then allowed to cool to 60 °C in a waterbath.
Four g of D-sorbitol were added to 9.6 ml of distilled water and heated to
60°C in the waterbath. Similarly 10.2 ml of 10% (w/v) Triton X-100 were added
to 10 g of urea and placed in the 60°C waterbath. The sorbitol solution and urea
in Triton X-100 were then added and mixed. Just before incorporation of this
mixture into the agarose, 2.5 ml of pH 3.5 - 10.6 ampholines (LKB) and 0.5 pi
Beta-mercaptoethanol were added. The final mixture of 1% agarose, 4.3 mol/L
urea and 10% sorbitol was then gently stirred at 60°C and drawn up into a
preheated glass pipette. The solution was then pipetted onto the hydrophobic
surface of a GelBond sheet (LKB) which had been placed on the LKB 2217
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ultrophor electrofocusing unit. A few drops of kerosene were spread over the
surface of the cooling unit to ensure good contact between the GelBond and the
cooling unit. The gel had approximately a 1 mm overall thickness. The gel was
left overnight (with the lid firmly down to prevent the gel drying out) to achieve
mechanical strength.
Sample preparation
The Beta-lactamase samples used for AUS gel electrophoresis were
obtained from the pooled peak fractions obtained from the gel permeation
experiments.
The sample size was equalised with time as described before. Five pi of
Beta-lactamase were added to 1 pi of sample concentrate. The composition of the
sample concentrate was as described in Table 55 apart from 200 pi of ampholines
(40% w/v) pH 3.5 - 10.6 instead of a 50:50 mixture of pH 3.5 - 10.6 and pH 9 -
11.
As before, just prior to application to the gel the sample mixture was
The samples (and isoelectric point markers) were applied to the surface
of the gel but near the middle - rather than 2 cm from the anode as with
conventional polyacrylamide IEF gels.
Running Conditions
Electrode wicks (LKB) were applied to the gel, the anode soaked in
O.IN phosphoric acid (BDH Analar) and the cathode soaked in O.IN NaOH
(BDH Analar). The electrofocusing unit was maintained at 15 - 20°C since urea
precipitates at temperatures below 15 °C.
A constant power was maintained at 30 W with the voltage and current
set at the limiting values of 1500 V and 30 mA respectively.
saturated with urea. The excess urea was pelleted by brief centri
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Gels were electrophoresed until the pi markers had focused i.e. around
2.5 h.
Staining
AUS gels were stained with nitrocephin solution (500 mg/L) as described
previously . As with the urea/polyacrylamide gels almost 100 ml of nitrocephin
solution was required to visualise the bands of Beta-lactamase activity. The
staining period being 30 minutes to 1 hour.
The problem was exacerbated by the need to use IN NaOH as the
cathode buffer. This strong alkali hydrolysed the nitrocephin causing the gel in
the cathodic area to turn red. This made visualising the Beta-lactamase bands
near the cathode difficult. The problem was partially overcome by overlaying this
area with a weak acid prior to staining with nitrocephin.
Results
The AUS gel system was initially tried without the sample solubilisation
step but poor focusing resulted. After some experimentation eight of the nine
Beta-lactamases focused on two separate gel runs. (See figurel5 ). Figure 16 is
also included to show the same enzymes electrophoresed on a conventional
polyacrylamide IEF gel for comparison.
The Beta-lactamase from FI63 (not shown) was found on another AUS
gel run to be identical to 6B230.
Therefore there appeared to be at least four different focusing patterns on
AUS gels. Six of the nine enzymes have very similar focusing patterns; the Beta-
lactamases from strains HI7, H26, H63, H68, H141 and 6B230 all had major
bands at pi 8.6 and 8.8. However the enzyme from H26, which was run on both
Gel 15a and Gel 15b as an internal control, had additional minor bands at pi 9.8
and 10.1 on Gel 15b. H17 also had a minor band at pi 10.3. The other three
enzymes were completely different, H162 had a single band at pi 8.7; HI 26 has a
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major band at pi 8.2 and a minor band at pi 8.1 and 5B86 has a major band at pi
7.3 and a minor band at pi 7.7.
Table 59
ACE+ types by AUS
*
gel isoelectric focusing










ACE+ = Acinetobacter chromosomal enzyme
AUS* = Agarose / Urea / Sorbitol
Therefore at least four different Acinetobacter chromosomal enzymes
(ACE) types were characterised by this technique, ACE 1 to ACE 4 (see Table
59). The same four groups (with the same order of pi's) were found with the
polyacrylamide/urea IEF system but there was poorer focusing and more gel
distortion.
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BIOCHEMICAL CHARACTERISATION OF THE ACE ENZYMES
The biochemical characterisation of the nine Acinetobacter Beta-
lactamases essentially follows the recommendations for the evaluation of novel
Beta-lactamases as suggested by Bush & Sykes (1986) and Bush (1989 a).
Biochemical characterisation was first carried out by measuring the
specific activity of the nine Acinetobacter strains against nine penicillin,
cephalosporin and monobactam substrates.
Antimicrobial sensitivities
The MIC values of the strains to these substrates are shown in Table 60 .
The results showed that all the. Acinetobacter strains studied had a high degree of
resistance to penicillins and first, second and third generation cephalosporins.
There was some correlation between the resistance levels and the enzyme
produced. All the strains encoding the ACE-1 enzyme had very similar MICs to
all the drugs tested. H162, which encoded ACE-2, could not be distinguished
from the ACE-1 strains on its resistance profile. However, strain HI26, which
encoded ACE-3 was generally more resistant to the drugs tested than the ACE-1
or ACE-2 producers. Specifically, H126 was more resistant to the third
generation cephalosporins and the monobactam, aztreonam. On the other hand,
strain 5B86, which encoded ACE-4, was generally less resistant than the other
ACE producers. It was, particularly, less resistant to the penicillins and the first
generation cephalosporins tested.
Substrate profiles
The enzyme preparations were partially purified by gel permeation. The
spectrophotometric assay employed was that of O'Callaghan et al. (1972).
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Cephalosporins and the monobactam were used at concentrations of
either 100 pM or 1000 pM and the penicillins at a concentrate of 1000 pM
The relative rates of hydrolysis of the nine enzymes are presented in
Table 61. The values were expressed as a percentage of the value for nitrocephin
which was the substrate most rapidly hydrolysed by all these enzymes (Bush &
Sykes, 1986). Cephaloridine was also hydrolysed, albeit much more slowly, by
all the enzymes. Cephradine was hydrolysed (again much slower than the
nitrocephin) by all the enzymes apart from 5B86 and H26. All the enzymes apart
from 5B86 hydrolysed penicillin G but at around 1000 times more slowly than
nitrocephin. There was no detectable hydrolysis of cefuroxime, cefotaxime,
ceftazidime, aztreonam, ampicillin or carbenicillin by any of the nine enzymes.
These results show no clear differences in the substrate profiles of the
enzymes, however, they are clearly all cephalosporinases rather than
penicillinases or broad spectrum enzymes.
Kinetic parameters of the ACE enzymes
The kinetic parameters (Km and Vmax) of all nine enzymes were
calculated by measuring the rate of hydrolysis at limiting substrate (nitrocephin
and cephaloridine) concentrations and constructing Lineweaver - Burk plots (data
not shown). The K m and Vmax values are shown in Table 62.
The Km values obtained with both nitrocephin and cephaloridine were
broadly similar to each other. The Km values to cephaloridine ranged from 150
pM to 710 pM and were similar to the values of Acinetobacter Beta-lactamases
found by Morohoshi & Saito (1977) and Hikida et al. (1989) of 250 pM and 511
pM respectively. These results show that all four ACE enzymes have moderate
affinity for cephaloridine and nitrocephin. All the Km values were within the
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another. Thus none of the ACE enzymes demonstrated greater substrate affinity
than the others and K m values were a poor discriminator.
All the enzymes hydrolysed nitrocephin at similar rates apart from ACE-
4 (5B86) which is one order of magnitude lower than the others. All the enzymes
hydrolysed cephaloridine at similar rates and between one to two orders of
magnitude lower than the rates of hydrolysis for nitrocephin. The enzymes all
have very similar relative efficiency values (Vmax/Km) for the hydrolysis of
cephaloridine (Table 62).
Therefore hydrolysis rates and relative rates of efficiency were poor
discriminators of the ACE enzymes.
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Inhibition Studies
Table 63 shows the effect of the Beta-lactamase inhibitors aztreonam,
cloxacillin and clavulanic acid, expressed as the concentration required for 50%
inhibition (ID50) of enzyme activity. The enzymes from all the strains were
readily inhibited by cloxacillin. Most were inhibited within the range of 0.003 -
0.022 p.M. However, two enzymes required at least 0.1 p,M cloxacillin for 50%
inhibition. One of these was an ACE-1 but this level of cloxacillin is still
considered to be very low. Thus cloxacillin inhibition also seems to be a poor
discriminator of the ACE enzymes, although a characteristic feature of them all is
that they are cloxacillin-sensitive.
Table 63
^TO^pM) ofACE enzymes with Nitrocephin as substrate.
Strain ACE type Aztreonam Cloxacillin Clavulanic acid
5B86 4 >100 0.18 >100
6B230 1 28 0.012 >100
H17 1 8 0.005 >100
1126 1 5 0.022 >100
H63 1 2 0.016 >100
H68 1 9 0.1 >100
H126 3 0.08 0.003 >100
H141 1 1.8 0.02 >100
H162 2 23 0.022 >100
*ID^q((^M) = amount of inhibitor required to inhibit 50% of hydrolysis of Nitrocephin
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Similarly, the enzymes from all the strains were extremely resistant to
clavulanic acid inhibition. The inability of any of these enzymes to be inhibited
significantly by 0.1 mM clavulanic acid shows that clavulanic acid resistance is a
characteristic feature of all these enzymes but is incapable of being used as a
discriminator.
Differences in inhibition were, however, identified when aztreonam was
used as an inhibitor. There was little difference in the ID50 for the ACE-1 and
ACE-2 enzymes which were in the range of 1.8 to 28 pM. The ACE-3 enzyme
from strain H126 was much more sensitive to aztreonam inhibition than the others
(ID50 = 0.08 pM), while the ACE-4 enzyme from strain 5B86 was much more
resistant (ID50 = >100 pM). Therefore the inhibitor profiles with aztreonam
provide good discrimination of the ACE-3 and ACE-4 enzymes.
Table 64 shows the effect of 1 mM EDTA, 1 mM HgCl2 and 0.1 mM p-
chloromercurobenzoate (pCMB)
All the enzymes were inhibited to the same extent by a fixed
concentration of HgCl2 but were virtually unaffected by moderately high levels of
pCMB. Thus no discrimination between these enzymes could be obtained from
these profiles.
The effect of ImM EDTA on the enzymes, with either nitrocephin or
cephaloridine as the substrate, was variable although generally below 20%.
EDTA had no effect on the Acinetobacter Beta-lactamase described by Hikida et
al. (1989). Elowever since many of the enzymes described here are of large Mr
and, therefore may exist in subunit form, it is possible that metal ions play a role
in their function. Therefore further experiments with a more purified enzyme will
be required to elucidate these findings.
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Table 64






5B86 4 <20 89 0
6B230 1 <20 98 0
H17 1 <20 96 0
H26 1 <20 97 0
H63 1 <20 98 0
H68 1 <20 95 0
H126 3 <20 95 0
H141 1 <20 98 0






Induction experiments were carried out on all nine strains employing
cefoxitin as the inducer at one quarter of the MIC value for the strain. The
method employed was that described by Minami et al. (1980).
No discernable Beta-lactamase induction was found with any of the
strains studied.
CONJUGATION EXPERIMENTS
Conjugation experiments were carried out on all nine strains as
previously described in the Materials and Methods.
However, despite varying the times of incubation of the mixture of the
donor and recipient, these conjugation experiments were unsuccessful and no
transconjugants were detected.
Perhaps, plasmid curing experiments should have been carried out (for
the sake of completeness) but it is most unlikely that these enzymes are plasmid
mediated.
CONCLUSIONS
The above data therefore suggests that all the Acinetobacter (ACE)
enzymes studied are non-inducible, chromosomal cephalosporinases of Bush
Group One (CEP-N) (Bush, 1989b).
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FAST PROTEIN LIQUID CHROMATOGRAPHY
The work on the development of the AUS isoelectric focusing technique
showed that the chromosomal Beta-lactamases of Acinetobacter could be
separated on the basis of their charge. However it also showed that this technique
was not ideally suited to the screening of a large population of Acinetobacter.
This was for two reasons. Firstly it was technically demanding and was not
guaranteed to work every time and secondly it was enormously expensive in
terms of the amount of nitrocephin used in each run. This was in the region of 50
- lOOmg per gel and was therefore unsustainable. Therefore some other technique
for easy separation was required.
The work on the Mr of these enzymes employing conventional low
pressure gel permeation chromatography also encouraged us to pursue the reasons
for the enzymes' apparent large size. To measure the Mr of these enzymes by
conventional SDS-PAGE techniques requires the enzyme(s) to be purified to
homogeneity since nitrocephin can no longer be used as a probe for the Beta-
lactamase activity in these denaturing conditions. The most appropriate
techniques to continue along these lines of investigations were
(i) Fast liquid Protein Chromatography (Pharmacia) employing initially
high performance ion exchange chromatography.
(ii) Reversed polarity native PAGE for basic proteins on the PhastSystem
(Pharmacia) employing nitrocephin as the probe for Beta-lactamase
activity.
(iii) SDS-PAGE with silver staining on the PhastSystem.
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Fast Protein Liquid Chromatography of the ACE Beta-lactamases
FPLC was an appropriate technique for the purification of these enzymes
because of:
a) its high resolution
b) its high recoveries of sample mass with retention of
structural integrity and biological activity
c) its high loading capacities - up to 50mg of protein could
be loaded onto each 1ml column
d) its fast separation time - in exchange chromatography
runs could be completed in 30 minutes with a 1 hour
turnaround
These attributes coupled with the rapidity of the nitrocephin spot test
makes FPLC the most powerful technique so far described for the separation and
purification of Beta-lactamases.
Initially the remainder of the frozen pooled aliquots of the Acinetobacter
Beta-lactamases derived from the low pressure gel permeation chromatography
were applied to the FPLC system.
FPLC Method
Two ml of the partially purified enzyme (containing between 0.02 - 3.3
mg protein/ml) equilibrated in 50 mM sodium phosphate buffer pH 7.0 (Buffer A)
were passed through a 0.2 micron filter (Gelman) and applied to a MONO S (HR
5/5, 1ml) cation exchange column. The system consisted of a LCC 500 Plus
controller, UV-M monitor (protein measured at 280 nm) and FRAC 100 collector.
The column was equilibrated with Buffer A.
The flow rate was 1 ml/min. Separation was achieved by elution with a
linearly increasing concentration of sodium chloride (in Buffer A) to a
concentration of 1M. Thirty-four fractions (1ml) were collected from each
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separation. Each aliquot was probed for Beta-lactamase activity with the
nitrocephin spot test as described previously. Beta-lactamase activity was
therefore correlated to the retention volume and the protein peaks (if present).
The results from enzymes produced from 8 of the 9 strains can be seen in
Table 65. Insufficient enzyme (ACE-4) from 5B86 remained from the original
gel permeation and enzyme characterisation experiments.
Table 65
FPLC of aliquots of partially purified (^-lactamase, from low pressure gel
permeation, on MONO S ion exchange.










It can be seen that there were at least 3 groupings of retention volumes
with these 8 enzymes. The ACE-1 and ACE-2 enzymes appear indistinguishable
by this technique with retention volumes of around 15 to 18 ml. However, there
appeared to be a subgroup of ACE-1 enzymes e.g. with the enzymes from H63,
H68 and H141 - major activity existed at 12 - 13 ml, but in the cases of H68 and
H141 - activity also sometimes appeared at 15 - 17 ml. The ACE-3 enzyme
produced from H126 was clearly different with a retention volume of 4 ml. The
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latter result suggested that ACE-3 would be more appropriately separated on a
MONO-Q high performance anion exchange column.
Very small or no protein peaks were visible at the fractions that
corresponded with the areas of Beta-lactamase activity except in the case of ACE-
3 which was essentially unseparated in the midst of other proteins in the void
volume.
A more significant problem however became apparent, namely the loss
of biological activity. All the 'purified' Beta-lactamases (except ACE-3) lost their
activity within 24 - 48 hours whether they were stored at 4°C, -20°C or -70°C; or
if they were dialysed overnight against sodium phosphate buffer (50mM, pH 7).
Preservation of activity with (3-lactoglobulin A
After 'purification' of the Beta-lactamase by ion exchange
chromatography the loss of biological activity could be prevented by the addition
of (3-lactoglobulin A (to a concentration of 1%) to the fractions containing the
activity.
It is therefore likely that the loss of biological activity was due to dilution
and removal of the protein from its normal cellular environment. This is also
inferred by the fact that HI26 - ACE-3 did not lose its activity after passage
through a MONO-S column, presumably because it remained in solution with
many other proteins in the void volume.
The results of these findings therefore made further investigation into the
characteristics of these proteins a little more difficult. To investigate their
properties on reversed polarity SDS-free PAGE or by SDS-PAGE on the
PhastSystem all of them had to be purified by ion exchange on the same day as
their application to either technique.
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Application of crude Beta-lactamase preparations onto the FPLC with a
MONO-S column
All of the partially purified Beta-lactamase from pooled aliquots from the
conventional gel permeation chromatography were employed during the
preliminary experimentation and it was not possible to repeat the larger column
work within the constraints of time.
It was noted that the columns could take up to 50 mg of protein per run
and that the protein concentrations of crude Beta-lactamase preparations derived
from the induction experiments contained in the range of 10 - 15 mg/ml.
Therefore, 1 ml of crude enzyme diluted to 2 ml with 50 mM phosphate buffer
(pH 7) was added to the MONO-S columns as before. Crude enzyme
preparations of ACE-3 (H126) and ACE-4 (5B86) were made in 25 mM Tris/HCl
pH 8 and applied to a MONO Q anion exchange column and run as described for
MONO-S columns (the eluant being Tris/HCl pH 8 ).The results are seen in Table
66.
Application of crude preparations of the Acinetobacter Beta-lactamases
gave very similar results to the application of the same partially purified enzymes
except that in each case an ionic variant appeared in the void volume, albeit weak.
The results also confirmed that ACE-2 is very similar to ACE-1 and that ACE-3
and ACE-4 are completely different. However, there did seem to be variation
within the ACE-1 group with major activities either at a retention volume of
around 16 to 18 ml or 12 to 13 ml. However there was usually weak activity, in
each case, at the other retention volume e.g. H26 with major activity at 18 ml and
weak activity at 2/3 ml and 11/12 ml; H63 with major activity at 12 ml and weak
activity at 2/3 ml and 17/18 ml.
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Table 66
FPLC of crude ACE enzymes on high performance ion exchange.




6B230 1 2,3; 15=716




H68 1 2,3; 12*/13
H141 1 2,3; 13/14*
MONO Q
anion exchange
H126 oO 2,3,4; 13*
5B86 4 2,3,4;29*
^signifies the retention volume with maximum activity
REVERSED POLARITY SDS-FREE (NATIVE) PAGE ELECTROPHORESIS
ON THE PHASTSYSTEM
The purified enzymes obtained from the FPLC ion exchange and crude
enzyme preparations were applied to this gel system which had been devised to
resolve basic proteins on a polyacrylamide mini-gel.
Method
The sample preparation and running conditions were those described by
Olsson and Tooke (1988).
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Sample preparation
Equal amounts of sample (in 50mM sodium phosphate buffer pH 7) were
mixed with double strength sample buffer - 0.112 M acetate , 0.112 M Tris pH
6.4. 4 \xL of sample were loaded onto the gel.
Buffer-strips





glacial acetic acid 4ml
distilled water 95ml
The components were mixed and boiled with stirring. The solution was
cooled to 70°C and then poured into casting moulds and allowed to solidify by
cooling to room temperature.
PhastGelmini-gel
The separations were run on PhastGel Homogeneous 20 (Pharmacia).
Running conditions
The gel was run with the polarity reversed. The separation conditions
were: 200 V, 10 mA, 2.5 W at 15 °C for 100 Vh.
Staining




Reversed polarity SDS-free PAGE on the PhastSystem employing a
Homogeneous 20 mini-gel loaded with partially purified ^-lactamase


















Reversed polarity SDS-free PAGE on the PhastSystem employing a
Homogeneous 20 mini-gel loaded with crude [3-lactamase preparations, stained
with nitrocephin
Cathode
Track A OXA-1 + TEM-2





Track G OXA-2 + TEM-2
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Results
Purified preparations of ACE-1 (H63, H68, H141 and 6B230) and ACE-
2 (H162 not shown) migrated similar distances from the cathode whereas ACE-3
(H126) migrated slightly less far (see figure 17 ). The control SHV-1 migrated
less far than ACE-1 but slightly further than ACE-3.
Interestingly 6B230 was very unstable and its activity as shown by
nitrocephin lasted for a very short time only (<10 minutes).
These results were confirmed utilising crude enzyme preparations of
ACE-1, ACE-2 and ACE-3 (not shown) which suggests that this system would be
ideal for the screening of large numbers of Acinetobacter Beta-lactamases (See
figure 18 ). The control Beta-lactamases of OXA-2, TEM-2, SHV-1 and TEM-1
migrated to appropriate positions in the gels i.e. TEM-1 and TEM-2 stayed at the
cathode while SHV-1 and OXA-2 migrated to a point just behind the ACE-1
enzymes. There was insufficient ACE-4 to test on this system.
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FURTHER PURIFICATION AND MOLECULAR MASS ESTIMATION OF
THE ACE-1 BETA-LACTAMASE OF THE ACINETOBACTER
BAUMANNII STRAIN H63 EMPLOYING FPLC AND THE PHASTSYSTEM
The above results with the FPLC suggested that the next stage was to
attempt purification to homogeneity employing the FPLC with additional
purification steps ending with Mr estimation on SDS-PAGE (which would also
give an indication of purity ).
The following purification scheme (see Harris,1989) was devised:
1. 1L of culture
2. Harvest by centrifugation
3. Disruption by sonication
4. Clarification by centrifugation
5. Ion exchange chromatography
FPLC with MONO-S
6. Gel permeation *
FPLC with Superose 12
7. Concentration
Ultrafiltration with an Amicon concentrator
8. SDS-PAGE*
Phast System minigel with silver stain
*Molecular size estimations were carried out at steps 6 and 8.
Steps 1 to 3 and Step 5 have been described previously, Steps 6 to 8 are described
here.
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Ion exchange on MONO S
For these experiments the fraction collector was set to collect individual
peaks and not to collect a uniform volume as previously.
Gel permeation on FPLC
0.5 ml of the fractions containing the maximum Beta-lactamse activity
from the ion exchange step were applied to a Superose 12, HR10/30 (Pharmacia)
gel permeation column. The column was equilibrated with 50 mM sodium
phosphate buffer pH 7 (Buffer A). The flow rate was 0.5 ml/min and each run
lasted approximately 1 h. The Beta-lactamase activity was rapidly detected, as
before, by the nitrocephin spot test.
Calibration of the Superose 12 column
Mr estimations were carried out after the Superose 12 column had been
calibrated. The column was equilibrated with Buffer A. 0.5 ml of a protein
standard solution was applied to the column. The protein standard solution
contained thyroglobulin, IgG, bovine serum albumin, carbonic anhydrase and
Cytochrome C. The resultant protein trace is shown in Figure 19 . The retention
volumes of the protein standards were plotted against log Mr and a standard curve
obtained (Figure 20 ). The retention volumes of the Beta-lactamase peaks were
then applied to the calibrated column and their Mr estimated from the standard
curve.
Results
The ion exchange step on the Mono S resulted in 4 peaks of activity with
retention volumes of : 2.0 ml (f2:"a"), 14.0 ml (fl8:"b"), 15.1 ml (f22:"c") and
15.6 ml (f24:"d"). The activity at 2.0 ml was relatively weak .
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0.5 ml of each of these peaks ( "a","b","c"&"d") were then applied to the
gel permeation column. The resultant protein traces and retention volumes of the




Protein Mr (Kd) Retention (ml)
1. Thyroglobulin 669 7.8
2. IgG 160 12.0
3. BSA 66 14.0
4. Carbonic anhydrase 30 16.0
5. Cytochrome C 12.4 17.6
Time (min) 30































FPLC® trace of high performance ion exchange (Mono S) of the crude B-lactamase
preparation from strain H63. B-lactamase activity was probed for by employing the
nitrocephin spot test The presence of B-lactamase activity is indicated by the arrows
(* represents the major activities)











FPLC® trace of gel permeation of activity "a" obtained from the ion exchange step.
B-lactamase activity was probed for by employing the nitrocephin spot test and is












FPLC® trace of gel permeation of activity "b" obtained from the ion exchange step.
B-lactamase activity was probed for by employing the nitrocephin spot test and is









FPLC® trace of gel permeation of activity "c" obtained from the ion exchange step.
B-lactamase activity was probed for by employing the nitrocephin spot test and is









FPLC® trace of gel permeation of activity "d" obtained from the ion exchange step.
B-lactamase activity was probed for by employing the nitrocephin spot test and is
indicated by the arrows.
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The retention volume of "a" was 7.7 ml; "b" split into two major
activities at retention volumes of 15.3 and 18.5 ml; "c" had a retention volume of
18.6 ml and "d", with a single protein peak, had a retention volume of 18.9 ml.
The experiment was repeated several times with the same results, the retention
volumes and M r estimates are seen in Table 68 .
Table 68
Molecular size estimations on Superose 12.











It can be seen that the Mr of the Beta-lactamase of H63 (ACE-1) seems
to exist in at least 3 sizes. Firstly at 700 Kd, which correlates with its estimated
Mr of 580 Kd on conventional gel permeation, but it also exists in two other sizes:
one around 40 Kd and (in the case of H63) a predominant M r of around 12 Kd.
These experiments were repeated with the ACE-1 enzyme from H68 and
similar results were obtained but the predominant activity was an Mr of around 40
Kd with minor activity around 10 Kd.
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Mr estimation of the enzyme from H63 by SDS-PAGE on the PhastSystem
250 [xl of the single protein peak at retention volume 18.9 ml, from the
gel permeation column, was concentrated to 30 p.1 with an Amicon centriprep
concentrator.
A 8 - 25% gradient PAG mini-gel was employed, with a Sigma
molecular size marker kit (14,000 - 78,000) as standards. The protein samples
were boiled for 5 minutes in a mixture of SDS (2.5%), (5-mercaptoethanol and
bromophenol blue. Four p.1 of the standards and samples were applied to the
mini-gel. The running conditions were as described in the PhastSystem
Separation Technique File No. 110 (Pharmacia). Protein bands were visualised
with a silver stain (Pharmacia) according to the manufacturer's instructions. The
electrophoresis run and staining of the gel took approximately 1 hour 20 minutes.
Results
The Phastgel is shown in Figure 26. Calibration of the gel is shown in
Figure 27. The result shows a major band at Mr 14 - 15 Kd and minor bands at
22 Kd, 33 Kd and 35 Kd.
These results would suggest confirmation of the Mr of the enzyme in the
region of 10 - 15 Kd and 30 - 40 Kd. However, the presence of 4 bands of protein
in the SDS-PAGE suggested that the Beta-lactamase was not purified to
homogeneity.
It should also be noted that this SDS-PAGE system was not particularly
accurate at the low molecular size range.
These results while posing new questions about the nature of these
proteins also helps answer and explain previous questions and observations.
Firstly, it explains why these enzymes retain their activity in the presence
of 4 M urea. It would seem that they exist in high Mr aggregates which
depending on the conditions break up into several different M r subunits with
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Figure 26
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differing ionic charges. This could explain their behaviour in ordinary IEF
systems and the variable bands obtained in AUS gel systems.
Secondly, it explains why other workers have described Acinetobacter
chromosomal Beta-lactamases as being of Mr around 35 - 40 Kd (Morohoshi &
Saito, 1977 and Hikida et al. 1989).
While all the above evidence suggests that these enzymes exist as
aggregates and therefore seem (under certain conditions) to have a high Mr it was
still important to determine whether these proteins were membrane bound or
present free in the periplasm.
PREPARATION OF CELL MEMBRANE FRACTIONS OF
ACINETOBACTER BAUMANNII, H68.
In order to determine the major position of these enzymes within the
Acinetobacter cellular structure, washed cell membrane (WCM) preparations
were prepared.
The growth, harvesting, disruption and WCM preparation of these cells
are described in the Materials and Methods. Disruption by both the French
pressure cell and ultrasonication were employed to ascertain the best method for
the preparation of these enzymes (with a view to future purification). Some doubt
has been cast recently on the use of ultrasonication in the preparation of Beta-
lactamases (Nichols & Hewinson, 1989).
Total enzyme activity and specific activities (umol/mg/protein) were
measured at various steps of the procedure. The percentage of the total enzyme
activity present at these various steps was calculated with 100% enzyme activity
taken to be present in the low speed supernatants, after the broken cell
suspensions had been treated by centrifugation.
The results of these experiments are shown in Table 69.
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Table69 PurificationofAcinetobacter(H68)^-lac amaseshowingrel ivam untswithithep riplasm cp





































































Firstly, it was clear that the best method for the initial purification of
these enzymes is disruption by French pressure cell, with higher specific activities
being obtained by this method.
Secondly it was quite clear that (at least in the case of H68) the Beta-
lactamase is mostly present in the periplasmic space with, 87.6% of the enzyme
activity there and only 10.8% residing in the washed cell membrane component
(in the case of French pressure cell disruption).
Therefore it is likely that these enzymes exist as aggregated proteins and




Four hundred strains of Gram negative oxidase-negative aerobic bacilli
were collected over a two year period (January 1986 to December 1987). From
them, 200 strains with clear resistance to cefuroxime (MIC>32mg/L), were
studied further. Their MIC's to 12 different antimicrobials were obtained.
The results were very much as expected. Within this group of
cefuroxime-resistant organisms there was total resistance to ampicillin and
cephradine. There was 84% resistance to the other 2nd generation cephalosporin
cefoxitin. Aztreonam and the 3rd generation cephalosporins cefotaxime and
ceftriaxone had significantly better levels of resistance at 25.5%, 24% and 29%
respectively. Ceftazidime had a resistance slightly higher at 35%. Not
surprisingly the resistance to imipenem and ciprofloxacin, drugs which at that
time were not on the market, had resistance levels of 1% and 2% respectively.
The resistance levels to the aminoglycosides tested (netilmicin and
gentamicin) were similar at 19.5% and 26.5%.
CEFUROXIME RESISTANT SPECIES
The proportion of different species forming this group of 200 cefuroxime
resistant organisms was also not surprising with 50% Enterobacter spp., 12%
Serratia spp., 4.5% Citrobacter spp. with 21.5% Acinetobacter spp. In other
words the majority of these strains were organisms known to produce inducible
R&S Class I chromosomal Beta-lactamases (Sanders & Sanders, 1988).
The relationship of resistance to particular bacterial species was also very
much as expected.
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BETA-LACTAMASES PRODUCED BY CEFUROXIME - RESISTANT
ORGANISMS
Of the 200 strains studied 192 produced a typical species-specific
chromosomal Beta-lactamase. Of these 192, 139 produced a typical
chromosomal enzyme alone while 52 produced a chromosomal enzyme and the
plasmid-associated enzyme TEM-1 while one strain produced a chromosomal
enzyme and SHV-1. Eight strains produced TEM-1 alone.
Interestingly within the 43 Acinetobacter strains, no plasmid-mediated
enzymes were detected. This is in contrast to the study of Joly-Guillou et al.
(1988) where out of 100 strains, 34 produced a TEM-1 Beta-lactamase and 7
produced a CARB-5 Beta-lactamase. However this was carried out in an general
group of bacteria and not those specifically with cefuroxime resistance.
Therefore it is likely that the cefuroxime resistance in the vast majority of
the strains studied by us was due to the presence of a chromosomal Beta-
lactamase.
TRANSFERABLE 3RD GENERATION CEPHALOSPORIN RESISTANCE
A study in collaboration with Dr D J.Payne amongst the majority of
strains which exhibited resistance to the third generation cephalosporins showed
no evidence of transferable third generation resistance.
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ANTIMICROBIAL RESISTANCE RATES WITHIN SPECIFIC WARD
AREAS
Phillips (1988) had the following points to make concerning studies on
the prevalence of antimicrobial resistance within various populations:
"...having detected resistance, the diagnostic microbiologist has the problem of
determining its prevalence. The microbiologist will need to :
1. exclude multiple isolates from the same patient assuming that he can
identify both of these
2. attempt to separate organisms by their sources (community vs nosocomial;
intensive care units, paediatrics)
3. separate organisms by type of infection (e.g. urinary tract infection,
septicaemia)
Then, if rates of resistance are to be compared with these or other
institutions, or even longitudinally within the same institute, prevalence must be
related to the numbers and types of patients seen. Thus it is not surprising that
results are seldom available for outside scrutiny".
Our study consisted of some 14,000 isolates of Gram negative, oxidase
negative aerobic bacilli that had been isolated from 18 different units within a
large Scottish teaching hospital (which contained many of the regional services
for the East of Scotland) over a 5 year period.
This is certainly the largest study of its kind undertaken in the UK.
With reference to the points made by Phillips (1988):
1. Multiple isolates from the same patient were excluded as far as was
possible
2. The organisms were separated into the areas where they had originated
from within the hospital. It was not possible to split the isolates into those
patients who had recently come from the community or who had acquired
their organisms while in the hospital.
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3. Separation of the organisms into infection types could have been
carried out but was not. It was decided not to do this because there were
enough data to discuss without introducing yet another variable.
4. The resistances were related to the bed occupancy of each area and the
antimicrobial usage in that area over a period of time.
5. It was not possible to relate the resistance to specific organism type since
their identification was not accurate, to even the genus level.
VALIDITY OF THE STOKES' METHOD FOR DETERMINING THE
ANTIMICROBIAL SENSITIVITY
Some may feel that the use of Stokes' method for the determination of the
antimicrobial sensitivity in this study makes it less credible. I would make the
following points.
1. This was a retrospective study using the existing information that was
available in the archives of our computer system.
2. This method is good enough to be used in the day to day running of the
Clinical Microbiology Laboratories of the great majority of hospitals
throughout the UK. The results generated by these tests are used to initiate
or change treatment in large numbers of infected patients.
3. There is considerable debate as to what method microbiologists should use
to determine antimicrobial resistance (See Edwards, 1991 and Hamilton-
Miller, 1991) and what relevance the results have to clinical practice.
4. The resistance figures for the three major areas studied (surgical, medical
and ITU) were found to be similar in the general population (determined
by Stokes' method) and in the blood culture isolates (determined by MIC
estimation).
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5. It would have been technically difficult (in terms of manpower and time)
and financially prohibitive to have collected these 14,000 isolates and
carried out MIC determinations in all of them.
6. Others have used their disc sensitivity test results in resistance studies
(Phillips et al., 1990).
7. The same people were employed using the same method on isolates from a
single institution over the 5 year period.
Therefore, although there will be discrepancies in a study this size, the
methods employed are entirely valid.
RESULTS
Cefuroxime resistance over a five year period
The results showed clear differences between various units within the
hospital.
The overall resistance in the Surgical hospital was 12.7% with a range
between 4.7% and 23.3%. In the Medical hospital these figures were similar to
those in the Surgical hospital at 11.8% with a range between 6.7% and 20.4%.
The overall resistance in the Intensive care areas was significantly greater
at 33.1% with a range between 18.9% and 42.2%.
Gentamicin resistance over a five year period
The results for gentamicin resistance did show variation between units
but it was not so marked as with cefuroxime, nor was the level of resistance
particularly high.
The overall resistance in the Surgical hospital was 1.7% with a range
from 0.7% to 3.8%. In the Medical hospital these figures were 2.4% with a range
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from 1.0% to 4.7% and in the ITU areas they were 3.9% with a range from 2.6%
to 6.5%.
Cefuroxime and gentamicin resistance trends over five years
In two of the three areas (Surgical hospital and Intensive care areas) there
was a significant increase in the resistance to cefuroxime.
In one of the three areas (Medical hospital) there was a significant
decrease in the resistance to gentamicin.
The relationship between antimicrobial usage and the prevalence of
resistance
In some cases there did seem to be a simple relationship between
antimicrobial use and the resistance to that antimicrobial, for instance in the
vascular surgery unit the cefuroxime resistance was 26% (the highest within the
Surgical hospital) and the Beta-lactam use was 5.4g per patient (which was the
highest in the Surgical hospital).
Similarly the cefuroxime resistance was 4.6% in the gynaecology unit
and the usage was 1.6g/patient (both figures were the lowest for the Surgical
hospital).
However in other instances this relationship was clearly not so simple.
For example general surgical units 1 and 3 had similar usage of aminoglycosides
at 0.06g/patient and 0.05g/patient respectively. However the gentamicin
resistances were 0.5% in unit 1 and 2% in unit 3.
The Beta-lactam usage in surgical unit 2 was 1.8g/patient and in surgical
unit 3 was 2.8g/patient yet the resistance to cefuroxime was 15.4% in unit 2 and
7.7% in unit 3.
Scatter diagrams showed that there was no clear correlation between
antimicrobial usage and resistance in most of the areas studied.
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These results are not entirely surprising. Phillips et al. (1990) made the
following comment: "Most discussions of antibiotic resistance concentrate on its
increasing incidence correlated with antibiotic usage. We have found that the
trends are more complex and more interesting. For some species resistance has
increased while for others, extensively subjected to the same selective pressures it
has declined".
McGowan (1983) also pointed out that the relationship between
antimicrobial use and resistance was far from simple.
He made several important observations:
1. The pathogens causing nosocomial infection over the last 50 years have
changed, with surveys showing a decrease in the frequency of relatively
susceptible pathogens such as the pneumococcus but with an increase in
relatively resistant organisms such as Pseudomonas and Serratia.
2. These changes have largely been attributed to the use of the antimicrobial
agents.
3. However there are many other factors that have contributed to these
changes:
(i) The development of new therapies and technology have decreased
mortality therefore patients survive instead of dying. These
patients often (as either the result of their disease or therapy) have
impaired host defences. This relative susceptibility allows
organisms of limited virulence to cause problems that normally
would not occur in a normal host. Many of these opportunistic
pathogens are inherently resistant to the commonly prescribed
antimicrobials.
However, they probably colonise these patients primarily because
of the patient's poor host defences rather than because the organism
is resistant to antibiotics.
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"For example, the respiratory flora of severely ill patients often
changes after hospitalisation to include a higher prevalence of
Gram negative bacilli. This change depends primarily on the
severity of the patient's illness rather than on antimicrobial usage",
ending he quoted Sen et al. (1982).
(ii) A second factor involved in the change in pattern of organisms is
the increasing use of invasive monitoring and instrumentation in
patient care. Some organisms have attributes that allow them to
survive in or around these devices or equipment. He noted that
these characteristics may be entirely independent of the organism's
susceptibility or resistance to antimicrobial agents.
Subsequently the above observations have been supported by the work of
Craven et al. (1988) and Maki (1989) who have studied the risk factors for
infection and mortality within the ITU. These and other relevant points have been
discussed previously in the Introduction.
Taking into consideration the points made by McGowan (1983) one can
easily explain why the resistance to both cefuroxime and gentamicin is greater in
the ITU areas than in either the Surgical or Medical hospital. It also uncovers
possible reasons for the presence of differences (or lack of differences) in
resistance rates which cannot simply be explained in terms of the antimicrobial
usage.
In other words the resistance in each area must be related not only to the
antimicrobial use but to the underlying condition of the patient; the procedures
that the patient underwent; the length of hospital stay; age; sex and the location
within the hospital etc. For instance the types of operations and underlying
conditions of the patients in the different surgical units may well have had an
important effect on their subsequent acquisition of a resistant coliform.
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However it was not possible, nor will it be possible, to obtain these data
and relate them to the antimicrobial resistance figures in our study.
Further evidence that the relationship between the use of antimicrobials
and the resistance was seen in data not presented. Each of the Medical and
Surgical "units" described consists of an identical male and female ward.
Therefore the resistance figures are available for males and females in both
hospital areas. The differences between males and females is quite striking. A
male is almost twice as likely to have a resistant coliform than a female, in both
the medical or surgical areas. These findings can be partially (but not completely)
explained by the fact that a female is more likely to have a urine specimen with a
sensitive coliform in it than a male. But a great many other factors may be
involved, and require further investigation.
The other fascinating piece of data produced by this survey comes from
the special care baby unit. This unit admits all the seriously ill and premature
babies from the East of Scotland. It admits in the region of 500 babies per
annum, many of whom are ventilated. In terms of the percentage of the
population of a ward receiving aminoglycosides, this unit has the highest at about
50%. The absolute level of aminoglycoside use per patient is almost as high or
higher than for adult areas of the hospital. Yet the resistance to gentamicin is
reasonably low at 2.5%.
Similarly in terms of their Beta-lactam use many of the babies are
treated, but their resistance rate is lower than any of the other ITU wards.
This leads to the hypothesis that it is the amount of antimicrobial used
2
per metre that is an important determinant of resistance rather than the amount of
antimicrobial used per patient.
In summary therefore we have shown that:
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1. There are clear differences in the rates of resistance to both cefuroxime
and gentamicin in Gram negative aerobic, oxidase-negative bacilli within
different areas of a large teaching hospital over a 5 year period.
2. The differences are not only due to the antimicrobial use within these areas
but also due to the underlying conditions of the patients and to other
variables which are as yet not identified.
3. We have shown that over the five year period there was an increase in the
resistance to cefuroxime which was clearly significant in the Surgical
hospital and Intensive care areas. On the other hand the resistance to
gentamicin showed a decreasing trend but this was only clearly significant
in the case of the Medical hospital.
(Unfortunately these trends could not be related to the trends in
antimicrobial prescribing since this information was not available).
4. The resistance to cefuroxime in these organisms was clearly much greater
than the resistance to gentamicin.
Therefore the long term outlook for the continued use of Beta-lactam
drugs such as cefuroxime seems bleak with an inexorable rise in their
resistance. Phillipon (1988) has also described an increase in resistance to
a Beta-lactam (cefotaxime) in the Pitie-Salpetriere Hospital in Paris from
1980-1985. He noted that within strains of Enterobacter cloacae
resistance to cefotaxime had risen from 6.4% to 20.7% and within Serratia
spp. it had risen from 0.8% to 22%.
The outlook for the aminoglycosides is however less bleak. These drugs
have been in clinical practice for about twenty years and in our study the
resistance rates are still rather low. One might argue that the lower
resistance rate is simply due to the fact that less aminoglycosides are being
used - but this is not the whole story. In the special care baby unit where
most aminoglycoside (in patient terms) is used, the resistance to
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gentamicin resistance actually fell from 4.5% to 3.3% over the five year
period.
The lower resistance to the aminoglycosides may be related to the fact
that these agents are toxic and therefore require careful serum monitoring
i.e. they are used much more judiciously than their Beta-lactam
counterparts.
5. Finally this study has shown that quoting global figures of resistance to
various antimicrobial agents for a single hospital, pooled figures for groups
of hospitals and pooled figures for countries or groups of countries, are
likely to be totally meaningless and serve only to hide the considerable
variation that exists in resistance rates to antimicrobial agents within
different subgroups of patients.
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ACINETOBACTER CHROMOSOMAL BETA-LACTAMASES
At first sight it would appear that the properties of the presumed
chromosomal Beta-lactamases of the genus Acinetobacter have been fully
characterised without the need for any reference to the work presented in this
thesis.
Isoelectric points (pi) in polyacrylamide gel systems were first described
by Matthew and Harris (1976) and reiterated by Sykes and Matthew (1976).
Other workers since then have described the pi's of Acinetobacter Beta-
lactamases as ranging from 7.5 to >10 (Medeiros et at., 1985); >8 (Joly-Guillou et
al., 1987) and 9.9 (Hikida et al., 1989). Similarly the Mr of Acinetobacter Beta-
lactamase has been described as 30,000 by Morohoshi and Saito (1977) and as
38,000 by Hikida et al, (1989).
The kinetics of hydrolysis to various Beta-lactam antibiotics have been
most fully described (initially) by Morohoshi and Saito (1977) and subsequently
to the newer agents by Hikida et al. (1989). These authors also examined the
effect of a variety of Beta-lactamase inhibitors.
There is little doubt however from the data previously published that
these Acinetobacter enzymes are cephalosporinases (Sykes & Matthew, 1976;
Morohoshi & Saito, 1977; Medeiros, 1984; Bauernfeind, 1986; Neu, 1986b; Joly-
Guillou etal, 1987; Hikida et al, 1989).
The inducibility of these cephalosporinases by specific Beta-lactam
inducers however, has been far from clear.
On the basis of the work by Morohoshi and Saito (1972), Bush (1989b)
classified the Acinetobacter chromosomal Beta-lactamase in Group One, i.e. a
cephalosporinase not inhibited by clavulanic acid (CEP-N). The subsequent
substrate profile and inhibition studies of Hikida et al. (1989) suggested that this
classification is correct.
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ISOELECTRIC POINTS ON CONVENTIONAL POLYACRYLAMIDE GEL
ELECTROPHORESIS
Matthew and Harris (1976) listed pi's of around 8.6 for two Beta-
lactamases produced by strains of Acinetobacter. A.inotti 1786E and
Acinetobacter sp. 1787E. These same two strains appear in Sykes and Matthew
(1976) as A.inotti (1786E) pi 8.6 and A.mallei (1787E) pi 8.7. The latter strain
(A.mallei) 1787E was therefore not an Acinetobacter but a Pseudomonas mallei.
This organism had somewhat controversially been placed in the genus
Acinetobacter by Cowan and Steel (1965) - it became P.mallei in subsequent
editions (Cowan & Steel, 1974).
Therefore, this enzyme can no longer be considered as one produced by
the genus Acinetobacter. The former strain (A.inotti) 1786E is equally interesting.
An extensive taxonomic literature search has failed to find any previous or
subsequent mention of the specific epithet "inotti". This strain is part of the Glaxo
Research Laboratories' collection and one of the original authors (Miss A. M.
Harris) kindly sent us strain 1786E for further study. The freeze dried vial was
still marked as A.inotti but was identified by the API 20NE system as A.lwoffii
(new specific epithet: A.junii). On reflection, we suggest that "lwoffi", when
written could easily have been wrongly transcribed to "inotti" and perhaps this
error took place somewhere between its original entry in the strain book and the
subsequent publications.
Medeiros et al. (1985) were the first to mention that not all of the
chromosomal Beta-lactamases of Acinetobacter focused on conventional
polyacrylamide isoelectric focusing systems. Of 14 strains of A.calcoaceticus,
the pi was stated to be 8.8 for one enzyme, 9.0 for one, 9.7 for one, 10.0 for four,
>10 for three and a "blur" for four. Joly-Guillou et al. (1987) described 30 strains
of Acinetobacter with a chromosomal cephalosporinase of pi >8. This again
suggests poor focusing of these enzymes on conventional polyacrylamide IEF
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systems. More recently, Hikida et al. (1989) described a pi of 9.9 for a purified
cephalosporinase from a A.calcoaceticus (ML 4961). However, these authors
employed broad range ampholines of pH 3.5 - 10.0 in their IEF gel. This suggests
that the enzyme had migrated to, or almost to, the cathode. Unfortunately, there
was no photograph of the IEF gel in their publication..
In our initial screening study we found only one Beta-lactamase from 43
strains of Acinetobacter focused in a conventional polyacrylamide IEF system.
So, clearly this system did not work.
SDS-FREE PAGE
Our first thought was to attempt to separate these enzymes in another
polyacrylamide system but to separate them on (what we initially believed to be)
their Mr. Therefore the enzymes were applied to SDS-free PAGE. This allowed
the Beta-lactamase activity to be probed by nitrocephin. Experiments employing
this system revealed that most of the Beta-lactamase activity electrophoresed to
the anode! This led us to believe (correctly but perhaps for the wrong reasons)
that the problem was one of solubility. Subsequently, after experiments with the
same enzymes utilising a SDS-Free PAGE run on the PhastSystem the following
observations could be made:
(i) we were not separating these enzymes in the above system by their
Mr but by their charge.
(ii) therefore it was unlikely to have worked since the electrodes
needed to be reversed! Otherwise the enzymes would not have
migrated from the cathode. On reviewing the photographs it could
be seen that some of the Acinetobacter enzyme preparations did
appear at the cathode where they had been loaded.
(iii) the enzymes apparent lack of solubility in the system (i.e. a broad
band at the anode) was probably because they needed some SDS in
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the sample buffer i.e. enough to allow them to solubilise but
without loss of their biological activity.
IEF IN POLYACRYLAMIDE INCORPORATING UREA
AND TRITON X-100
The next logical step was therefore to attempt to solubilise these enzymes
in a conventional polyacrylamide gel system. This was initially tried by
incorporating approximately 4M urea and 2.5% Triton X - 100 into the gel
matrix. However it was not until the sample itself was solubilised - with urea,
Triton X-100, (3-mercaptoethanol and ampholines - that some focusing occurred.
This allowed an initial tentative classification of these enzymes.
It was at this point of the work that nine particular enzymes produced by
nine Acinetobacter strains had been collected. These nine strains: 5B86, 6B230,
H17, H26, H63, H68, H126, H141 and H162 were therefore employed in all the
further experimentation discussed in this thesis.
Although some initial classification was possible it was clear that the
technique was not optimal with both considerable distortion of the gels and
extremely slow staining of the enzyme activity with the nitrocephin.
Concomitantly the initial Mr estimations had been carried out on
conventional low pressure gel permeation. This showed that only two enzymes
had Mr's of the expected values for chromosomally-mediated Beta-lactamases i.e.
H126 at 32.5Kd and H162 at 60.5Kd. All the others (7) had values which ranged
from 580Kd to >1000Kd.
Interestingly the lowest Mr of 32.5Kd produced by H126 was the only
enzyme which focused normally on a conventional polyacrylamide IEF system.
Therefore it seemed likely that the large Mr of these enzymes was at least
partially responsible for their poor solubility in polyacrylamide gel systems.
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AGAROSE, UREA AND SORBITOL (AUS) GELS
It therefore seemed pertinent to change the separation matrix from
polyacrylamide to agarose since the molecular masses of these enzymes were so
large that sieving (and therefore distortion) was likely to occur in the
polyacrylamide gels. Vecoli et al. (1983) had previously employed agarose IEF
for the investigation of Beta-lactamases with some success and Saravis and
Zamcheck (1979) described thin layer IEF gels containing agarose which had
resolved proteins with a molecular mass of greater than 2xl0*\ The problems of
incorporating urea with agarose in these gels had been outlined previously by
Olsson and Laas (1981). This included lower mechanical strength of the gels and
the risk of carbamylation of the proteins under study. We therefore incorporated
sorbitol and (3-mercaptoethanol (as they had) into the gels - which also contained
1% agarose, 2.5% Triton X-100 and 4M urea. As in the polyacrylamide/urea gel
system focusing only occurred after the initial solubilisation of the samples.
This system resulted in all nine of the Beta-lactamases studied focusing.
It therefore allowed a classification of these enzymes into 4 groups - ACE-1 to
ACE-4. These are shown in Table 70 .
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Table 70.
Classification ofACE enzymes by pi on AUS gel electrophoresis
Strain no Species pi (s) of (3-lactamase ACE type
5B86 A.lwoffii 7.3, 7.7 4
6B230 A.junii 8.6, 8.8 1
H17 A.baumannii 8.6, 8.8 (10.3) 1
H26 A.baumannii 8.6,8.8 (9.8, 10.1) 1
H63 A.baumannii 8.6, 8.8 1
H68 A.baumannii 000000 1
H126 A.junii 8.2,8.1 3
H141 A.baumannii 8.6,8.8 1
H162 A.baumannii 8.7 2
This was similar to the groupings obtained from the previous studies
employing urea and polyacrylamide gels. However more questions were posed
than answered.
In some gels the Beta-lactamases produced by HI7 and H26 had
additional minor bands between pi 9 and 10.5. It was possible that this was the
result of carbamylation, however the major problem was in actually visualising
the bands of activity in this area. This was because the cathodic buffer (IN
NaOH) hydrolysed (quite rapidly) the nitrocephin around this area.
There are two major problems associated with this novel IEF technique
which make it unlikely that it will be used in the future for the screening of large
numbers of Acinetobacter Beta-lactamases. Firstly it is technically demanding
and secondly it is extremely expensive in terms of the quantities of precious
nitrocephin that it consumes during each experiment.
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Clearly, therefore alternative techniques needed to be sought both to
corroborate the above results and to provide a quicker and easier means of
discriminating between these enzymes.
In summary however, the AUS technique had shown that there were
differences between these enzymes (at least 4 groups) with the ACE-1 type
predominant within the strains of A.baumannii tested.
The fact that we have shown at least four different enzyme types on the
basis of pi in Acinetobacter is not surprising. We found at least five different
chromosomal Beta-lactamases in Enterobacter spp. in this thesis and Medeiros
(unpublished data) described at least 8 different types of chromosomal Beta-
lactamases in Enterobacter spp. on the basis of their differences in pi. Bakken et
al. (1988) described at least four different (presumed chromosomal) enzymes in
Aeromonas spp. and Matthew and Harris (1976) noted that there were several
species of bacteria with more than one Beta-lactamase type.
HIGH PERFORMANCE ION EXCHANGE CHROMATOGRAPHY ON FPLC
Ion exchange chromatography on a FPLC system had several important
attractions:
(i) It separates the enzymes on the basis of their charge
(ii) High resolution
(iii) High recoveries of sample with retention of structural and
biological activity
(iv) High loading capacities
(v) A fast separation time with completion within 30 minutes
The above factors coupled with the rapid assay capability offered by the
use of nitrocephin made this the most powerful tool for the purification and study
of Beta-lactamases.
253
The use of FPLC in the purification of Beta-lactamases has been
described by Kesado et al. (1989) in the purification of the Beta-lactamase from
Clostridium butyricum and in the purification of the Beta-lactamase from
Pseudomonas paucimobilis by Corkhill et al. (1991). We have shown ion
exchange chromatography on FPLC to be the most powerful method to date in
rapidly separating multiple Beta-lactamases from the same strain (Payne et al.
1990).
Initial experiments were carried out employing cation exchange with a
MONO-S column utilising the aliquots that had been obtained from partially
purifying these Beta-lactamases on the large gel permeation columns (and in
estimating their Mr). Eight of the nine Beta-lactamases were investigated, as
insufficient ACE-4 enzyme from 5B86 remained.
The results revealed that ACE-3 enzyme produced by H126 was
completely different from the other ACE-1 and ACE-2 enzymes, injfact its
retention volume (in the void volume) suggested the employment of anion
exchange chromatography for its further purification. The ACE-1 and ACE-2
enzymes appeared indistinguishable by this method, however within the ACE-1
group of enzymes there seemed to be two areas of activity at retention volumes of
12 - 13ml and 15 - 17ml. Clearly the reasons for this needed further investigation.
It was at this point that a classical problem of protein purification
occurred - namely loss of the purified protein's activity.
There are many possible reasons for protein inactivation: removal of
proteins from their normal cellular environment subjects them to a wide variety of
conditions and processes which can lead to loss of activity or alteration of their
structure. These include: dilution; change in solution conditions; exposure to
degradative enzymes; oxygen; heavy metals; surfaces; and change in physical
conditions (e.g. freezing and thawing) (Deutscher, 1990).
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Stability trials and storage conditions were therefore initiated. These
revealed that
(i) One freeze/thaw cycle resulted in complete inactivation of the
enzymes
(ii) Activity persisted for 24-48h if the enzymes were kept at 4 °C
though their activity waned over time
(iii) The loss of activity could be prevented completely by the addition
of pure P-lactoglobulin A to a concentration of 1% in the purified
enzyme preparations.
These preparations could then be stored for up to 6 months at -20°C
without appreciable loss of activity.
However the rapid inactivation of these enzymes in their (perhaps) native
state meant that any structural studies e.g. application to SDS-PAGE or native
PAGE gels had to be carried out on the same day as the ion exchange steps.
MONO-S AND MONO-Q CHROMATOGRAPHY WITH CRUDE BETA
LACTAMASE PREPARATIONS
The frozen aliquots of the partially purified Beta-lactamases that had
been obtained from the large scale gel permeation experiments were entirely used
up in the previous experiments. Due to time constraints it was not possible to
repeat these large scale and time consuming procedures. Therefore the
application of crude enzyme preparations onto these ion exchange columns was
investigated. ACE-1 and ACE-2 enzymes on a MONO-S (cation exchange) and
ACE-3 and ACE-4 on MONO-Q (anion exchange).
These experiments revealed that ACE-1 and ACE-2 were very similar
but ACE-3 and ACE-4 were completely different. It also revealed that within the
ACE-1/2 group there seemed to be ionic variants with only one variant
predominating. Weak activity was found in the void volume in each and then
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there was activity at both around 12-13ml and 18ml (retention volumes) but
strong activity was at either 12-13ml (e.g. in H68) or 17/18ml (e.g. H17).
These results (up to a point) certainly confirm the ACE enzyme
groupings although ACE-1 and ACE-2 appeared identical.
On AUS IEF however ACE-2 was clearly different from the ACE-1
enzymes by producing a single focused band; and its Mr (60.5Kd) is much
smaller than the ACE-1 enzymes (580->1000Kd). Therefore further experiments
are required before amalgamating the ACE-1 and ACE-2 groupings.
Clearly, if it had not been due to the rapid inactivation of these enzymes,
it would have been interesting to have applied the various aliquots, obtained from
the above ion exchange chromatography, onto both ordinary polyacrylamide and
AUS IEF gels. This might have shed light on the multiple banding (and variable
banding) obtained on these systems.
REVERSED POLARITY ELECTROPHORESIS ON SDS-FREE (NATIVE)
PAGE ON THE PHASTSYSTEM
Both crude Beta-lactamase preparations and the purified preparations
obtained from the high performance ion exchange experiments were applied to
native PAGE minigels in the PhastSystem.
This particular gel system had been devised for the rapid discrimination
of basic proteins (Olsson & Tooke, 1988). It is a rapid system with each run of
electrophoresis and staining taking less than 2 hours to complete. It has not
previously been employed (in this form) to discriminate Beta-lactamases,
however Huovinen (1988) utilized isoelectric focusing on the PhastSystem for the
rapid identification of plasmid mediated Beta-lactamases.
The initial experiments with both crude and pure Beta-lactamase
preparations showed similarity between all the ACE-1 enzymes tested and ACE-2
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but a clear difference between them and ACE-3 (insufficient ACE-4 was available
for testing).
Therefore although further experimentation is required it would seem that
this rapid method will prove an extremely useful screening technique for the study
of Beta-lactamases obtained from clinical isolates of Acinetobacter.
MOLECULAR MASS ESTIMATIONS
As previously mentioned Morohoshi and Saito (1977) gave the Mr of
their cephalosporinase from A.anitratum NCTC 7844 as 30Kd when measured by
gel permeation on a sephadex G-75 column. Hikida et al. (1989) described the
Mr of their cephalosporinase from A.calcoaceticus ML4961 as 38Kd. This had
been estimated by SDS gel electrophoresis after purification of the enzyme with
strong cation exchange and conventional gel permeation.
Conventional low pressure gel permeation
We estimated the Mr of the Beta-lactamases of nine strains of
Acinetobacter, initially on Sephadex G-75 and then if required on Sephacryl S-
300. Only one enzyme (ACE-3 from strain HI26) had a similar Mr (32.5Kd) to
that described by Morohoshi and Saito (1977) and Hikida et al. (1989).
The ACE-2 enzyme from strain H162 had an Mr of 60.5Kd, but the other
seven enzymes ranged from 580Kd to > l,000Kd. This made these Beta-
lactamases the largest yet described - after the LI chromosomal Beta-lactamase of
Xanthomonas maltophilia with an M r of 123Kd (Bicknell et al., 1985).
Their size raised the interesting question as to why these enzymes
seemed so large on conventional gel permeation systems - do they exist in multi-
subunit form or are they attached to other cell membrane components?
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If they are attached to other cell membrane components then they are
unlike almost all previously described chromosomal Beta-lactamases of Gram
negative bacteria which are normally highly soluble (Medeiros, 1984).
In Gram positive bacteria membrane-associated Beta-lactamases are well
known (Coles & Gross, 1967; Collins, 1979). Only one such membrane-
associated Beta-lactamase has previously been described in Gram negative
bacteria. This was the Beta-lactamase of Pseudomonas pseudomallei (Livermore
et al„ 1987). These workers based the membrane association not on the enzyme's
Mr (which was 29.5 Kd estimated on SDS-PAGE) but on the finding that 83% of
the Beta-lactamase activity was associated with the pellet ofmembrane material.
Other workers have made similar claims for the Beta-lactamase produced
by Capnocytophaga sp. (Foweraker et al. ,1990). However they based this
assumption simply because isoelectric focusing could only be achieved if a non
ionic detergent was added to the gel "suggesting the presence of a hydrophobic
enzyme akin to a membrane-bound Beta-lactamase of Gram positive bacteria".
They did not prepare membrane fractions and measure Beta-lactamase activity.
Therefore their claims are largely speculation.
We carried out whole-cell membrane preparations of the Beta-lactamase
from strain H68 of A.baumannii which had a Mr (estimated on conventional gel
permeation) of >1000Kd. This experiment revealed almost 90% of the Beta-
lactamase activity was present in the periplasm with about 10% associated with
the membrane component. This suggests that these Beta-lactamases exist in
multi-subunit or aggregated form.
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PURIFICATION SCHEME FOR AN ACE-1 ENZYME (PRODUCED BY H63)
WITH Mr ESTIMATIONS EMPLOYING GEL PERMEATION ON THE FPLC
AND SDS-PAGE ON THE PHASTSYSTEM
So far we had elucidated the following about ACE-1 Beta-lactamases
(i) apparent large size on conventional gel permeation
(ii) at least three charge variants produced after high performance
cation exchange
(iii) soluble in the periplasm not attached to cell membrane
Experiments were therefore carried out to estimate the Mr of this enzyme
by gel permeation on FPLC and SDS-PAGE. In order to carry out the latter the
Beta-lactamase had to be purified to homogeneity since denaturing conditions are
required. Therefore a purification scheme for this enzyme was devised.
After application of the ACE-1 Beta-lactamase (from the strain H63)
onto a gel permeation column on FPLC it was consistently shown that this
enzyme existed in at least 3 molecular sizes. One major and two minor. Firstly a
small quantity of the enzyme exists at a size of 700Kd (which correlated with its
estimated size of 580Kd on conventional low pressure gel permeation). It also
exists at a size of around 40Kd, but its predominant size in this particular system
is around 12Kd.
The same procedures were repeated with the ACE-1 Beta-lactamase
produced by H68 and very similar results were obtained except that the
predominant activity existed at around 40Kd with minor activity around lOKd.
From a gel permeation run with the ACE-1 enzyme of H63, a single peak
of protein, which correlated with most of the Beta-lactamase present and therefore
presumed to be homogenous protein, was applied to an SDS-PAGE mini-gel on
the PhastSystem. This denatured protein was stained using silver nitrate. The
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results revealed a major band of Mr 14-15Kd but with minor bands not only at
35Kd but also at 22Kd and 33Kd. This to some extent, confirms the sizes found
in the gel permeation studies. However it is not clear whether these other bands
indicate that the protein is not totally pure or whether they represent irregular
amounts of disaggregated Beta-lactamase. It would perhaps have been useful to
have electroblotted the proteins separated on the SDS-PAGE gel and then probed
with nitrocephin to see if all the bands were infact active Beta-lactamase.
Alternatively a method described by Tai et al. (1985) might have been tried.
They found that Beta-lactamase activity could be restored in SDS-PAGE gels
after electrophoresis by the addition of a carrier protein.
It should be noted that this particular SDS-PAGE system is not as
accurate at the low molecular size range as it is at the higher ranges.
These results suggest the following thesis:
(i) these Beta-lactamases exist under certain conditions as high
molecular size aggregates
(ii) under different conditions they break up into different "subunits"
with differing ionic charges which may exist in different M r
(iii) under certain conditions these proteins exist predominantly in a low
molecular size subunit of around 10-15Kd or alternatively in a 35-
40Kd size
These results also offer possible explanations for various observations
that have been made about these enzymes by others and in this thesis.
-e.
(a) their existance in large M r aggregates (in certain conditions) would
explain why they are poorly soluble in conventional
polyacrylamide IEF systems
(b) it would also explain why their activity remains in the face of
denaturing conditions such as 4M urea in AUS gels and the
denaturing effects of the sample preparation for these gels
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(c) it would explain why their eventual focusing in AUS gels resulted
in some variation in the banding observed
(d) it explains why other workers have described Acinetobacter
chromosomal enzymes have M r estimated at 35-40Kd (Morohoshi
& Saito, 1977; Hikida et al., 1989).
It is perhaps a little ironic that initially we believed that these Beta-
lactamases had the largest Mr described and now they seem to have one of the
smallest.
BIOCHEMICAL CHARACTERISATION OF THE ACE ENZYMES
This was carried out by following the recommendations of Bush and
Sykes (1986) and Bush (1989a).
All biochemistry was carried out employing partially purified enzyme
obtained from large scale gel permeation.
Substrate profiles
Relative rates of hydrolysis of all nine enzymes showed generally poor
hydrolytic activity. Nitrocephin was hydrolysed by all the enzymes as was
cephaloridine to a similar extent by all the enzymes. All the enzymes apart from
ACE-4 (from 5B86) hydrolyse penicillin G albeit some 1000 times slower than
nitrocephin.
These results showed no clear differences between the Beta-lactamases
but that they were clearly all cephalosporinases.
Kinetic parameters
The Km, Vmax and efficiency of hydrolysis values were calculated for
each enzyme. The major substrates were nitrocephin and cephaloridine. The
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relative efficiency of hydrolysis values were expressed as a percentage of the
value for nitrocephin.
The Km values for both nitrocephin and cephaloridine showed that all
the enzymes had moderate affinity for these substrates.
The Vmax values were also similar for all these enzymes, against both
the substrates, but with the rate for cephaloridine one to two orders of magnitude
lower than those for nitrocephin.
All the enzymes had similar relative efficiency values (Km/Vmax) for
the hydrolysis of cephaloridine.
Therefore kinetic parameters did not show any convincing differences
between each of the ACE Beta-lactamases.
However the Km values for cephaloridine which varied from 150 to
710pM were very similar to the values of 250p.M and 511p.M described for their
enzymes by Morohoshi and Saito (1977) and Hikida et al. (1989) respectively.
Inhibition studies
These revealed that all the enzymes were inhibited by cloxacillin but
none wqs inhibited by clavulanic acid. All were inhibited by a fixed
concentration of HgCl2 but none by moderately high levels of pCMB. ID50
results did however discriminate between the ACE-3, ACE-4 and ACE-1 / ACE-2
groups. The ID50 to aztreonam for ACE-4 was significantly higher than that for
the ACE-1 / ACE-2 enzymes tested and the ID50 for the ACE-3 enzyme was
significantly lower than those for the ACE-1 / ACE-2 enzymes.
The effect of ImM EDTA on the activity of all these enzymes was
variable but generally less than 20% inhibition was observed when investigating
partially pure enzyme preparations. The inhibition study was repeated using a
purer preparation obtained from high performance ion exchange chromatography
Si-
of the ACE-1 enzyme produced from H63. This consistantly showed very little
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inhibition by ImM EDTA (<10%) and therefore metal ions do not seem to play a
part in the function of this Beta-lactamase.
In summary these inhibition profiles place these enzymes firmly in the
Bush Group One (CEP-N) i.e. chromosomal Beta-lactamases typical of Gram
negative bacteria.
INDUCTION STUDIES
The inducibility of these cephalosporinases by specific Beta-lactam
inducers has been far from clear. Morohoshi and Saito (1977) described how the
enzyme activities of five strains of A.anitratum "increased by about five to ten¬
fold" following treatment with lOOpg of benzylpenicillin, cephaloridine or 6-
aminopenicillanic acid for 1 hour at 37°C. Hikida et al. (1989) quoted Morohoshi
and Saito (1977) as having shown that Acinetobacter cephalosporinases are
inducible, but they did not carry out induction experiments themselves.
They are quoted as being inducible by Sykes and Matthew (1976),
Medeiros (1984) and Neu (1986b). Baurenfeind (1986) classified them as
inducible or constitutive whereas Joly-Guillou et al.{ 1988) stated that inducibility
in Acinetobacter spp. had not yet been demonstrated. Sykes and Smith (1979)
stated that they were non-inducible.
I carried out induction experiments with all nine strains employing
cefoxitin as the inducer at one quarter the MIC value for that strain. The method
described by Minami et al. (1980) was employed.
No discernable Beta-lactamase induction was found with any of the
strains studied. In discussions with D. Livermore and C. C. Sanders (personal
communications) it was stated that evidence of induction had not yet been found
in any strain of Acinetobacter so far tested. This includes the use of cefoxitin,
imipenem and penicillin as inducers. Much more convincing evidence would
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therefore be required before it can be claimed that these enzymes are inducible,
since current evidence suggests that they are not.
However, recent work carried out by Kleber's group in Leipzig
(Blechschmidt et al., 1989; Borneleit et al., 1991) may result in a reassessment of
the role of Beta-lactamase induction in Acinetobacter.
They studied two strains of Acinetobacter (69V and CCM 5593). These
strains were obtained from the Czechoslovak Collection of Microorganisms,
Brno. It is not clear where they originated - from environmental samples or
clinical specimens.
They suggested that the Beta-lactamases produced by these strains were
(i) inducible
(ii) predominantly extracellular in location rather than in the periplasm
They believe that the extracellular location of these enzymes does not
result from periplasmic leakage since the other normally periplasmic enzymes e.g.
alkaline phosphatase and glucose dehydrogenase are not found extracellularly in
these strains. Nor do they feel that it is the result of cell lysis since the level of the
cytoplasmic enzyme, malate dehydrogenase is not raised in the cell free medium.
If the induction experiments were carried out only measuring the Beta-
lactamase activity in the periplasm - no evidence for induction was found,
however measuring the activity in the supernatant revealed that induction was
taking place.
They also described concomitantly with the increase in extracellular
Beta-lactamase a steady increase in the release of lipopolysaccharide.
They suggest that the Beta-lactamase export was dependant on "enzyme
over production in a cooperative manner" with a "self promoted perturbation of
the outer membrane by overproduction of the enzyme leading to a semi-selective
increase in membrane permeability".
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It is clearly important to ascertain whether these findings can be repeated
in clinical isolates of Acinetobacter since if correct, these data will throw further
light on these fascinating but complicated enzymes.
PROTEIN AGGREGATION
If the thesis that many of these Acinetobacter Bcta-lactamases exist in
aggregated form is correct, then one must pose the question: why?
Under particular circumstances newly synthesised proteins do not fold
properly in vivo and the result is amorphous protein aggregates (Bowden &
Georgiou, 1990).
Protein aggregation is seen:
(i) in cells that are grown at elevated temperatures
(Goldenberg &King, 1981)
(ii) during the synthesis of abnormal polypeptides
(Prouty & Goldberg, 1972)
(iii) in cells expressing cloned gene products (Marston, 1986; Kane &
Hartley, 1988; Mitraki & King, 1989; Schein, 1989)
Bowden and Georgiou (1990) stated that solubilisation of the aggregated
proteins resulting from the expression of recombinant proteins usually required
strong denaturing conditions indicating that the polypeptide chains were
incorrectly folded.
Detailed studies in vitro have shown that protein aggregation arises from
the association of partially folded intermediates and is dependant on the protein
concentration (Brems, 1988; Jaenicke & Rudolph, 1989).
Haase-Pettingel and King (1988) have shown that the aggregation of P22
tail spike protein in Salmonella typhimurium is caused by the association of
polypeptide molecules that fail to enter the folding pathway. The extent of in vivo
aggregation depends on the accumulation of a soluble, partially folded,
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intermediate.
This may either fold to the native conformation or participate in
intermolecular association processes that lead to protein aggregates. Folding and
aggregation are parallel pathways in kinetic competition with each other. So the
ratio between native and aggregated products is determined by the rate of
accummulation of the folding intermediate which is dependant on the rate of
translation and the rates of polypeptide folding and association.
The relation between intracellular conditions such as ionic strength or
interactions with cellular components, and protein aggregation is not clear
(Bowden & Georgiou, 1990).
However growth temperature has been shown to effect drastically
aggregation of the P22 tail spike protein, this may be related to the rate of
translation and the interactions of the partially folded polypeptides with
chaperonins (which exhibit strong temperature dependence) (Rothman, 1989).
Little is yet known about the folding and assembling of secreted proteins
in procaryotes (Richey et a!., 1987; Hardy etal., 1988).
It is believed however, that in the cytoplasm the precursor form of
secreted polypeptides must be maintained in a conformation suitable for export
(Randall & Hardy, 1989).
This secretory process appears to be modulated in two ways.
(i) The presence of the signal sequence which among other roles
retards folding (Liu etal., 1988)
(ii) By interactions with chaperonins e.g. GroEL, GoES, trigger factor
and SecB (Lecker et al., 1989)
The folding events that follow membrane translocation are not well
defined (Georgiou & Bowden, 1990).
Some work has been carried out in the secretion of Beta-lactamases.
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Minsky et al. (1986) established in E.coli with TEM-1 Beta-lactamase
that an intermediate bound on the periplasmic side of the inner membrane is
formed prior to the release of the protein in soluble form into the periplasmic
space.
Bowden and Georgiou (1990) again studying TEM-1 in E.coli found that
aggregation occurred when the rate of expression exceeded 2.5% of the total
protein synthesis rate.
Therefore further work is required to establish whether the apparent
aggregation of Acinetobacter (3-lactamases is due to abnormal folding.
Interestingly, the (3-lactamases of Staphylococcus aureus behave in a
very similar fashion, in conventional polyacrylamide IEF gel systems, as the
Acinetobacter enzymes (personal communication, Beecham Research
Laboratories). Taking this into account with the work of Borneleit et al.(1991)
leads one to speculate on the evolutionary place of the Acinetobacter |3-
lactamases. Perhaps they are intermediate between the Gram positive and Gram
negative groups?
ROLE OF PRESUMED CHROMOSOMAL BETA-LACTAMASES OF
ACINETOBACTER IN BETA-LACTAM RESISTANCE
Although it seems likely that these enzymes are largely responsible for
the observed resistance to Beta-lactam drugs, it is also probable that other factors
e.g. altered permeability or alterations in the penicillin-binding proteins may be
equally important in some strains.
The ultimate test must involve the cloning of the Beta-lactamase gene
into a suitable shuttle vector which would then allow the true role of this gene in
the resistance to be ascertained.
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THE DIRECTIONS FOR FUTURE RESEARCH
As has previously been alluded to, the future work on these fascinating
enzymes should take at least three paths.
1. Microbiology
It is crucial that the Acinetobacter strains studied are correctly identified to
the species level perhaps by the physiological and biochemical
characterisation scheme delineated by Grimont and Bouvet (1991).
2. Molecular biology
This must involve the cloning of the Beta-lactamase gene (from perhaps
more than one strain of the Acinetobacters studied here) into a suitable
cloning vector.
This would allow:
(i) The role of the gene in the resistance mechanism to be determined
and
(ii) After placement into a suitable sequencing vector, the nucleotide
sequence could be established.
Once the sequence(s) is (are) known, then the position of these
Acinetobacter Beta-lactamases in the evolutionary tree of Beta-lactamases can be
ascertained.
The sequence data would also be important in allowing correlation with
X-ray crystallographic data (if available). These data would allow study of the
structure- activity relationships of these enzymes. Such information is crucial to
the basic understanding of antimicrobial drug resistance and therefore in




The four ACE types enzymes should be purified to homogeneity and their
N-terminal sequences determined. If possible X-ray crystallography
should be carried out.
The purification to homogeneity will be necessary to allow more precise
biochemical and kinetic characterisation of these enzymes e.g. the
estimation of K^ (turnover numbers) of these enzymes.
The purification will also hopefully clarify the molecular size of these
proteins
The results presented in this thesis suggest that these enzymes exist in
aggregated form. To investigate further these enzymes, and in particular to
ascertain whether they actually do exist as aggregates or whether the aggregation
was merely an artefact of the systems that I have used to study them, two
techniques will be employed.
(i) Analytical ultracentrifugation
Determination of the sedimentation equilibrium provides the single
most accurate and powerful method for the determination of the
native molecular size of a protein. It is simple, non-destructive and
relatively rapid to perform (Laue & Rhodes, 1990).
(ii) Gel electrophoresis
Native gel electrophoresis on gels containing differing
concentrations of polyacrylamide will be carried out.
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ENDPIECE
And now I shall complete the circle.
We started this thesis in the John Radcliffe Hospital in Oxford, with the
first serious therapeutic use of penicillin and went on to discuss the fascinating
evolution that has taken place both in the host and the parasite over the last 50
years. This took us through the evolution of Intensive therapy and the problems
that infection poses in such units. We saw the shift from aggressive pathogens to
less aggressive pathogens, from Gram positive to Gram negative, and back to
Gram positive; infecting fit healthy patients to infecting very compromised
patients.
This set the scene for the up and coming nosocomial pathogen -
Acinetobacter.
In the initial cefuroxime resistance screen Acinetobacter was the
commonest species present after Enterobacter.
We then looked at the resistance to cefuroxime and gentamicin in Gram
negative, oxidase negative, aerobic bacilli within the whole hospital over a period
of 5 years. This showed enormous variation (in the case of cefuroxime resistance)
between different units but also underscored the particular problems in the
Intensive therapy areas where the resistance was highest.
We then studied in some detail the fascinating (3-lactamases of the genus
Acinetobacter, discovering that they are completely different from any other (I-
lactamases previously described.
We pondered their possible role as an intermediary between Gram
positive and Gram negative ^-lactamases - but this is largely speculative.
Finally we have discussed the very basic, complicated yet fascinating,
work on the chemistry of protein folding and aggregation.
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Perhaps now I should close that circle by returning to where we started.
It would then complete our journey from the bedside to the test tube back to its
ultimate relevance - the patient.
During an eight week period in the summer of 1986 the Clinical
Bacteriology department of the RIE noticed a sudden increase in the isolation of
Acinetobacter spp. from the tips of arterial and central venous pressure lines from
patients within the Cardiothoracic ITU.
This resulted in 14 cases, 3 with septicaemia and one related death. The
strains were of the same biotype and resistance phenotype. There had been no
isolation of similar strains from specimens of urine or tracheal secretions.
Interestingly, 11 of the 14 cases had been first on the list with a high
proportion the first on the list on a Monday.
These lines are part of a complicated series of tubes which are attached to
a plastic dome which in turn is in contact with a pressure transducer. The
transducer measures either the arterial or venous pressure of the patient depending
where the tip of the line is placed.
These lines and transducers are very complicated to set up and take some
skill to do so quickly.
A new procedure had been instituted, just prior to this outbreak, and a
new technician had just taken up post.
Previously the lines and transducer sets had been primed with saline as
and when the need arose. However the unit had lost a great many of their senior
staff nurses to Australia and the Middle East. Therefore due to the inexperience
of the technician and the loss of these skilled nurses, a transducer set was primed
each evening, to be used for any emergency that night or used for the first person
on the operating list next day (or the following Monday if a weekend).
On investigation the same strain of Acinetobacter was isolated from the
stored transducer sets and from the soap and sink in the preparation area.
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It is therefore likely that the technician who set up most of these
transducer sets, heavily contaminated his hands from the transducer heads and
then contaminated the fluid that was being used to prime the sets.
The Acinetobacter then happily grew at room temperature within the
giving set until it was introduced into the patient.
Cleaning the transducer heads with alcohol prior to storage and setting up
the sets immediately prior to their use, resulted in no more cases.
Therefore we can see how subtle changes in the behaviour of the host
allowed the parasite to gain a foothold. Such are the nuances of the host-parasite
relationship.
I shall end with two quotes:
" The DNA itself is lifeless, its language cold and austere. What gives the
cell its life and personality are enzymes ... Nothing in nature is so tangible and
vital to our lives as enzymes, and yet so poorly understood and appreciated by all
but a few scientists Arthur Kornberg.
And a quote from Peter Medawar - a constant source of encouragement.
On the qualities needed by a scientist:
" A sanguine temperament that expects to be able to solve a problem;
power ofapplication and that kind offortitude that keeps them erect in the face of
much that might otherwise cast them down; and above all, persistence, a refusal,
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MICs of 200 strains of Gram negative, oxidase negative, aerobic bacilli, with
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IIOODNO LABNO ORGANISM CXMMIC P-lactamase
H349 343 CITF 128.00 T-l
H037 37 ECO 64.00 C
II084 85 ECO 32.00 C
H175 174 ECO 256.00 C
II002 2 ENB >256.00 P99+T-1
H005 5 ENBC 64.00 >P99
H008 8 ENBC 256.00 P99+T-1
H014 14 ENBC 128.00 P99+T-1
II015 15 ENBC 256.00 P99+T-1
II022 22 ENBC 64.00 T-l
H030 30 ENBC 256.00 P99+T-1
H031 31 ENBC >256.00 P99+T-1
H038 38 ENBC >256.00 P99+T-1
H043 43 ENBC 32.00 >P99+T-1
II051 52 ENBC >256.00 P99+T-1
H053 54 ENBC 64.00 >P99
H054 55 ENBC >256.00 P99+T-1
H055 56 ENBC 256.00 P99+T-1
II057 58 ENBC 64.00 P99
H058 59 ENB 128.00 P99
H059 60 ENBC 32.00 P99+T-1
II060 61 ENBC 128.00 P99
11061A 62 ENBC 128.00 P99
H064 66 ENBC >256.00 T-l
II066 68 ENBC 256.00 P99+T-1
H067 69 ENBC 256.00 <P99
H073 74 ENB 64.00 P99+T-1
H077 78 ENBC 32.00 >P99
H083 84 ENBC >256.00 P99+T-1
H092 91 ENBC >256.00 >P99
H093 92 ENB/CI >256.00 P99
H099 97 ENBC 64.00 P+>P+T-1
H103 101 ENBC >256.00 P99+T-1
HI 04 102 ENBC 256.00 P99+T-1
H105 103 ENBC >256.00 P99+T-1
H106 104 ENBC 256.00 P+>P+T-1
H108 106 ENBC 256.00 P99
H109 107 ENBC 256.00 I'99+T-l
H118 117 ENBC 256.00 P99
III 19 118 ENBA >256.00 P+>P
H122 121 ENBC 256.00 P99+T-1
II127 126 ENBC 256.00 >P99
H132 131 ENBC 256.00 P99+T-1
11137 136 ENBC >256.00 P99+T-1
11150 149 ENBC 64.00 >P99
H153A 152 ENBC 128.00 P99+T-1
H155 155 ENBA 64.00 >P99
11156 156 ENBC 128.00 >P99+T-1
H164 163 ENBC 128.00 1>99+T-1
337
HOODNO LABNO ORGANISM CXMMIC P-lactamase
II166 165 ENBC 32.00 P99+T-1
II182 182 ENBC 128.00 P99
II190 192 ENBC 128.00 P99+T-1
H191 193 ENBC 256.00 >P99+T-1
H192 194 ENBC 64.00 P99
H193 195 ENBC 128.00 P99+T-1
H197 198 ENBC >256.00 >P99+T-1
11251 251 ENBC 256.00 P99+T-1
H252 252 ENBC 256.00 P99+T-1
H262 261 ENBA 256.00 >P99
IL267 266 ENB 256.00 P99
II272 271 ENB 64.00 P99
H280 279 ENBC 256.00 T-l
II283 282 ENBC 256.00 P99+T-1
II289 287 ENBC 128.00 P99+T-1
H292 289 ENB >256.00 P99+T-1
11294 291 ENBC 128.00 P99
II296 293 ENBC 128.00 P99+T-1
H302 298 ENB 128.00 P99+T-1
H314 310 ENBC >256.00 >P99
II322 318 ENBC 256.00 >P99
H326 320 ENBC >256.00 P99
H327 321 ENBA 64.00 >P99
H330 324 ENBC >256.00 P99+T-1
H333 327 ENBC 128.00 P99+T-1
H341 335 ENBC 32.00 >P99
H358 352 ENBC 128.00 1'99
H367 361 ENBC 64.00 P99
11368 362 ENBC 256.00 P99
H372 366 ENBC >256.00 P99+T-1
11380 375 ENBC >256.00 >P99
H381 376 ENBC 256.00 I'99
11384 380 ENBC 128.00 >P99
11385 381 ENB 128.00 >P99
11386A 382 ENBC 128.00 >P99
H387B 385 ENB 128.00 >P99
H390 388 ENBC 256.00 >P99
11392 390 ENBC 32.00 >P99+T-1
11394 392 ENBC 256.00 P99
11397 395 ENBC 256.00 P99+T-1
H398 396 ENBC 256.00 P99
11400 398 ENBC 128.00 >P99
II405 112 ENBC 128.00 P99
11298 295 ERWA 32.00 C
11120 119 IIAFA 64.00 C+T-l
11123 122 I IAEA 64.00 C+SHV1
11019 19 KLEOX 128.00 Kl+T-1
H020 20 KEEP >256.00 C+T-l
II023 23 KLEOX 64.00 K14
H052 53 KLEB 64.00 K14
IIOODNO LABNO ORGANISM CXMMIC (1-lactamase
11062 64 KLEB 64.00 K14
II139 138 KLEP 32.00 T-l
H199 200 KLEOX 64.00 K14
II249 249 KLEOX 64.00 C
11276 275 KLEOX 64.00 K14
II281 280 KLEOX 64.00 K14
II312 308 KLEOX 64.00 K14
H082 83 MORM 32.00 C
H088 87 MORM >256.00 C
II181 181 MORM 64.00 C+T-l
11250 250 MORM 32.00 C
H007 7 PROSTU 256.00 C
11024 24 PROVU 64.00 C
II269 268 PROP 256.00 C
II011 11 SERM 64.00 C
H013 13 SER >256.00 C
11029 29 SERL 32.00 C
11034 34 SERM 128.00 C
11049 50 SERM 32.00 C
11087 86 SERL 32.00 C
11148 147 SERO 32.00 €
H171 170 SERM 256.00 C
II178B 178 SERM 256.00 C+T-l
11198 199 SERM >256.00 C
H277 276 SERL 64.00 C
11288 286 SER >256.00 C
11310 306 SERM >256.00 C
11342 336 SERM 256.00 C
11344 338 SERM 256.00 C
11346 340 SERM >256.00 C
11359 353 SERM >256.00 C
11360 354 SERM >256.00 C
11363 357 SERM 64.00 C
11373 367 SERM >256.00 C
11374 368 SERM 32.00 c
I1376A 370 SERM >256.00 c
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The characterization of the chromosomal beta-lactamases of Acinetobacter has
proved difficult because of the poor focusing of these enzymes in conventional iso¬
electric focusing on polyacrylamide gels. We describe a novel isoelectric focusing
method, which employs an agarose gel incorporating a detergent with sorbitol and
urea, to examine the beta-lactamases produced by eight clinical strains of Acineto¬
bacter calcoaceticus; we have identified four different beta-lactamases. The molecu¬
lar masses of each of the beta-lactamases was estimated and most of them ranged
from 600 000 to > 1 000 000. These are the largest beta-lactamases so far described
and their size is likely to be one reason for their poor solubility in conventional
polyacrylamide systems.
Acinetobacter calcoaceticus is an increasingly
important cause of nosocomial infection
(Bergogne-Berezin et al. 1987) and one of the
particular attributes of strains isolated in hos¬
pitals is resistance to many antimicrobial
agents. The beta-lactam resistance of these
strains probably results from the production of
beta-lactamases (Joly-Guillou et al. 1987).
The exact nature and characterization of the
(presumed) chromosomal cephalosporinases of
Acinetobacter spp. is still not clear (Joly-Guillou
& Bergogne-Berezin 1986; Joly-Guillou et al.
1987, 1988). Morohoshi & Saito (1977)
described a beta-lactamase in one strain of
Acinetobacter as an enzyme with a preference
for cephalosporins rather than penicillins and
found that it had a mol. mass 30000. Medeiros
(1984) described the chromosomal beta-
lactamases of Acinetobacter anitratum as induc¬
ible enzymes whereas Baurenfeind (1986)
described them as either inducible or constitu¬
tive cephalosporinases. More recently, Joly-
Guillou et al. (1987) studied 100 clinical strains
of Acinetobacter and found that most of them
* Corresponding author.
(67) possessed a TEM-1 plasmid-mediated beta-
lactamase. On the other hand, 30 had a
chromosomal enzyme with a pi > 8 which was
presumed to be similar to that described by
Morohoshi & Saito (1977). No satisfactory
enzyme identification technique was available to
prove this point. Of these strains 7% had consti¬
tutive production and therefore high level resist¬
ance and 23 had both TEM-1 and the
chromosomal beta-lactamases. There were nine
strains that had a novel carbenicillin-
hydrolysing enzyme (presumably plasmid
encoded), which they called CARB-5. The same
group of workers (Joly-Guillou et al. 1988) now
describe a cephalosporinase activity in 41 of 100
clinical strains and state that beta-lactamase
inducibility in Acinetobacter spp. has not been
clearly demonstrated. These workers attempted
to classify Acinetobacter calcoaceticus into four
phenotypes based on the distribution of beta-
lactamases and their MIC values to 14 beta-
lactam antibiotics.
In the course of a study into beta-lactam
resistance in Gram-negative aerobic bacteria in
our hospital we found that a high proportion
(22%) were Acinetobacter spp. Most of the
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strains were var. anitratus although a few were
var. Iwqffi. We now describe a novel method
which allows isoelectric focusing of high molec¬
ular weight beta-lactamases and their distinc¬
tion from one another.
Materials and Methods
BACTERIAL STRAINS
Eight strains of Acinetobacter spp. with MICs
to aztreonam of >16 mg/1 were collected from
clinical sources in the Royal Infirmary Edin¬
burgh. They were identified by either API 20E
or API 20NE (API System. S.A., France), (see
Table 1).
PREPARATION OF CRUDE BETA-
LACTAMASES
Cells were grown in 4-5 ml of nutrient broth
overnight at 37°C and used to inoculate a 1 1
culture of nutrient broth and this was shaken
(200 osc/min) at 37°C for 18 h. Cells were har¬
vested at 5000 g for 15 min at 4°C (Sorvall
RC-5B Refrigerated Superspeed Centrifuge, Du
Pont Instruments) and the pellet was washed in
500 ml of 25 mmol/1 sodium phosphate buffer
(pH 7-0) and re-centrifuged at 5000 g for 15 min.
The pellet was then resuspended in 3 ml of
sodium phosphate buffer (pH 7-0) and the cells
were disrupted by ultrasonication with constant
cooling (8 /mi, 1 min x 3, MSE Soniprep 150,
MSE Instruments, Crawley). The cell debris was
removed by centrifugation at 38000 g for 15
min at 4°C (Sorvall).
PREPARATION OF PARTIALLY PURIFIED
BETA-LACTAMASE
One ml amounts of crude enzyme was initially
applied to a G-75 Sephadex gel filtration
column (2 cm2 x 90 cm) (Pharmacia, Uppsala,
Sweden). The beta-lactamase peak was first
identified by testing each volume for activity
with the chromogenic cephalosporin, nitro-
cephin. Thirty /il of each volume were added to
100 /d of nitrocephin solution (50 mg/1) in a
microtitre plate. Those which showed a rapid
colour change (<120 s) from yellow to red indi¬
cated the presence of beta-lactamase activity.
These were then further assayed by the spec-
trophotometric assay method of O'Callaghan et
al. (1972) to determine the peak beta-lactamase
activity. If the activity appeared in the void
volume another 1 ml of crude preparation was
added to a similar column containing Sephacryl
S-300 (Pharmacia) and the peak fractions deter¬
mined as before. The peak fractions were pooled




This was carried out using the method of
Andrews (1964). Appropriate proteins were
applied to both the G-75 Sephadex and the
Sephacryl S-300 columns. The position of the
peaks of the protein markers was established by
measuring the optical density of the fractions by
the method of Waddell (1956). Beta-lactamase
samples could then be applied to the calibrated
columns and their mol. mass determined from
the standard curves.
IEF POLYACRYLAMIDE GELS
The gels were prepared by the method of
Matthew et al. (1975) using pH 3-5-10-6 am-
pholines (LKB). Samples of the enzymes (up to
100 /il) were applied, about 2 cm from the
anode, on to the gel surface. The amount added
(in /d) being equal to the time taken (in s) for a
mixture of 30 /tl of beta-lactamase preparation
and 100 /d of nitrocephin solution (50 mg/1) to
change from yellow to red.
Isoelectric focusing was carried out at 4°C at
1 W (constant), 550 V (limiting) and 20 mA
(limiting) for 18 h. Five /d of isoelectric point
(pi) standard markers (BDH) were also spotted
on the gel to quantify the pi gradient of the gel.
1% AGAROSE, 4.3 mol/1 UREA, 10% SORBITOL
(AUS) GELS
AUS gels were prepared by melting 377 mg of
agarose (agarose for isoelectric focusing type
VIII, Sigma) in 15 ml of distilled water in a
microwave oven (550 W) for 30-40 s. This was
then allowed to cool to 60°C in a waterbath.
Four g of D-sorbitol (BDH) were added to
9-6 ml of distilled water and heated to 60°C in a
water bath. Similarly 10-2 ml of 10% (w/v)
Triton X-100 (BDH) were added to 10 g of urea
(BDH) and placed in the 60°C waterbath. The
sorbitol solution and urea in Triton X-100 were
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i . Sample
SHVI loaded
Fig. 1. Conventional polyacrylamide IEF gels of Acinetobacter chromosomal beta-lactamases and the plasmid
beta-lactamase SHVI. Enzyme activity identified with nitrocephin.
then added and mixed. Just before incorpo¬
ration of this mixture into the agarose, 2-5 ml of
3-5—10-6 ampholines (LKB) and 0-5 ml beta-
mercaptoethanol (Sigma) were added. The final
mixture of 1% agarose, 4-3 mol/1 urea and 10%
sorbitol was then gently stirred at 60°C and
drawn up into a preheated glass pipette. The
solution was then pipetted on the hydrophobic
surface of a GelBond sheet (LKB) which was
placed on the LKB 2217 ultrophor electro-
focusing unit. This gel gave approximately a
1 mm overall thickness. The gel was left over¬
night (with the lid firmly down to prevent the
gel drying out) to achieve mechanical strength.
The samples (and isoelectric point markers)
were applied to the surface of the gel but near
the middle rather than 2 cm from the anode as
with the polyacrylamide gels. Electrode wicks
(LKB) were applied to the gel, the anode soaked
in 01 n phosphoric acid (BDH Analar) and the
cathode soaked in 01 n NaOH (BDH Analar).
The electrofocusing unit was maintained at
15-20°C and a constant power was maintained
at 30 W, setting the voltage and current at the
limiting values of 1500 V and 30 mA respec¬
tively. The gel was electrophoresed until the pi
markers had focused (i.e. for around 2 h
30 min).
sample preparation
Sample size (in /d) was equalized with time, as
described above. However, it was found that to
aid the solubilization of the enzymes in the
system: (a) a sample concentrate was added to
each sample in the ratio of 1 /d of sample con¬
centrate for each 5 /d of beta-lactamase in an
Eppendorf tube. The sample concentrate con¬
sisted of (/d): LKB ampholines 3-5-10-6, 200;
beta-mercaptoethanol, 100; Triton X-100 10%
(v/w), 200; and (b) just before application onto
this gel the sample mixture was saturated with
urea (BDH). The excess urea was pelleted by
centrifugation (30 s at 2874 g, MSE Micro-
centaur).
staining
Polyacrylamide gels and AUS gels were stained
by repeatedly overlaying the surface with a
sheet of Whatman No 54 paper which had been
dipped in nitrocephin solution (500 mg/1). The
focused bands of beta-lactamase activity appear
red on a yellow background.
Results
Eight different strains of Acinetobacter were
chosen at random from the beta-lactam resist¬
ant population in the Royal Infirmary Edin¬
burgh. Cell-free extracts were obtained from
each and they were studied for the presence of
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beta-lactamases. The eight cell extracts were
first examined by the polyacrylamide IEF
system (Fig. 1). It was immediately obvious that
7/8 beta-lactamase preparations did not focus
satisfactorily. Streaks of enzyme activity were
seen between the anode and cathode but most
ended up against the cathode. In one case,
however, HI26, there was poor focusing of the
enzyme with a pi of about 91. These poor
results were not an artefact of the system used
as the plasmid-mediated beta-lactamase SHV-1
was included as a control to show normal focus¬
ing in this gel system. Faced with this problem,
we attempted to classify Acinetobacter beta-
lactamases by a sodium dodecyl sulphate-free
polyacrylamide gel system (i.e. differentiating
them by molecular weight). The results of this
were equally disappointing. In a similar manner
to the polyacrylamide IEF the Acinetobacter
enzymes migrated rapidly to the cathode during
electrophoresis while the plasmid-encoded
TEM-1, TEM-2 and OXA-2 beta-lactamase
controls migrated to their expected positions
(Hood and Amyes, unpublished data).
These results suggested to us that there was
an inherent problem in the use of polyacryl¬
amide as a separation matrix, perhaps as a
result of the mol. mass of the enzymes, so we
determined the mol. mass of each of these beta-
lactamases by gel filtration and these are shown
in Table 1. Most of these enzymes were very
large indeed, in the region of 600000 to greater
than 1000000. Thus their inability to migrate
satisfactorily, in the two polyacrylamide systems
described, suggested that the problem resulted
from poor enzyme solubility and it seemed
necessary to employ a system that promoted the
solubility of the large enzymes. Thus an agarose,
urea and sorbitol gel system was devised. By
this technique, we were able to focus the par¬
tially purified beta-lactamases from the eight
clinical strains (see Fig. 2). At least, four differ¬
ent focusing patterns were formed. Five of the
eight enzymes have very similar focusing pat¬
terns; the beta-lactamases from strains HI7,
H26, H68, H141 and 6B230 all had major bands
at pi 8-6 and pi 8-8. However, the enzyme from
H26, which was run on both Gel 2a and Gel 2b
as an internal control, had additional minor
bands at pi 9-8 and 101 on Gel 2b. H17 also
had a minor band at pi 10-3. The other three
enzymes were completely different, HI62 had a
single band at pi 8-7; HI26 has a major band at
pi 8-2 and a minor band at pi 81 and 5B86 has
a major band at pi 7-3 and a minor band at pi
7-7.
Discussion
SEPARATION BY ISOELECTRIC FOCUSING
The separation of the beta lactamases of Acine¬
tobacter (that are presumed to be chromosomal)
by IEF on conventional polyacrylamide gels has
proved totally unsuitable because of the inabil¬
ity of most of the enzymes to focus. Recently
Joly-Guillou et al. (1988) described IEF findings
of nine strains with 'a cephalosporinase type'
enzyme as having 'variable bands of beta-
lactamase activity located at pH > 8'.
In our series, in seven of eight preparations
tested, streaks of beta-lactamase activity






type Az* MIC Mol. masst ACEf type
5B86 var Iwoffi blood 16 >1000000 4
6B230 var anitratus blood 32 >1000000 1
H17 var anitratus urine 64 640000 1
H26 var anitratus sinus swab 32 >1000000 1
H68 var anitratus urine 64 >1000000 1
H126 var Iwoffi wound swab >256 32 500 3
HI41 var anitratus wound swab 64 >1000000 1
H162 var anitratus wound swab 64 60500 2
* Az, aztreonam MIC in mg/1.
+ Mol. mass, molecular mass.
J ACE, Acinetobacter chromosomal enzyme.










H17 H26 H68 HI4I
Sample
loaded
Fig. 2. Agarose, urea and sorbitol (AUS) IEF gels. Focused bands of Acinetobacter chromosomal beta-lactamase
activity identified with nitrocephin. (a) 6B230, ACE 1; H26, ACE 1; 5B86, ACE 4; H126, ACE 3; H162, ACE 2. (b)
H17, ACE 1; H26, ACE 1;H68, ACE 1; H141, ACE 1.
occurred from the point at which the enzymes
were placed on the gel, to the cathode. Two
facts led us to believe that the problem in this
system was one of solubility. Firstly the mol.
mass of these beta-lactamases varied from
32 500 to >1000000, and this would result in
considerable sieving effects in the polyacryla-
mide gel. Secondly, when the enzymes were
applied to a sodium dodecyl sulphate-free poly-
acrylamide gel system for separation on their
molecular size, all the Acinetobacter beta-
lactamases behaved in exactly the same way.
They migrated directly to the cathode whereas
control enzymes of TEM-1, TEM-2 and OXA-2
migrated as their size would predict.
The use of thin-layer IEF gels containing
agarose has previously been described for the
resolution of proteins with a mol. mass of
greater than 2 x 106 (Saravis & Zamcheck
1979). Vecoli et al. (1983) compared the use of
an agarose gel IEF with that of conventional
polyacrylamide gel IEF in characterizing low
molecular weight beta-lactamases and showed
good correlation with the isoelectric points in
most samples tested. Olsson & Laas (1981)
described a method which incorporated urea,
agarose and sorbitol into a gel allowing
complex mixtures of poorly soluble proteins to
focus, e.g. cheese and soya bean meal. They
noted the problems associated with urea and
agarose gels i.e. (1) the agarose matrix is dis¬
turbed, leading to lower mechanical strength
which results in a longer gelling time; and (2)
urea and ammonium cyanide form an equi¬
librium pair leading to a risk of carbamylation.
The use of sorbitol and beta-mercaptoethanol,
however, minimized this problem.
Olsson & Laas (1981) also noted that the pre¬
sence of urea may affect the pi of some proteins,
they gave the example of two isomers of lentil
lectin which have pis of 815 and 8-65, without
urea, and pis of 5 0 and 5-5 in 8 mol/1 urea. Our
findings show the pi of the beta-lactamase of
H126 to be around 91 without urea and 81 in
4 3 mol/1 urea. We would emphasize, however,
that our technique highlights the differences in
pis in these beta-lactamases under the same
preparation and running conditions rather than
giving their absolute values.
In this paper, we describe a modification of
the above technique that has allowed us to dis¬
tinguish at least four different Acinetobacter
beta-lactamases. We have designated the
common beta-lactamase found in HI7, H26,
H68, H141 and 6B230 as ACE1. We believe that
the extra minor banding found in H26 and H17
in Gel 2b may also be present in the others since
in Gel 2a (in which H26 also appears) poor
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focusing occurred at the pi 9-10-6 range with
the 10-6 pi marker itself focusing badly. The
enzyme present in strain HI62 we have desig¬
nated ACE2, and we have called the beta-
lactamase in strain H126, ACE3 and the enzyme
in strain 5B86, ACE4 (see Fig. 2).
We have found this technique to be repro¬
ducible. In its development, we tried incorpo¬
rating urea into a polyacrylamide IEF gel with
the same sample preparations. Electrophoresis
with this system resulted in four different beta-
lactamase patterns (in the same ascending order
of pi) but there was poorer focusing and greater
gel distortion. This presumably also resulted
from the sieving effects of the polyacrylamide on
the large molecular weight molecules (Hood and
Amyes, unpublished data).
We have also found that the bands take
longer to appear when the nitrocephin solution
is added (red on yellow background) than in
conventional polyacrylamide IEF gels. The
problem can be exacerbated by the need to use
In NaOH as the cathode buffer. This alkali
hydrolyses the nitrocephin causing the gel in the
cathodic region to turn red. This may make it
difficult to visualize the beta-lactamase staining
bands near the cathode. However, we have
found that the problem can be partially over¬
come by overlaying this area with a weak acid
before staining with nitrocephin.
separation by molecular mass
The mol. mass of most of these beta-lactamases
is surprisingly large. Morohoshi & Saito (1977)
studied an Acinetobacter chromosomal beta-
lactamase and estimated its molecular weight as
being 30000. We have one beta-lactamase,
H126, with a similar mol. mass. Sawai et al.
(1982) looked at the molecular weights of
cephalosporinases of Gram-negative bacteria
and found molecular sizes ranging from 29 800
to 38000 in Proteus vulgaris, P. morganii, Citro-
bacter freundii, Enterobacter cloacae, Serratia
marcescens and Escherichia coli.
The largest beta-lactamase so far described is
the LI beta-lactamase of Pseudomonas maltop-
hilia. Bicknell et al. (1985) estimated its mol.
mass as 123 000 existing as a tetramer with sub-
units of 31 600 whereas Saino et al. (1982) esti¬
mated that its mol. mass was 118 000 with
26000 mol. mass subunits. The gene encoding
this beta-lactamase was located in the bacterial
chromosomal DNA (Dufresne et al. 1988). It
seems likely that these Acinetobacter beta-
lactamases are coded for in the chromosomal
DNA and exist in subunit form. However, their
size may seem large because of covalent or
strong non-covalent linkage with other cell
envelope components. Therefore further work is
required to elucidate the above speculations.
The two lowest molecular weight beta-
lactamases, HI26 and HI62, focus best. The
beta-lactamase from strain HI26 (ACE-3) with
a mol. mass of 32 500, is the only enzyme to
focus on the ordinary polyacrylamide IEF and
the enzyme from strain HI62 (ACE-2) is the
only enzyme to focus into one band on the AUS
gel IEF.
The finding of four different beta-lactamases,
which are almost certainly chromosomally
mediated in the genus Acinetobacter may not be
surprising. In this instance there are two differ¬
ent enzymes in both the var anitratus and in the
var Iwoffi strains. Recently, Bakken et al. (1988)
have described at least four different inducible
(presumably chromosomal) beta-lactamases in
Aeromonas spp. and Matthew & Harris (1976)
noted there were several species of bacteria with
more than one beta-lactamase type.
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1. SUMMARY
We have devised a reliable procedure for the
separation of three //-lactamases of isoelectric
focusing points (p/), 5.4, 6.5, and 7.9 by Fast
Protein Liquid Chromotography (FPLC System).
All of these enzymes were transferable and
originated from a ceftazidime and cefotaxime re¬
sistant Klebsiella pneumoniae isolated in Bombay,
India. The complete separation of the enzymes,
achievable by this method, allowed each of the
different individual //-lactamases to be char¬
acterised biochemically. This analysis revealed that
the enzymes of p7 6.5 and p7 7.9 hydrolysed
ceftazidime and cefotaxime, and were responsible
for the resistance of K. pneumoniae, and its
Escherichia coli J53-2 transconjugant to third gen¬
eration cephalosporins. The enzyme of p7 5.4 was
the TEM-1 //-lactamase. The //-lactamase of p7
Correspondence to: S.G.B. Amyes, Department of Bacteriology,
The Medical School, University of Edinburgh, Teviot Place,
Edinburgh EH8 9AG, U.K.
FPLC System is a Registered Trade Mark of Pharmacia LKB
Biotechnology.
7.9 appears quite different from any previously
reported third generation cephalosporin hydrolys-
ing //-lactamase, and consequently given the pre¬
liminary designation DJP-1. This is also the first
example of extended spectrum hydrolysing //-
lactamases found in Asia.
2. INTRODUCTION
There have been recent reports of transferable
//-lactamases which confer resistance to broad
spectrum cephalosporins [1-8]. These enzymes
have been derived from the SHV and TEM //-
lactamase genes [1], In some cases these new en¬
zymes are produced along with other transferable
//-lactamases of different isoelectric points and
sometimes these distinct //-lactamases are encoded
by the same plasmid. Consequently, the investiga¬
tion and characterisation of these enzymes would
prove to be very difficult as they must be com¬
pletely separated from the other //-lactamases. As
many of these enzymes have similar molecular
sizes, separation techniques based on the enzyme's
ionic charge have been employed. This can be
0378-1097/90/S03.50 © 1990 Federation of European Microbiological Societies
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achieved by techniques such as preparative iso¬
electric focusing (IEF) which was used to isolate
TLE-2 from TEM-1 and SHV-1 [9] and electro-di¬
alysis which was used to separate TEM-E2 from
TEM-1 [8]. However, these methods are time con¬
suming and the amount and purity of the enzyme
recovered is unsatisfactory. We have developed a
Fast Protein Liquid Chromatography (FPLC Sys¬
tem) technique for the rapid separation of three
different //-lactamases produced by a ceftazidime
and cefotaxime resistant Escherichia coli J53-2
transconjugant of a Klebsiella pneumoniae strain.
In the past reverse phase High Performance Liquid
Chromatography (HPLC) techniques have been
used to purify //-lactamases such as SHV-1 [10],
and FPLC System has been implemented to purify
an inducible //-lactamase produced by Proteus
vulgaris [11], and a //-lactamase from Clostridium
butyricum [12], but neither procedure has ever
been used to separate three plasmid encoded //-
lactamases produced by the same strain.
3. MATERIALS AND METHODS
3.1. Strains
Klebsiella pneumoniae 8825 was isolated from a
lymphoma patient at the Tate Memorial Hospital,
Bombay, India. The rifampicin resistant E. coli
J53-2 was used as the recipient strain in conjuga¬
tion experiments.
3.2. Conjugation experiments
One ml of an overnight nutrient broth (Oxoid)
culture of E. coli J53-2 and 0.1 ml of an overnight
culture of K. pneumoniae were incubated with 4.5
ml of nutrient broth for 6 h at 37 °C. The E. coli
J53-2 transconjugants were selected on agar con¬
taining ceftazidime (1 mg/1) and rifampicin (50
mg/1) or carbenicillin (100 mg/1) and rifampicin
(50 mg/1).
3.3. Antibiotic susceptibilities
Minimum inhibitory concentrations (MIC) of
antibacterial drugs were determined on Diagnostic
Sensitivity Test Agar (Oxoid) at a concentration
of 105 cfu as described previously by Amyes and
Gould (1984) [13]. The MICs of ampicillin,
cefotaxime and ceftazidime were additionally
measured in the presence of clavulanic acid (2
mg/1).
3.4. /3-lactamase preparation
One litre of nutrient broth containing ceftazi¬
dime (4 mg/1) was inoculated with the E. coli
J53-2 transconjugant of K. pneumoniae 8825 and
grown overnight at 37 ° C. The cells were harvested
by centrifugation for 15 min at 6000 X g. The
bacterial pellets were washed in 25 mM sodium
phosphate buffer (pH 7.0) and the centrifugation
was repeated as described before. One ml of 25
mM sodium phosphate buffer (pH 7.0) was then
added to the final pellet and the cells were resus-
pended to give 3 ml of cell suspension which was
disrupted by ultrasound [14], The cell lysate was
cleared by centrifugation for one hour at 32 000 X
g. All of this crude //-lactamase preparation was
applied to a Sephadex G-75 gel filtration column
(2 cm2 X 90 cm) and eluted with 25 mM sodium
phosphate buffer (pH 7.0) at 15 ml/h [15]. The
column was calibrated with chymotrypsinogen, cy¬
tochrome c, and ovalbumin. The fractions which
exhibited //-lactamase activity were pooled and
dialysed against 50 mM Tris-HCl buffer (pH 8.2)
overnight.
3.5. /3-lactamase identification
The //-lactamases were identified by analytical
IEF on polyacrylamide gels [16] containing a 1:1
ratio of pH 3.5-10 and pH 4-6 ampholines (LKB).
The substrate profiles of the //-lactamases were
determined by assaying their hydrolytic activity
against fixed concentrations of six different //-
lactam drugs [14], The rates of hydrolysis were
expressed relative to ampicillin.
3.6. Fast protein liquid chromatography
Separation of the //-lactamases was carried out
with the Pharmacia FPLC System consisting of
LCC 500 Plus Controller, UV-M Monitor, FRAC
100 with an HR5/5 Mono Q column. The column
was equilibrated with 50 mM Tris-HCl buffer (pH
8.2). Two ml of the //-lactamase sample (from the
pooled peak fractions obtained by gel filtration
with the Sephadex G-75 column) were added to
the column. Separation was achieved by elution
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with a linearly increasing concentration of sodium
chloride (in the above buffer) to a maximum con¬
centration of 1 M. Approximately, 34 fractions (1
ml) were collected from each 30 min separation.
Each aliquot was tested for /^-lactamase activity
by the chromogenic cephalospoi in nitroccfin spot
test [17].
3. 7. Preparation of plusmid DNA
The method of Takahashi and Nagano [18] was
used to isolate and visualize the plasmid UNA of
the E. coli J53-2 transconjugant of K. pneumoniae
8825. The plasmid samples were run on an 0.5%
agarose gel with plasmids Kl (8*9 kb), R6K (38 kb)
as standards for large plasmids.
4. RESULTS
4.1. Conjugation experiments and plasmid analysis
experiments
E. coli J53-2 transconjugants of K. pneumoniae
8825 were detected on agar plates containing
ceftazidime or carbenicillin. The frequency of
transfer on the ceftazidime and rifampicin was
1.18x10"6 per donor cell, and the transfer
frequency for the selection on carbenicillin and
rifampicin was 3.53 X 10~6 per donor cell. Analy¬
sis of the plasmid DNA in the E. coli J53-2
transconjugant revealed plasmids of 100 kb and
2.5 kb (Fig. 1). This suggested that the /?-lacta¬
mase genes conferring resistance to carbenicillin
and ceftazidime were either one and the same or
they were located on the same plasmid.
4.2. Antibiotic susceptibilities
The K. pneumoniae 8825 strain was resistant to
all the penicillins and first, second, and third
generation cephalosporins, which were tested, with
the exception of cefoxitin. All these resistance
determinants were transferred to the E. coli J53-2
in the conjugation experiments (Table 1). In ad¬
dition, the clinical strain and the transconjugant
were both sensitive to imipenem. The K. pneumo¬
niae 8825 and its transconjugant were sensitive to
ampicillin, ceftazidime and cefotaxime in the pres¬
ence of clavulanic acid (2 mg/1), inferring that the
89Kb_
38Kb—
Fig. 1. Agarose gel electrophoresis of plasmid DNA from the
E. coli J53-2 transconjugant of K. pneumoniae 8825 along with
standard size plasmids. 1. R6K; 2. Rl; 3. Plasmid isolated
from E. coli transconjugant of K. pneumoniae 8825.
Table 1
Antibiotic susceptibilities of strains









Ampicillin > 250 > 250 4
+ clav * 8 4 4
Carbenicillin > 250 > 250 8
Cephaloridine 125 32 2
Cephalexin 125 64 8
Cefoxitin 4 4 4
Cefuroxime 32 125 4
Ceftazidime 125 64 <1
+ clav * 0.25 0.25 0.13
Cefotaxime 8 8 <1
+ clav * <0.06 <0.06 <0.06
Ceftriaxone 16 4 <1
Aztreonam 125 32 <1
Imipenem 0.13 0.25 0.25
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Fig. 2. 1EF of /3-lactamases produced by K. pneumoniae 8825
and its E. coli J53-2 transconjugant. A. ^-lactamases produced
by the E. coli transconjugant of K. pneumoniae 8825 selected
on ceftazidime and rifampicin; B. ^-lactamases produced by
K. pneumoniae 8825; C. /3-lactamases produced by the E. coli
J53-2 transconjugant of K. pneumoniae 8825 selected on
carbenicillin and rifampicin.
/8-lactamases responsible for resistance to these
drugs were either of the TEM or SHV groups.
4.3. Identification of ^-lactamases
The original K. pneumoniae isolate produced four
/8-lactamases which focused at pi 5.4, p7 6.5, pi
7.7 and p/ 7.9. The band at p7 5.4 aligned with
TEM-1, the enzyme of p7 6.5 focused between
TEM-3 (p7 6.5) and SHV-3 (p7 7.0), and the
enzyme of p7 7.7 aligned with SHV-1/2. Crude
enzyme preparations of the E. coli J53-2 transcon-
jugants selected on either carbenicillin and
rifampicin or ceftazidime and rifampicin pos¬
sessed the /8-lactamases which focused at p7 5.4.
p7 6.5, and p7 7.9. However, they additionally
produced another /8-lactamase which focused at p7
8.1 (Fig. 2). This high p7 band aligned directly
with the E. coli J53-2 chromosomal /3-lactamase.
When the crude preparation of the transconjugant
strain selected on rifampicin and ceftazidime was
separated through the Sephadex G-75 column the
intensities of the /8-lactamases of pi 7.9 and p7 8.1
were reduced.
4.4. Fast protein liquid chromatography
Two ml of the Sephadex G-75 purified (3-
lactamase sample were separated through the
Mono Q column in each run. This process was
repeated until sufficient quantities of the different
enzymes were obtained. In each FPLC System
separation, /8-lactamase activity was detected in
the following fractions: 2, 3 and 4 (the void
volume), 10/11, and 13/14. When these fractions
were examined by IEF the /8-lactamases of p7 7.9
and p7 8.1 were eluted in fractions 2, 3 and 4, the
enzyme of p7 6.5 in fractions 10/11, and the
/8-lactamase of p7 5.4 in fractions 13/14 (Fig. 3).
All the fractions, from the individual separations,
containing the same //-lactamase, were combined
so that sufficient enzyme could be characterised
biochemically.
4.5. Characterisation of f3-lactamases
The hydrolytic activity of each of the three
enzymes against six different /8-lactam antibiotics
are shown in Table 2. The /8-lactamase which
focused at p7 5.4 aligned with TEM-1, it also had
no hydrolytic activity against ceftazidime or
cefotaxime and was therefore assumed to be
TEM-1. The /3-lactamase of p7 6.5 had hydrolytic
activity against cefuroxime, cefotaxime, ceftazi-
Table 2
Relative rates of hydrolysis of FPLC system fractions *
/3-lactam Fraction: 2-4 10-11 13-14




Ampicillin 100 100 100
Carbenicillin 29 18 17
Cephaloridine 114 125 20
Cefuroxime 4.3 17 UM
Cefotaxime 17 9.2 UM
Ceftazidime 4.6 14 UM
* Rate for ampicillin = 100%; UM = immeasurable due to in¬
sufficient hydrolysis.
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Fig. 3. IEF gel of ^-lactamases separated by FPLC System. A.
/J-lactamases produced by E. coli J53-2 transconjugant of K.
pneumoniae 8825 purified by G-75 Sephadex gel filtration; B.
Fraction 2 eluted from FPLC System; C. Fraction 3; D.
Fraction 4; E. Crude y8-lactamase preparation of E. coli J53-2
transconjugant of K. pneumoniae 8825; F. Fraction 14 eluted
from FPLC System; G. Fraction 13; H. Fraction 15; I. as for
E; J. Fraction 10 eluted from FPLC System; K. Fraction 11.
the biochemical characterisation of each individ¬
ual /^-lactamase and permitted an assessment of
how each /^-lactamase contributed to the range of
/J-lactam resistances expressed by the host strain.
We were thus able to show that two of the en¬
zymes produced by the clinically derived K. pneu¬
moniae 8825 strain confer resistance to cefuro-
xime, cefotaxime, ceftriaxone, and ceftazidime.
Evaluation of the biochemical profile of each of
these enzymes strongly suggests that the /J-lacta-
mase pi 7.9 (/^-lactamase DJP-1) is a novel third
generation cephalosporin hydrolysing enzyme.
However, the plasmid mediated /S-lactamase of pi
6.5 may be the same as CAZ-hi [4], or CAZ-6 [2],
both of which have a reported pi of 6.5. The
majority of transferable third generation cepha¬
losporin resistance has emergence in France,
Germany, and the U.K. where broad spectrum
cephalosporin usage is high. However, these two
broad spectrum enzymes were found to be pro¬
duced by a strain isolated in India where the use
of these newer cephalosporins is much lower. The
occurrence of these two /3-lactamases is the first
report of transferable third generation cepha¬
losporin resistance in India and Asia, and also the
first example of two broad spectrum /3-lactamases
encoded by the same plasmid.
dime, and had a greater activity for cephaloridine
than TEM-1. The fractions containing enzymes of
pi 7.9 and pi 8.1 had a similar pattern of hydro-
lytic activities but the activity against the newer
cephalosporins must result from the enzyme of pi
7.9 and not the upper E. coli J53-2 chromosomal
/2-lactamase band, as control studies have shown
that this chromosomal enzyme has no hydrolysing
activity against these /3-lactam antibiotics.
5. DISCUSSION
These results have shown that Fast Protein
Liquid Chromatography has been the most power¬
ful method to date in the separation of multiple
/l-lactamases produced by the same strain. Its
rapid, complete separation of the enzymes enabled
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INTRODUCTION
At first sight it would appear that the properties of the presumed
chromosomal B-lactamases of the genus Acinetobacter have been fully
characterised. Isoelectric points (pi) in polyacrylamide gel systems were first
described by Matthew and Harris ( 1976) and reiterated by Sykes and
Matthew ( 1976). Other workers since then have described the pis of
Acinetobacter fl-lactamases as ranging from 7.5 to > 10 (Medeiros et al.,
1985); >8 (Joly-Guillou et al., 1987) and 9.9 (Hikida et al., 1989). Similarly,
the molecular mass (Mr) of Acinetobacter B-lactamase has been described
as 30,000 by Morohoshi and Saito (1977) and as 38,000 by Hikida et al.
(1989).
The kinetics of hydrolysis to various B-lactam antibiotics have been
most fully described by Morohoshi and Saito (1977) and, subsequently, to
newer agents by Hikida et al. (1989). These authors also examined the effect
of a variety of fl-lactamase inhibitors. There is little doubt, however, from
these data that the Acinetobacter fl-lactamases are cephalosporinases
(Sykes and Matthew, 1976; Morohoshi and Saito, 1977; Medeiros, 1984;
Bauernfeind, 1986; Neu, 1986; Joly-Guillou et al., 1987; Hikida et al., 1989).
The Biology of Acinetobacter, Edited by K. J. Towner et al.
Plenum Press, New York, 1991
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1 The inducibility of these cephalosporinases by specific fl-lactam
inducers has been far from clear. They have been described as being
inducible by Morohoshi and Saito (1977) and quoted as inducible by Sykes
and Matthew (1976), Medeiros (1984), Neu (1986) and Hikida et al. (1989).
Bauernfeind (1986) classified them as inducible or constitutive, whereas
Joly-Guillou et al. ( 1988) stated that B-lactamase inducibility in
Acinetobacter had not yet been clearly demonstrated. On the basis of the
work by Morohoshi and Saito (1977), Bush (1989) classified the
Acinetobacter chromosomal B-lactamase in Group One, i.e. a
cephalosporinase not inhibited by clavulanic acid (CEP-N). Subsequent
substrate profile and inhibition studies by Hikida et al. (1989) suggested that
this classification was correct.
This article presents evidence that the true character of the
chromosomal B-lactamase of the genus Acinetobacter is not as simple as
has been proposed. Indeed there appears to be considerable heterogeneity,
with at least four distinct B-lactamases produced by this genus.
ISOELECTRIC POINTS ON POLYACRYLAMIDE
ELECTROPHORESIS
Matthew and Harris (1976) listed pis of around 8.6 for two B-
lactamases produced by strains of Acinetobacter: A. inotti 1786E and
Acinetobacter sp. 1787E. These same two strains appear in Sykes and
Matthew (1976) as A. inotti (1786E) pi 8.6 and A. mallei (1787E) pi 8.7.
The latter strain (A. mallei) 1787E was not an Acinetobacter at all, but a
Pseudomonas mallei. This organism had somewhat controversially been
placed in the genus Acinetobacter by Cowan and Steel (1965) - it became
P. mallei in subsequent editions (Cowan and Steel, 1974). Therefore, this
enzyme can no longer be considered as one produced by the genus
Acinetobacter.
The former strain (A. inotti) 1786E is equally interesting. An
extensive taxonomic literature search has failed to find any previous or
subsequent mention of the specific epithet 'inotti'. This strain is part of the
Glaxo Research Laboratories' collection, and one of the original authors
(Miss A.M. Harris) kindly sent us strain 1786E for further study. The freeze-
dried vial was still marked as A. inotti, but it was identified by the API 20NE
(API System. S.A. France) as A. Iwoffii (new specific epithet: A. junii).
On reflection, we suggest that iwoffi', when written, could easily have been
wrongly transcribed to 'inotti' and perhaps this error took place somewhere
between its original entry in the strain book and the subsequent publication.
Medeiros et al. (1985) were the first to mention that not all of the
chromosomal fl-lactamases of Acinetobacter focused on conventional
polyacrylamide isoelectric focusing (IEF) systems. Of 14 strains of A.
calcoaceticus, the pi was stated to be 8.8 for one enzyme, 9.0 for one, 9.7
for one, 10.0 for four, > 10 for three and a 'blur' for four. Joly-Guillou et al.
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'(1987) described 30 strains of Acinetob acter with a chromosomal
cephalosporinase of pi >8. This again suggests poor focusing of these
enzymes on conventional polyacrylamide IEF systems. More recently, Hikida
et al. (1989) described a pi of 9.9 for a purified cephalosporinase from A.
calcoaceticus (ML 4961). However, these authors employed broad range
ampholines of pH 3.5-10.0 in their IEF gel. This suggests that the enzyme had
migrated to, or almost to, the cathode. Unfortunately, there was no
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Fig. 1. Conventional polyacrylamide IEF gels of Acinetobacter chromosomal
B-lactamases and the plasmid B-lactamase SHV-1. Enzyme activity
identified with nitrocephin
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aAz=aztreonamMICinmg/1 =molecularassr c ACE=cinetobacterchromosomalenzyme
We have studied eight partially purified B-lactamases of
Acinetobacter, obtained from aztreonam-resistant strains collected in the
Royal Infirmary, Edinburgh (Table 1; Hood and Amyes, 1989). These B-
lactamases were applied to a conventional IEF system (Fig. 1), but seven of
these enzymes did not focus in this system. Only the fl-lactamase from strain
H126 (A. Iwoffii, now A. junii) focused, with a pi of about 9.1. We
postulated that the failure of these enzymes to focus resulted from two
factors. Firstly, the basic nature of the enzyme (high pi), and secondly, their
high molecular masses (see Table 1 and subsequent discussion on molecular
masses). An agarose, urea and sorbitol (AUS) gel system was therefore
devised for isoelectric focusing of these enzymes. This combination allowed
the focusing of these basic enzymes (Fig. 2) and their classification into four
groups, termed ACE-1 to ACE-4. fi-Lactamases from five of the eight strains
studied were placed in the ACE-1 group. Four of these ACE-1 enzymes were
derived from A.baumannii - the most prevalent Acinetobacter species
isolated from clinical specimens (Bouvet and Grimont, 1987). A complete
description of the AUS gel technique and further explanation of the IEF
patterns has been published elsewhere (Hood and Amyes, 1989). Further
confirmation of these groupings has been obtained from preliminary studies
employing two additional techniques. Crude enzyme preparations from all
eight strains were applied to either a MONO S or a MONO Q high
performance ion-exchange column connected to a Fast Protein Liquid
Chromatography (FPLC<R)) system (Pharmacia, Uppsala, Sweden).
The FPLC method has been described fully elsewhere (Payne et al.,
1990). Peaks of B-lactamase activity obtained on the columns were detected
by the nitrocephin spot test (Table 2) and demonstrated the clear differences
between ACE-1, ACE-3 and ACE-4, while suggesting that ACE-2 is similar
to ACE-1. In addition, the results suggest that there may be two subgroups
within the ACE-1 group: one with a retention volume of 15-18 ml, the other
with a retention volume of 12-14 ml. However, further work is required to
verify these sub-groupings.
The purified enzymes obtained from the FPLC/ion exchange were also
applied to a gel system on the PhastSvstem(R>(Pharmacia, Uppsala, Sweden).
This gel system was devised to resolve basic proteins on a poiyacrvlamide
(PAGE) minigel. The exact sample preparation and running conditions were
those described by Olsson and Tooke (1988). A Phastgel Homogeneous 20
(i.e. sodium dodecyl sulphate-free) was run with the reversed polarity
electrodes. After electrophoresis, the enzvmes were visualised by
nitrocephin solution (500 mg/l). ACE-1 (e.g. H141) and ACE-2 (e.g. H162)
preparations migrated similar distances from the cathode, whereas ACE-3
(H126) migrated slightly less far. Insufficient ACE-4 (5B86) was available to
test on this system. Control preparations of the plasmid-mediated B-
lactamases SHV-l/TEM-1 and OXA-2/TEM-2 migrated to appropriate
positions in this gel system, i.e. TEM-1 and TEM-2 stayed at the cathode,
while SHV-1 and OXA-2 migrated to a point just behind the ACE enzymes.
Further experimentation employing this technique is required. If it proves
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Fig. 2. Agarose, urea and sorbitol (AUS) IEF gels. Focused bands of
Acinecobacter chromosomal fi-lactamase activity identified with
nitrocephin
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extremely useful rapid technique for the study of B-lactamases obtained from
clinical isolates of Acinetobacter.
MOLECULAR MASS ESTIMATIONS
Morohoshi and Saito (1977) gave the Mr of their cephalosporinase
from A. anitratum NCTC 7844 as 30,000 when measured by gel filtration on
a Sephadex G-75 column. Hikida et al. ( 1989) gave the M. of their
cephalosporinase from A.calcoaceticus ML4961 as 38,000. They estimated
this Mrby SDS gel electrophoresis after purification of the enzyme with
strong cation exchange and gel filtration.
We estimated the Mrof the B-lactamases in our eight strains of
Acinetobacter by gel filtration, initially on Sephadex G-75 and then, if
required, on Sephacryl S-300 (Hood and Amyes, 1989). The results are listed
in Table 1. One enzyme (ACE-3 from strain H126) had a similar Mr(35,000)
to that described by Morohoshi and Saito (1977) and Hikida et al. (1989).
The ACE-2 fl-lactamase from strain H162 had an M of 60,500, but the other
six enzymes ranged from 640,000 to > 1,000,000. The results suggested that
some of the B-lactamases of Acinetobacter are either very large, or seem
large because they are linked to other cell envelope components and the
enzyme purification techniques used were incapable of removing these
components. This raises the exciting hypothesis that these enzymes could be
an intermediate step between penicillin binding proteins and the fl-
lactamases. Alternatively, these enzymes may exist in multiple subunit form.
Further experiments are being undertaken to examine these possibilities.
BIOCHEMISTRY
The specific activities of the eight ACE enzymes were measured for a
selection of cephalosporins, penicillins and a monobactam (Table 3). The
enzyme preparations were partially purified by gel filtration (Hood and
Amyes, 1989). The spectrophotometric assay employed was that of
O'Callaghan et al.(1969) and was carried out on a Pye-Unicam SP1800
UV/VIS spectrophotometer. Cephalosporins and the monobactam were
used at concentrations of either 100 /xM or 1000 /iM (Table 3) and the
penicillins at a concentration of 1000 ^M. The specific activities of the eight
ACE enzymes (Table 3) show clearly that these enzymes are
cephalosporinases, although most of them also have some activity against the
penicillins tested. The apparent detection of weak activity against
cefuroxime in half the strains and weak activity against ampicillin and
carbenicillin in one strain may be dismissed since the spectrophotometer was
working at the limit of its sensitivity and, therefore, activity against these
substrates may also be possible in the other strains. The only clear difference
was the specific activity of ACE-4 obtained from strain 5B86, which was
considerably lower than the others. Interestingly, ACE-1 from strain 6B230
and ACE-3 from H126 seemed similar - they are the only A.junii strains in
the study.
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Table 4 shows the MIC values of the substrates used in Table 3 for
these strains. The results showed that all the Acinetobacter strains
studied had a high degree of resistance to penicillins and first, second and
third generation cephalosporins. There was some correlation between the
resistance levels and the enzyme produced. All the strains encoding the
ACE-1 enzyme had very similar MICs of all the drugs tested. H162, which
encoded ACE-2, could not be distinguished from the ACE-1 strains on its
resistance profile. However, strain H126, which encoded ACE-3, was
generally more resistant to the drugs tested than the ACE-1 or ACE-2
producers. Specifically, H126 was more resistant to the third generation
cephalosporins and the monobactam, aztreonam. On the other hand, strain
5B86. which encoded ACE-4, was generally less resistant than the other ACE
producers. It was particularly less resistant to the penicillins and the first
generation cephalosporins tested.
Table 5 shows the kinetics of hydrolysis for each of the enzymes, i.e. Rm
values with nitrocephin and cephaloridine as substrates. This value was
obtained by measuring the rate of hydrolysis at limiting substrate
concentrations and Lineweaver-Burk plots. The Revalues obtained with both
nitrocephin and cephaloridine were broadly similar to each other (Table 5).
The Revalues to cephaloridine ranged from 150 /iM to 710 /jM and were
similar to the values found by Morohoshi and Saito (1977) and Hikida et al.
(1989) of 250 /iM and 511 /xM respectively.
These results show that all four ACE enzymes have moderate affinity
for cephaloridine and nitrocephin. All the Rmvalues were within the same
order of magnitude and could not convincingly be distinguished from one
Table 5. Kinetic data for ACE enzymes
Strain no. ACE type K[na(/xm) Kma(pM)
Nitrocephin Cephaloridine
5B86 4 220 710
6B230 1 280 150
H17 1 550 160
H26 1 250 150
H68 1 280 180
H126 3 150 380
H141 1 220 210
H162 2 250 260
aKm, this value was obtained by measuring rates of hydrolysis
at limiting substrate concentrations and determined by
Lineweaver-Burk plots
127
Table 6. I°5oa °f AC^ enzymes with nitrocephin as substrate ()
Strain no. ACE type Aztreonam Cloxacillin Clavulanate
5B86 4 >100 0 .18 >100
6B230 1 28 0..012 >100
H17 1 8 0..005 >100
H26 1 5 0..022 >100
H68 1 9 0 .1 >100
H126 3 0.08 0..003 >100
H141 1 1.8 0..02 >100
H162 2 23 0..022 >100
aID50 = amount of inhibitor required for 50% inhibition of
nitrocephin hydrolysis
another. Thus none of the ACE enzymes demonstrated greater substrate
affinity than the others and Kmvalues were a poor discriminator.
Table 6 shows the effect of the fl-lactamase inhibitors
aztreonam, cloxacillin and clavulanic acid, expressed as the concentration
required for 50% inhibition (ID50) of enzyme activity. The enzymes from all
the strains were readily inhibited by cloxacillin. Most were inhibited within
the range of 0.003-0.022 fiM. However, two enzymes required at least 0.1 fiM
cloxacillin for 50% inhibition. One of these enzymes was ACE-1, but this
level of cloxacillin is still considered to be very low. Thus cloxacillin
inhibition also seems to be a poor discriminator of the ACE enzymes,
although a characteristic feature of them all is that they are cloxacillin
sensitive. Similarly, the enzymes from all the strains were extremely resistant
to clavulanic acid inhibition. The inability of any of these enzymes to be
inhibited significantly by 0.1 mM clavulanic acid shows that clavulanic acid
resistance is a characteristic feature of all these enzymes, but is incapable of
being used as a discriminator.
Differences in inhibition were, however, identified when
aztreonam was used as an inhibitor. There was little difference in the ID50for
the ACE-1 and ACE-2 enzymes, which were in the range of 1.8 to 28 /jM
(Table 6). The ACE-3 enzyme from strain H126 was much more sensitive to
aztreonam inhibition than the others (IDJ0 = 0.08 /xM), while the ACE-4
enzyme from strain 5B86 was much more resistant (ID?0 = > 100 mM). We
believe that the inhibition profiles with aztreonam provide good
discrimination of the ACE-3 and ACE-4 enzymes.
Table 7 shows the effect of EDTA, HgCl2and pCMB. All the enzymes
were inhibited to the same extent by a fixed concentration of HgCl2, but were
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Table 7. Effect of inhibitors and metal ions on ACE enzymes with
nitrocephin as substrate
Percentage inhibition
Strain no. ACE type EDTAa HgCl^k pCMBc
5B86 4 <20 89 0
6B230 1 <20 98 0
H17 1 <20 96 0
H26 1 <20 97 0
H68 1 <20 95 0
H126 3 <20 95 0
H141 1 <20 98 0
H162 2 <20 98 0
a 1 mM EDTA (inhibition variable: see text)
b 1 mH HgCl2
c 0.1 mM p-chloromercuribenzoate
virtually unaffected by moderately high levels of pCMB. Thus no
discrimination of these enzymes could be obtained from these profiles.
The effect of 1 mM EDTA on the enzymes with either nitrocephin or
cephaloridine as the substrate was variable, although generally below 20%.
Hikida et al. ( 1989) found that EDTA had no effect on their enzyme's
activity. Since many of the enzymes described here are of large M and,
therefore, may exist in subunit form, it is possible that metal ions play a role
in their function. This may explain the variable effects of EDTA on their
activities. However, further experiments with more purified enzyme will be
required to elucidate these findings.
The above biochemical data (EDTA apart) place all of these B-
lactamases firmly in Bush Group One (Bush, 1989).
INDUCTION EXPERIMENTS
Morohoshi and Saito (1977) described how the enzyme activities of
five strains of A. anitratum "increased by about five to ten-fold" following
treatment with 100 pg of benzylpenicillin, cephaloridine or 6-
aminopenicillanic acid for 1 h at 37°C. Hikida et al. (1989) quote
Morohoshi and Saito ( 1977) as having shown that Ac i n e t o b ac t e r
cephalosporinases are inducible, but they did not carry out induction
experiments themselves.
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. We have carried out induction experiments with all eight strains,
employing cefoxitin as the inducer at one quarter the MIC value for the
culture. The method employed was that described by Minami et al. (1980).
No discernible B-lactamase induction was found with any of the strains
studied. In discussions with D. Livermore and C.C. Sanders (personal
communications) it was stated that evidence of induction had not yet been
found in any strain of Acinetob acter tested. This includes the use of
cefoxitin, imipenem and penicillin as inducers. Much more convincing
evidence would therefore be required before it can be claimed that these
enzymes are inducible, since current evidence suggests they are not.
ROLE OF PRESUMED CHROMOSOMAL fl-LACTAMASES OF
ACINETOBACTER IN B-LACTAM RESISTANCE
Although it seems likely that these enzymes are largely responsible for
the observed resistance to B-lactam drugs, it is also probable that other
factors, e.g. altered permeability or alterations in the penicillin binding
proteins,may be equally important in some strains. The ultimate test must
involve the cloning of the B-lactamase gene from each of these strains into a
suitable recipient, thereby allowing further study of the resistance
mechanism. This would also enable their place on the bacterial chromosome,
rather than on a plasmid, to be confirmed.
CONCLUSIONS
As one would expect from a genus that is very
heterogeneous, with at least 17 genospecies (Grimont and Bouvet, this
volume), the presumed chromosomal fl-lactamases are also heterogenous.
At least four different ACE enzymes have been described in Acinetobacter
on the basis of IEF in AUS gels, molecular mass and biochemical properties.
As has been outlined above, these are very basic proteins with pis probably
greater than 10. So basic, in fact, that it is difficult to explain how the cell
might secrete them into the periplasmic space; thus they may be bound to
the cell membrane. As a group, they generally do not focus well, or at all, in
conventional polyacrylamide IEF systems. It is possible that further different
chromosomal enzymes exist, since we describe ACE-1 to ACE-4 in only three
of the possible 17 genospecies, i.e. in A. b aumannii, A. junii and A.
Iwoffii.
Further work is needed to explain the large Mr of the enzymes found in
six of the eight strains. This may then shed light on the possible evolutionary
place of these interesting enzymes. Future work on the eight enzymes should
include further purification, perhaps by FPLC. This would allow closer
comparison with the biochemical kinetic data obtained by Hikida et al.
(1989) for their enzyme. It would be interesting to know the exact
genospecies of both the Hikida and Morohoshi strains. It is clear, however,
that the enzymes described in this article, together with those described by
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^Morohoshi and Saito ( 1977) and Hikida et al. ( 1989), are all
cephalosporinases, not inhibited by clavulanic acid, and can be placed in
Bush Group One (CEP-n).
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Teviot Place EDINBURGH,EH8 9AG
The regional cardiothoracic unit of the Royal Infirmary
Edinburgh has a 12 bedded intensive therapy unit.We describe
two separate episodes of nosocomial infection,firstly 20
cases of infection/colonisation with a multiresistant
Enterobacter.This outbreak was related to poor handwashing
facilities and major design faults in the waste disposal
area,particularly the lack of a "slop hopper".This resulted
in the misuse and malfunction of the bedpan washer.This in
turn led to contamination of the hands of the nursing staff
with resultant cross infection.Appropriate control measures
are described.
Secondly we describe the sudden increased isolation of
Acinetobacter spp.from arterial line and CVP tips.14 cases
were infected,11 of which were first on their operating
list.This coincided with a new "monitor" technician and a
lack of experienced nursing staff.Therefore the transducer
sets and lines were primed with fluid the evening prior to a
list (and used if an emergency case arose that
evening).Acinetobacter was grown from the preparation
area,transducer heads,domes and tubing.Measures taken
included the priming of devices as required without storage.
These outbreaks illustrate the problems of infection
acquired in the ITU with respect to unit design,device and
patient handling.
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LACK OF TRANSFERABLE THIRD GENERATION
CEPHALOSPORIN RESISTANCE IN SCOTLAND
D.J. Payne, J. Hood, R. Paton & S.G.B. Amyes
Department of Bacteriology, The Medical School, University of Edinburgh, Teviot Place, Edinburgh,
EH8 9A0, Scotland
Four hundred and thirteen Oram-negative strains, which appeared resistant to cefuroxime
by disk sensitivity testing, were isolated from patients of the Royal Infirmary, Edinburgh,
Scotland over a period from January 1986 to January 1989. This collection of strains
excluded Pseudomonas spp.. Seventy-nine of these strains had MICs of ceftazidime,
cefotaxime or ceftriaxone of 4 mg/L or greater. The /S-lactamases produced by 54 of
these third generation cephalosporin (3GC) resistant strains were examined by analytical
isoelectric focusing. This same group of 3GC resistant organisms were also tested to see
if they exhibited transferable resistance to either ceftazidime or cefotaxime.
This study revealed that none of the 54 30C resistant strains conferred transferable
resistance to either ceftazidime or cefotaxime. Indeed, none of these strains produced
any of the TEM or SHV derived /3-lactamases which have recently been reported to
confer transferable resistance to 3GCs. Consequently, the 3GC resistance conferred by
strains in this survey most probably resulted from the production of chromosomal
cephalosporinases. This survey yielded only one novel chromosomal /3-lactamase which
was produced by Xanthomonas maltophilia and focused as 3 distinct bands of pi 5.2
to 5.6 and possessed different characteristics to the L-l or L-2 ^-lactamases of
X. maltophilia. In conclusion this survey has illustrated that TEM or SHV derived /3-
lactamases which mediate transferable resistance to 3GCs do not appear to be threatening
the future use of 3GCs in Scotland.
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Mycobacterial antigens studied because they cause
antibody responses in the BALB/c mice used to raise
monoclonal antibodies, may not be relevant to T cell-
mediated responses in man. Moreover, mice are immu¬
nised with killed bacilli which lack secreted antigens,
though these are likely to be important for rapid
recognition of infecting organisms, and, following diffu¬
sion to the spleen where they can be presented to T cells
in the absence ofadjuvant effects ofcell wall components,
they may induce suppression. We have used 35S-
methionine-labelled supernates of 4-7-day cultures of
Mycobacterium tuberculosis and BCG to identify secreted
antigens. These antigens, characterised by SDS-PAGE,
^-scanning, and polyclonal and monoclonal antibodies,
constitute a small subset of those present in long-term
supernates, when leakage from dead organisms may be
significant. Abundant 30- and 31-Kda secreted antigens
ofM. tuberculosis and BCG bind strongly to fibronectin.
Moreover, leprosy patients have high levels of antibody
to them suggesting that'antigenically related molecules
are also important antigens of this non-cultivable species.
In view of the regulatory roles of fibronectin in macro¬
phage and lymphocyte function, these 30-31-Kda anti¬
gens are likely to play a role in the pathogenesis of human
mycobacterial disease.
Mycobacterial lipoarabinomannan is a
potent trigger of release of tumour
necrosis factor from macrophages
C. Moreno, Janice Taveme*, Angela Mehlert, C. Bate*,
R. Brealeyt, J. Playfair* and G. Rookf
MRC Tuberculosis and Related Infections Unit, RPMS,
Hammersmith Hospital, London W12 and Departments of
* Immunology and fMedical Microbiology, University Col¬
lege and Middlesex School ofMedicine, London W1
The fever, weight loss, necrosis, acute phase responses
and raised agalactosyl IgG in patients with tuberculosis
are probably due to release of cytokines, including
Tumour Necrosis Factor (TNF), from macrophages
activated by exposure to y interferon, and further
activated following autocrine stimulation by l,25-(OH)2
vitamin D3. However cytokine release requires not only
activation, but also a subsequent trigger. We have shown
that the lipoarabinomannan (LAM) from Mycobacterium
tuberculosis can trigger the release of TNF from human
monocytes and activated mouse peritoneal macrophages
in vitro. Release is enhanced by pre-incubation in the
presence of indomethacin or y interferon. Lipomannan is
not active. LAM also causes release of TNF in vivo in
mice pretreated with Propionibacterium acnes, with a
potency comparable to that of the lipopolysaccharide
(LPS) from gram-negative organisms. We have shown
that the effect is not due to contaminating LPS by affinity
chromatography, and by a treatment with dilute alkakli
which inactivates LAM but not LPS. Moreover when
LAM was subjected to SDS-PAGE, and then electro-
phoretically blotted on to nitrocellulose, the TNF trigger¬
ing activity was localised in the part of the blot where
LAM could be demonstrated with specific monoclonal
antibody.
Clonal origin of multiresistant serotype
Ol 2 PSEUDOMONAS AERUGINOSA in europe
T. L. Pitt, D. Livermore*, D. Pitcher, A. Vatopoulosf
and N. J. Legakisf
Division of Hospital Infection and National Collection of
Type Cultures, Central Public Health Laboratory, 61
Colindale Avenue, London NW9 5HT, *Department of
Medical Microbiology, The London Hospital Medical
College, Turner Street, London El 2AD and fDepartment
of Microbiology, National University of Athens, PO Box
8540,100 10 Athens, Greece
Antibiotic multiresistant Pseudomonas aeruginosa
strains are rare in clinical specimens but in recent years
a number of reports have documented outbreaks of
multiresistant strains of an uncommon serotype, 012, in
Greece, Italy and Belgium. Two hundred and eight
epidemiologically distinct strains were identified from
10 countries by typing, 48 of which were resistant
to carbenicillin (MIC> 128 mg/L) and gentamicin
(>4mg/L). One quarter of the resistant strains were
serotype 012 and these orginated from 8 countries. A
panel of012 strains, which included the sensitive serotype
strains, was examined to determine the homogeneity of
the strains. All strains were indistinguishable by phage
and pyocin typing but lysogenic phage profiles indicated
that one of the English isolates was distinct. Electropho-
retic characterisation of outer-membrane proteins,
lipopolysaccharides and esterase enzymes supported the
results of traditional methods. Restriction fragment
length polymorphism ofDNA fragments hybridised with
a cDNA probe copy of rRNA from the 012 serotype
strain provided proof of the genetic relatedness of the
strains. All clinical 012 isolates produced PSE-1 /I-
lactamase which conferred high level resistance to
azlocillin, carbenicillin, cefsulodin and cefotaxime but
not ceftazidime. Plasmids were found in only 5 strains.
We propose that the similarity of resistance mechanism,
phenotype and genotype of012 strains in Europe suggests
a clonal origin of the strain.
A novel method to identify and
distinguish ACINETOBACTER chromosomal
/Llactamases
J. Hood and S. G. B. Amyes
Department ofBacteriology, Medical School, University of
Edinburgh, Teviot Place, Edinburgh EH8 9AG
Acinetobacter strains are an increasingly important
cause of nosocomial infection. An outbreak of acineto-
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bacter infection associated with arterial pressure trans¬
ducers was described. A study in our hospital of
cefuroxime resistance in gram-negative aerobes found
that 22% of this resistance resulted from Acinetobacter
strains (42 of 192). Eight of these organisms (6 var.
anitratus and 2 var. Iwoffi) were studied further. All of
them were found to produce a cephalosporinase (presum¬
ably chromosomal). The molecular sizes of these enzymes
were determined by gel filtration and they were studied
by: (a) a novel isoelectric focusing technique incorporat¬
ing urea and sorbitol in agarose gels; (b) measuring their
specific activities to a selection of //-lactam drugs; (c)
estimating their ID50s to aztreonam; (d) determining
their Kms to nitrocefin and cephaloride. The molecular
weight of six of these enzymes was found to be high—in
the range 500,000- > 1,000,000. These are the highest
molecular weights described so far for //-lactamases. It
has not previously been possible to use the standard
polyacrylamide gel IEF to distinguish acinetobacter //-
lactamases because of their insolubility in this system.
Their high molecular weights are partly responsible for
this. Our novel IEF system clearly distinguishes at least
four different acinetobacter //-lactamases.
Characterisation of Neisseria
gonorrhoeae from bahrain
K. M. Bindayna and Catherine A. Ison
Department ofMedical Microbiology, St Mary's Hospital
Medical School, Paddington, London W2 IPG
Sixty one strains ofNeisseriagonorrhoeae were collected
between February 1988 and August 1988 from the main
hospital in Bahrain (Salmanyia Medical Center) which
is located in the heart of the capital city Manama. Most
of the gonococcal strains were collected from men
attending different small medical centers throughout the
country and sent to the main hospital. These strains were
characterised by serotyping, auxotyping and antibiotic
susceptibility testing. In the total population only 7
serovars were found; 34 (56%) of the strains belonged to
serovar IB-5/7, 9 (14%) to IB-1 and 18 (30%) belonged to
other serovars (IB-3, IB-4, IB-8, IB-22 and IA-6). Only
two auxotypes, prototrophic and proline requiring, were
identified. Eleven (18%) of the strains were penicillinase-
producing N. gonorrhoeae (PPNG). Among non-PPNG,
36 (72%) of the 50 strains were resistant to penicillin
(MIC>1 mg/L) and 22 (44%) showed increased resist¬
ance to cefuroxime (MIC^O-5 mg/L). This compares
with 41 serovars and a level of penicillin resistance of
5-10% in gonococci isolated in London. The level of
antibiotic resistance in these strains was unexpectedly
high. This could be due to the uncontrolled use of
antibiotics which may have applied a selective pressure,
or these strains may have been imported from the Far
East which has a history of antibiotic resistance.
The use of gene probes for the detection of
toxigenic Escherichia coli
M. J. Woodward, C. Wray and P. J. Carroll
Ministry of Agriculture, Fisheries and Food, Central
Veterinary Laboratory, New Haw. Wevbridge, Surrey
KT15 3NB
Gene probes to LT, STpa, STpb. VT1 and VT2 were
used to examine 1031 strains (339 from cattle and 692
from pigs) ofEscherichia coli isolated from cases of enteric
disease. Of the bovine strains, 60 hybridised with the
STpa probe and the presence of this gene correlated with
the possession of either the K99 (F5) or F41 adhesin.
Five bovine strains possessed STbp genes and five
produced either VT1 or VT2. Thirty-six percent of the
porcine strains hybridised with the gene probes. Most of
the 160 K88 (F4)-positive strains produced both LT and
STpb, although some cultures were detected which
produced LT or STpb alone; both STpa and STpb were
found in four cultures. Strains possessing the K99 (F5)
adhesin, with the exception ofone LT producer, possessed
STpa, STpb or VT2 genes alone, or in combination.
Strains belonging to serogroup 0138:K81 were more
heterogeneous as to their toxin genes and many combi¬
nations of toxin genes were found. Thus, of the 52 strains,
eight produced only VT2; 32 VT2 STpa STpb; one
LTVT2 STpa STpb; 2 STpb; 4 STpa STpb; one LTVT2;
2 LT, STpa. Gene probes were found to provide a rapid
means of toxin detection in E. coli and a replacement for
animal experimentation.
Resistance to a veterinary aminoglycoside
antibiotic (apramycin) causing cross
resistance to gentamicin in human clinical
isolates of Enterobacteriaceae
A. P. Johnson, N. Woodford, E. J. Threlfall* and R. C.
George
Antibiotic Reference Laboratory, Division of Hospital
Infection and *Division ofEnteric Pathogens, Central Public
Health Laboratory. Colindale Avenue, London NW9 5HT
Apramycin is an aminoglycoside antibiotic used
extensively but exclusively in veterinary medicine. Apra¬
mycin resistance mediated by production of the modify¬
ing enzyme AAC (3) IV encoded on transferable plasmids
has been reported in animal isolates of Salmonella and
Escherichia coli. The AAC (3) IV enzyme also confers
resistance to gentamicin and other aminoglycosides used
to treat serious human infections. We have screened a
large number ofgentamicin-resistant Enterobacteriaceae
for cross-resistance to apramycin in order to investigate
the occurrence of this resistance pattern in human
isolates. Six ■ strains of E. coli and one of Klebsiella
pneumoniae isolated from human infections have now
been shown to be resistant to both apramycin (MIC>
16 mg/L) and gentamicin (MIC >4 mg/L). All the strains
contain large plasmids of molecular weight 40-90 Mda,
with four of the E. coli strains also harbouring plasmids
in the range 10-4-7 Mda. The larger plasmids were
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endocarditis in susceptible groups. A questionnaire was
included in an issue of the British Deptal Journal and
circulated to 16,500 dental surgeons. Questionnaires were
also sent nationwide to 650 cardiologists and 1390
members of four infection societies and 2500 general
physicians through the Royal College of Physicians of
Edinburgh. The response rate overall was 17% providing
3544 questionnaires for analysis. Preliminary results of
the survey were presented. It appears from the question¬
naires returned that there is now widespread acceptance
of the BSAC recommendations; >90% of respondents
indicated that they would prescribe amoxycillin 3 g less
than 2 h before the dental procedure. Erythromycin was
themost popular alternative in penicillin-allergic patients
with 95% choosing this option although often with
suboptimal dosage. Dental procedures considered for
prophylaxis included extractions (99-9%), scaling
(97-6%), root canal work (78%) and cavity filling (35%).
Only 12% of respondents used topical oral antiseptics
with chlorhexidine being chosen in most cases (79%).
Cefuroxime and gentamicin resistance in
non-pseudomonal gram-negative aerobic
bacilli isolated from different units
within a large teaching hospital
J. Hood and S. G. B. Amyes
Department of Bacteriology, University of Edinburgh
Medical School, Teviot Place, Edinburgh EH8 9AG
The Royal Infirmary of Edinburgh is a large teaching
hospital of 1000 beds containing most regional and
supraregional specialities. Over 8000 clinical isolates of
non-pseudomonal gram-negative aerobes were collected
over a 36-month period (March 1986-March 1989).
Resistance to cefuroxime and gentamicin was estimated
by the Stoke's method. Overall resistance to cefuroxime
was 13% while resistance to gentamicin was only 2-6%.
The resistance to cefuroxime was related to specific ward
areas: General medical, 8-2%; Haematology, 12-7%;
General surgery, 13-7% (range 7-0-20-9%); Urology,
15-9%; Orthopaedics, 11-7%; Cardiothoracic ITU,
34-9%; General ITU, 38-0%; Head injury unit, 24-6%;
Acute renal dialysis unit, 22-0%; Special Care Baby Unit,
16-9%. The incidence of cefuroxime resistance was
related to the overall use of /Mactam drugs. The highest
resistance was found in areas where cefuroxime was the
main treatment or prophylactic agent. Gentamicin
resistance was generally lower: Surgical hospital, 1-9%
(range 0-5-5%); Medical hospital, 3-1% (range 1-0-6-1%);
Intensive care areas, 4-5% (range 1 -5—6-7%). The resist¬
ance to gentamicin was low even in areas of high use,
e.g., 4-1% in the Special Care Baby Unit. The extra care
exercised in the use of these potentially more toxic drugs
may be one reason for the lower incidence of resistance.
Use of a DN A hybridisation technique to
study the effect of quinolone antibiotics
on plasmid curing in an experimental
model of urinary tract infection
A. C. Phillips and K. J. Towner
Department of Microbiology and PHLS Laboratory, Uni¬
versity Hospital, Nottingham NG7 2UH
The determination ofplasmid copy number by conven¬
tional methodology presents considerable logistical diffi¬
culties when applied to large numbers of samples. In an
attempt to overcome these problems, a biotin-labelled
DNA probe was used in dot-blot tests to detect the
presence of bacteria carrying plasmid DNA in an
experimental model simulating infection of the urinary
tract. The colour intensity generated in positive hybridi¬
sation tests was measured using a computer-controlled
image analysis system and was shown to be proportional
to the number of plasmid copies present. When the
system was used to investigate the effect of quinolone
antibiotics on plasmid carriage by bacteria it was
demonstrated that ciprofloxacin, used at a concentration
of half the MIC, was effective at reducing plasmid copy
number, while nalidixic acid, used at a similar concentra¬
tion, had a considerably reduced effect. Up to 96 samples,
e.g. taken at different time intervals with varying
concentrations of antibiotic, can be screened simultane¬
ously. The method can be used to investigate plasmid
curing and copy numbers in any system for which a
suitable DNA probe is available.
A new method of measuring opsono-
phagocytosis using luminescent bacteria
H. Kenny, C. A. Webster, R. C. B. Slack and J. P.
Arbuthnott
Department of Microbiology and PHLS Laboratory,
Queen's Medical Centre, Nottingham NG7 2UH
Conventional direct methods of assessing phagocytosis
usually involve labour intensive and poorly reproducible
methods of viable counting. We have used the recombi¬
nant Escherichia colistrain HB101 (pSBlOO) carrying the
lux AB gene sequences cloned from Vibrio harveyi* to
compare luminescence with conventional plate counts
and turbidimetry. Bacteria containing the lux AB gene
emit light when long chain aldehydes, e.g., decanal are
added. Human and casein-induced murine polymorpho-
nuclearneutrophils (PMNL) were used with both immune
and non-immune serum for opsonisation. The results of
the calibrations showed a good correlation between
luminescence and conventional methods. The reprodu¬
cible lower limit of detection with a luminometer was 106
bacteria/ml; with a scintillation counter it was 102
bacteria/ml. The luminescence method allowed assess¬
ment of phagocytosis and intra-cellular killing within the
time scale of the experiment whereas the conventional
methods only measured intra-cellular killing and required
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RELATIONSHIP BETWEEN ANTIMICROBIAL PRESCRIBING PATTERNS AND THE RESISTANCE
PROFILES IN GRAM NEGATIVE AEROBIC BACILLI WITHIN SPECIFIC UNITS OF A LARGE
SCOTTISH TEACHING HOSPITAL.
J. Hood* and S.G.B. Amyes, Department of Bacteriology, The Royal Infirmary and




The Royal Infirmary of Edinburgh is a 1000 bedded teaching hospital
containing most regional and supraregional specialities. The study consisted
of 5890 clinical isolates of, non-pseudomonal, gram negative aerobes. They
were collected over a 21 month period in 1986-1987. Their resistance to
cefuroxime was estimated by the Stoke's method. Overall resistance to
cefuroxime was found to be 12.3%. The resistance to cefuroxime was related
to specific ward areas. General medical : 7-9%; Haematology : 12%; General
surgery : 13% (range 5.5 -> 19.8%); Urology : 16%; Orthopaedic surgery :
10.4%; Cardiothoracic surgery : 33%; General intensive care area : 32%; Head
and spinal injury unit : 25.7%; Acute renal dialysis unit : 17.6%; Special
care baby unit : 13.1%. The incidence of cefuroxime resistance was related to
the overall use of beta-lactam drugs in a given area; the highest resistance
was found in areas where cefuroxime was the main treatment/prophylactic
agent. The lowest incidence was found in areas where aminoglycosides were the
main treatment/prophylactic agent. Resistance was also much greater in the
intensive care areas. A clearly resistant subgroup of these bacteria with MIC
> 32 mg/1 cefuroxime was studied further. The predominant species involved
were Enterobacter (45%) and Acinetobacter (22%). MIC^'s (in mg/L) were:
ceftazidime = 8; cefotaxime = 64; aztreonam = 64; imipenem = 4; gentamicin
= 32; netilmicin = 8; ciprofloxacin = 0.5. Amongst the cefuroxime resistant
strains a slightly higher proportion were resistant to aztreonam than
ceftazidime and almost the same proportion were resistant to cefotaxime but
there was generally a lower proportion of resistance to the aminoglycosides.
PROCEEDINGS OF THE PATHOLOGICAL SOCIET
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Hospital Legionnaires' disease: virulence
among strains of LEGIONELLA PNEUMOPHILA
serogroup 1
A. Colville, R. C. B. Slack and J. L. Crowley
Public Health Laboratory, University Hospital, Queen's
Medical Centre, Nottingham NG7 2UH
An outbreak of Legionnaires' disease occurred in a
large teaching hospital during 1988-89. The hospital has
four interconnected blocks, each with its own domestic
hot water system supplied by a common main. Three of
the blocks house ward areas. After an extensive case
finding exercise, 12 episodes of Legionnaires' disease
were identified, which may have been acquired nosocom-
ially. All these cases were associated with one block, but
several wards on different levels were implicated. Legi¬
onella pneumophila was isolated from one patient and
from several points in the domestic hot water supply in
two of the blocks. The clinical and environmental isolates
were typed by monoclonal antibody and restriction
fragment length polymorphism (RFLP) techniques. The
only strain isolated from the block where cases occurred
was Benidorm, RFLP type 14, which was identical to the
clinical isolate. In other areas, in which susceptible
patients were cared for, several different strains of L.
pneumophila serogroup 1 were isolated, but not the
Benidorm RFLP type 14. In addition, L. pneumophila
serogroup 1 was found in the hospital during the earlier
PHLS survey of hospital and hotel water supplies, yet no
nosocomial cases were identified until 1988. Epidemiol¬
ogical evidence suggests that the outbreak was due to a
single strain. As this was not identified in the first survey,
it is suggested that nosocomial disease may have occurred
only when a "virulent" strain of L. pneumophila colonised
the domestic hot water system in one block of this large
building. Further investigation of possible virulence
mechanisms is in progress.
Quantitation of bacteria in patients with
positive blood cultures
P. S. Rice and R. C. Spencer
Department ofBacteriology, Royal Hallamshire Hospital,
Glossop Road, Sheffield S10 2JF
A 3-year review of blood cultures showed that 122
and 279 clinically significant positive peripheral blood
cultures were received from patients with and with¬
out ("others") haematological malignancy respectively.
Using a pour plate containing 2 ml of blood, colonies
were counted and stratified into five groups—0, 1-10,
11-100, >100 but <1000, and >1000 colonies per
plate. In "other" patients.colony counts per plate were:
0, 60-9%, 1-10, 21-8%; 11-100, 10-5%; >100<1000,
3-9%; and > 1000, 2-9%. By comparison, counts in
haematology patients were: 0, 37-7%; 1-10, 25-4%;
11-100, 21-3%; >100<1000, 6-6% and >1000, 9%.
When only gram-negative septicaemias are examined,
colony counts > 100 were found in 7-4% of haematology
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patients compared with 0-72% in "other" patients.
Mean numbers of circulating organisms in gram-
negative septicaemia show a similar trend with an
average of 8 organisms/ml in "others" compared with
49 organisms/ml in haematology patients. Thus the
bacterial load appears to be greater in haematology
patients and the difference is amplified in gram-
negative sepsis. This may, in part, be due to the role
of endotoxin in the stimulation of neutrophil activity.
PASTEURELLA MULTOCIDA meningitis in
infancy—a rare and preventable disease
B. 1. Duerden and C. A. MacKenzie*
Departments ofMicrobiology and *Paediatrics, Children's
Hospital, Western Bank, Sheffield
Pasteurella multocida, a commensal of the mouth and
upper respiratory tract of dogs and other animals, causes
infected animal bites; systemic infection is uncommon
in man. P. multocida meningitis is very rare, but may
occur in infants in close contact with animals. A 3-week-
old girl developed signs of meningitis and septicaemia.
CSF examination showed 140 white cells/cm3 (95%
polymorphs), glucose 2-9 mmol, protein 3-2 g/L; orga¬
nisms were not seen by microscopy. A gram-negative
cocco-bacilluswith bipolar staining was isolated; initially
thought to be Haemophilus influenzae, it was identified
24 h later as P. multocida. The same organism was isolated
from blood cultures. Agglutinating antibodies were
demonstrated in convalescent serum samples but not in
a sample taken on admission. Initial treatment with
ceftazidime was effective for 72 h; benzyl penicillin was
then added. The baby made a good recovery and left
hospital after 2 weeks. Close contact with two dogs at
home was confirmed. The dogs were encouraged to "get
to know" the baby (and vice versa) and had been known
to lick her, including her face. The presumed route of
infection was either the nasal or upper respiratory tract
mucosa, or the conjunctiva. Such close contact between
neonates or infants and animals should be avoided.
Large or small? The molecular mass of the
chromosomal ^-lactamase of
ACINETOBACTER BAUMANI estimated by fast
protein liquid chromatography (FPLCR)
J. Hood and S. G. B. Amyes*
University Department of Bacteriology, Royal Infirmary,
Glasgow G4 0SF and *Department ofBacteriology, Univer¬
sity ofEdinburgh Medical School, Teviot Place, Edinburgh
EH8 9AG
The combination of FPLCR for separation and nitro-
cephin for detection is the most powerful tool yet devised
for the purification of ^-lactamases. Employing this
method, we purified crude enzyme derived from an ACE-
1 producing strain (H63) ofAcinetobacter bauman, which
had a molecular mass (Mr) previously estimated as 580 x
103 by conventional gel filtration on Sephacryl-300. Three
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peaks (one major and two minor) were found after
FPLCr with a strong cation exchanger (MonoS). These
peaks were then applied, employing FPLCR, on to a
previously calibrated gel filtration column (Superose 12).
The major peak of activity eluted with an Mr of about
(11-12) x 103. This was then concentrated and applied to
a sodium dodecyl sulphate-polyacrylamide electro¬
phoresis gel (stained with silver) on a PhastSystemR. A
major band was found corresponding to an Mr of about
14 x 103. The other minor peaks of activity on the ion
exchange step produced peaks corresponding to Mrs of
500 x 103 and (35—40) x 103. These results show that this
enzyme, through apparently large on conventional gel
filtration, actually exists in several ionic forms with a
subunit size of about (10-15) x 103. These ^-lactamases
are clearly novel and may well be an evolutionary
intermediate between penicillin binding proteins and
conventional /^-lactamases.
a method for typing neisseria
meningitidis by analysis of restriction
fragment length polymorphisms
D. M. Jones, A. J. Fox, S. J. Gray and N. S. Saunders*
PublicHealth Laboratory, Withington Hospital, Manchester
M20 8LR and *Central Public Health Laboratory, 61
Colindale Avenue, London NW9 5HT
A typing technique for Neisseria meningitidis which
employs restriction fragment length polymorphisms
(RFLPs) has been developed. A library ofN. meningitidis
EcoK 1 fragments in the vector AgtWES. 2B was prepared
and the recombinant J.phage DNAs from a number of
clones were assessed for use as probes. One such probe
(2NM3) was found to give excellent discrimination
between unrelated strains of N. meningitidis. Southern
blotsofmeningococcal DNA digested with the restriction
endonuclease Aval revealed 1-10 bands following hybri¬
disation of biotinylated 2NM3 and subsequent detection
with a streptavidin-alkaline phosphatase conjugate.
Preliminary results demonstrated a high degree of
typability and reproducibility (c. 100%). When applied
to epidemiological^ unrelated strains the method has a
high numerical index of discrimination (0-92) which is of
the same order as phenotyping (0-94) and isoenzyme
analysis (0-95) of the same strains. Repeated isolates from
long term carriers and isolates from multiple sites of
single individuals give identical typing patterns. Strains
of the phenotype B15P1.16, regarded as clonally related,
show some limited heterogeneity and the different typing
patterns are constant in strains from different parts of the
country. The method may throw some new light on the
epidemiology of meningococcal infection.
Polypeptide composition of flagella of
Helicobacter pylori
C. J. Luke, E. Kubiak,* A. Cockayne, T. S. J. Elliot*
and C. W. Penn
xi
School of Biological Sciences, University of Birmingham,
Birmingham B15 2TT and *Department ofClinical Micro¬
biology, Queen Elizabeth Hospital, Birmingham B15 2TH
Flagella of Helicobacter pylori were removed from
intact organisms by shearing and collected by differential
centrifugation. The isolated flagella were treated with
detergent, and the polypeptide composition of native and
detergent-treated flagella was compared by electronmi-
croscopy and sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE). While native flagella
were covered by a sheath of membranous material,
detergent-treated flagella appeared devoid of this cover¬
ing. By SDS-PAGE, the detergent-treated flagella con¬
tained a single major polypeptide of 54 Kda while native
flagella contained this polypeptide as well as others of 26,
30 and 66 Kda. The latter are thus putative components
of the flagellar sheath, and if, as has been postulated,
there is a relationship between the sheath, a membranous
structure, and the outer membrane, these proteins
may also represent possible outer membrane proteins.
Immunogold electronmicroscopy with a polyclonal
mouse antiserum, monospecific to the 54 Kda polypep¬
tide by Western blot, showed that detergent-treated, but
not native flagella were reactive with the antibody, thus
confirming the location of the 54 Kda polypeptide on the
flagellar core and the absence of exposure of this antigen
on native flagella.
a novel method to prevent catheter-
associated infections
T. S. J. Elliot, J. Holford, P. Sisson* and P. Byrne*
Department of Clinical Microbiology, Queen Elizabeth
Hospital, Edgbaston, Birmingham B15 2TH and *Depart¬
ment of Microbiology and Public Health Laboratory,
Newcastle General Hospital, Weslgate Road, Newcastle
upon Tyne NE4 6BE
Intravenous catheter-associated infections continue to
cause clinical problems, ranging from localised phlebitis
to bacteraemia and septicaemia. In an attempt to
overcome these infections, we have used a novel approach
which has involved electrical charge. Bacteria have an
overall negative electrical charge. In order to repel micro¬
organisms, catheters have been developedwith amodified
negative charge. The electrical charge with certain
physical properties has been produced by a small
generating unit. A suitable catheter material which will
conduct electricity has also been developed. A model test
system was subsequently designed to evaluate several
different electrical charges under variable conditions.
The electrical system has now been refined to produce
maximum bacterial repulsion. The development of the
test system, together with the electrical fields, has now
resulted in a device suitable for clinical trials. This novel
approach to catheter-associated infections, including the
preliminary in-vitro findings, were presented. .
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CEFUROXIME AND GENTAMICIN RESISTANCE IN GRAM
NEGATIVE AEROBIC BACILLI ISOLATED FROM IS UNITS V.TTHLN A
LARGE SCOTTISH TEACHING HOSPrTAL J.HOOD1 A.-B.HARR1S2 AND
S.G.BAMYES"*. University Department of Bacteriology*. Glasgow Royal
L-.firn-.ary, Glasgow,G4 OSF and Department of Medical Microbiology^. University
of Edinburgh, EHS 9AG.SCOTLAND.
The study investigated the resistance patterns of gentamicin and ccfuroxime within
non-pseudomonal Gram negative bacilli isolated in IS distinct units of a large
teaching hospital, over a 5 year pcriod(1986-1991). 13,000 (non-duplicate) isolates
had their sensitivities estimated by the Stokes Method. Cher a 12 month period
(1989-1990) all antimicrobial use within these areas was calculated and related to
the throughput of patients. Resistance was then related to actual antimicrobial
usage. Cefuroxime resistance varied from unit to unit. Surgery, overall: 12.8%
(range:4.6% in gynaecology to 23.7% in vascular). Medicine, overall:11.8%
(range:6.8% in general medicine to 20.5% in CAPD/renaI).The ITUs bad a
significantly greater cefuroxirac resistance, overall:33% (range:18.8% in special
care baby unit to 42.7% in the general ITU). Gentamicin resistance was much
lower. Surgery, overall:1.7% (range:0.7% in gynaecology to 4% in urology).
Medicine,overall:2.6%(range:l% in general medicine to 4.7% in CAPD/renal).
rTU.overa!l:4%(range:2J% in neurosurgery to 6.6% in the renal ITU).
Conclusions: ccfuroximc resistance is much higher than gentamicin resistance; there
is considerable variation in resistance from unit to unit;cefuroxime resistance is
increasing whereas gentamicin resistance appears stable; cefuroxime resistance is
not simply related to beta-lactam use but also to the nature of the patient's
underlying condition.
i 1 OH CONTRIBUTION OF BETA-LACTAHASES TOI I ZJ U RESISTANCE IN XANTHOMQNAS MALTQPHILIA.
H. Akova*, G. Bonfiglio, D. M. Livermore.
Hacettepe University School of Medicine, Ankara, Turkey,
and London Hospital Medical College, London, UK.
X.maltophi 11a produces two inducible beta-lactamases, L1
and L2, and resists beta-lactams, including carbapenems.
L1 is a zinc-metalloenzyme with carbapenemase activity,
L2 is an unusual cephalosporinase. We derived mutants
with h1gh-(stably derepressed) and low-level constitutive
(basal) beta-lactamase expression from 3 reference
strains. With a single exception the mutants had altered
expression of both enzymes, indicating shared regulatory
components. The exception was a mutant that became basal
for L1 enzyme but remained inducible for L2. A parent
strain with low 1nduc1b1l1ty was more susceptible to
penicillins, cephalosporins and carbapenems than those
where higher enzyme levels were Inducible. Mutational
beta-lactamase derepression increased resistance to
ureldopenici 111ns and newer cephalosporins. Basal mutants
were more susceptible than Inducible strains to these
drugs, Indicating that inducible expression was also
partly protective. Inducible and derepressed organisms
were similarly resistant to meropenem and Imipenem, but
basal mutants were more susceptible to meropenem than
imipenem. MICs of meropenem, penicillins and
cephalosporins, but not Imipenem, were greater on Mueller
-Hlnton than on Isosensltest and Diagnostic Sensitivity
Test agars. This behavior was Independent of beta-
lactamase 1nduc1b1lity, and may reflect permeability
differences between cells grown in different media.
1188 CHARACTERIZATION OF
AMINOGLYCOSIDE RESISTANCE IN ITALY
G.Molmari, G.C.Schito, RH.Hare, G.H.Miller. Institute ol Microbiology,
University of Genoa, Italy. Schering-Plough Research, Bloomfield, NJ,
USA.
A total of 286 aminoglycoside-resistant gram-negative bacilli were
collected in 9 institutions evenly dispersed in Italy. The pathogens analyzed
included: 66 Ssnaaaspp., 41 Er.terobactcr spp.. 35 P.mirabilis. 34 Klebsiella
5pp., 33 E.coIL 28 P.aeruginosa and 49 organisms belonging to other
spectes. Of these strains, 87% were resistant to tobramycin and
gentamicin, 78% to netilmicin, 27% to amikacin and 18% to isepamitin. The
aminoglycoside resistance patterns (AGRPs) were determined by disk
testing and DNA hybridization. Tne most common enzymes found were
AAC(3)-V (65%), AAC(6*)-1 (30%) and ANT(2M) (14%). Permeability,
bamers were detected in 10% of the strains. Combinations of resistance
mechanisms were present in 81 organisms (28%). The most frequent
AGR? in Serratla was AAC(3)-V (29%), followed by AAC(6')-I alone or
combined either with AAC(3)-I or ANT(2") or both (23%). The association
AAC(3)-V + AAC(6>I was found in 21% of the Serraria and, in
combination with two more enzymes, AAC(3)-I ♦ ANT(2"), in 12 strains
(18%). Permeability accounted for 36% of E.coli resistance mechanisms
while 18% of the strains contained AAC(3)-V and another 18% possessed
ANT(2"). In the remaining Enterobacteriaceae. AAC(3)-V alone (64%) or
combined with AAC(6>I (10%) was the prevalent pattern of resistance.
Five strains produced AAC(3)-TV, a rare enzyme. Of the Pseudomonas
29% had AAC(6')-II, 21% AAC(6>I and 11% ANT(2") or AAC(3)-Ia. Like
in other southern European studies, ACC(3)-V predominated in all
Lrisnrunons and the prevalence of this mechanism mi^ht explain the higher
resistance rates found for netilmicin in the italian strains.
1 1 Q 1 DECREASED SUSCEPTIBILITY OF PENIdLLD^-RESISTANr
FTSJMXDXI TO BETALACTAM ANTIBIOTICS.
J. Linares. T. Alcrtso, JL Perez, J. Ayats, A. Dcminguez, R. Pal lares,
R. liartin. Hospital de Bellvitge, Universidad de Barcelona, Spain.
During a 12-year period (1979-90), 1492 pneimococci recovered frcm
clinical sources were tested for antibiotic susceptibility; 270 (18£)
of than showed intermediate penicillin resistance (IPR) and 215
(14.4%) were highly resistant (R) to penicillin. Multiple resistance
(->3 antibiotics) was observed in 73 % of these IPR and R strains.
To compare the in vitro activity of 16 betalactam antibiotics, we tes¬
ted three groups of pneuitxocci by agar dilution method: 100 penici¬
llin susceptible (S), 100 1FR, and 100 R strains.
Minimal inhibitory concentrations, pg/ml, (MICs-90 of S/IPR/R), frcm
greater to lesser active antimicrobial, were as follows: imipenem
(0.01/0.25/0.5), meropenem (0.01/0.5/1), cefotaxime (0.01/0.5/1), cef¬
triaxone (0.01/0.5/1), cefpircme (0.01/0.5/1), penicillin (0.03/1/4),
ampicillin (0.03/1/8), cefuroxime (0.06/2/16), cephalotin (0.25/8/32),
cefamandole (0.25/8/32), cefixime (0.5/16/32), ceftizoxirne (0.5/16/32)
cefaclor (0.5/32/64), ceftazidime (0.5/32/64), cefoxitin (1/32/64),
and cefonicid (1/32/64).
CXir results slxw that IFR and R poeunococcal strains had decreased
sensitivity to other betalactam agents. However, soma of these agents
such as imipenem, meropenem, cefotaxime, ceftriaxone, and cefpirome,
with MICs 2 to 8 times lower than penicillin, could be useful for tlie
treatment of infections due to resistant strains. The remaining ce¬
phalosporins should not be used in empirical treatment of pnetxrtxxxxal
infections in our area, where 50 % of clinical isolates were resistant
to penicillin in 1990.
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First Dept of Medicine and Dept of Microbiology,The
General Hospital of Athens,Athens,Greece
IXie to a recent increase in the isolation rate of Klebsi¬
ella spp and the rates of their resistance to newer arti-
biotics in our hospital,we performed a prospective stud/
of the clinical importance of these organisms, involving
all patients(pts)from whom one of these organisms had
been isolated since January 1,1991. In 29 of the first 38
pts (34 K.pneumoniae,4 K.oxytoca)the bacterium was isolat¬
ed from urine and in 9 from bronchial secretions. In 27
pts the pathogen was considered responsible for a true
infection(15 hospital-acquired, 12 community-acquired).
Bnpiric treatment was given to all these 27 pts and this
was later proven inappropriate in 5 cases. 19 out of 22
with appropriate but only 1 out of 5 with inappropriate
treatment were cured.3 pts with LTTI died despite treat¬
ment : 1 with appropriate treatment for a multiresistant
hospital-acquired strain and 2 with inappropriate treat-
mentO sensitive,! multiresistant strain,both community-
acquired) .
In conclusion,increase in both isolation rate of Klebsi-
ellae and their resistance percentages was responsible
for a high treatment failure due to inappropriate empi¬
ric therapy.
1192 EVALUATION OF A RAPID METHOD AND AGAR DIFFUSIONKIR DETECTION OF EETALACTAM RESISTANCE PHEIOIYPES.
T.Foist1. P.Daoulas3. et HL.Garrigues3. Hfipitol
Pasteur-Nice[l). Hfipital Necker-Paris(2). et Diagnostics Pasteur(3).
A rapid iiethod in liquid medium, SIR £MB&HCTERIACEA£ 4H. was
conpared to agar diffusion (AD) on 409 vild strains; discrepant
results were analysed first by comparing data obtained in the tv»
sites of evaluation: inter-center variability vas found dependent on
careful control of inoculum density and incubation tire. Discrepant
strains have been tested again by detemining MIC for aapicillin
amoxicillin/clavulanic acid, piperacillin, cephalothin. cefuroxii and
cefotaxlm. Results of both rethods vere then confronted to KIC and to
each type of betalactamise. which was deducted from betalactam
resistance phenotype. Both rethod have been tested also vitk
reference strains (Collection 1 and 2. Unity of Antibacterial Agents.
Institut Pasteur), and analysed in the same vay.
Global correlation with MIC resulted in 71.1 and 72.2 X concordance
for AD and SIR <H respectively. Discordances expressed as minor
(24.4X and 20%). major (2.2 and 2.2), and very major (2.2 and 5.SI)
vere also closely related but were dependent essentially on different
phenotypes: compared to AD. SIR 4H detected most high level
penicillinases, but could hardly identify some Inducible
cefalosporinases. Very major errors with cefuroxim observed in this
case could be corrected with cephalothin results: this inter-
antlbiotic variability reflected variable expression of resistance
mechanisms.
We conclude that as for diffusion. SIR ENUXXAC7HIIACEAE4H results
have to be interpreted, and confronted with identification,
especially for inducible resistance detection.
